All India Active Pharma Ingredient & Bulk Drug Directory 2023 - 24

l l l l l l l l l

t

We firmly believe that SALE IS NOT AN END OF A RELATIONSHIP AT P,, BUT JUST A BEGINN NING OF OUR SERVICES...

l 3

WE OFFER FOLLOWING PRODUCTS BEING MANUFACTURED BY

AURANGABAD

METHYLCOBALAMIN IP / JP HYDROXYCOBALAMIN METHYLPREDNISOLONE IP METHYLPREDNISOLONE ACETATE DIACEREIN IP / EP KINDLY CONTACT FOR YOUR REQUIREMENT:

A-602, 6TH FLOOR, HERITAGE PLAZA, TELLI GALLI CROSS ROAD, NR. CITI POINT ANDHERI (EAST), MUMBAI – 400069.

Tel. No.: + 91 22 4002 3345 /4002 4456 l E-mail : apex.pravinchandra@gmail.com

4

“Servingg A Mul tude of Industriees” INDUSTRIES S SERV VED BY US PHARMACEUTICAL INDUST TRIES v Acetone v Acetonitrile v Chloroform v Di Methyl Formamide (DMF) v Di Methyl Sulphoxide (DMS SO) v Epichlorohydrine v Ethyl Acetate v Ethylene Dichloride (EDC) v Glycerin v Hydrazine Hydrate (HH) v Hydroxylamine Hydrochloride 99% (HHCL ) v Iso Propyl Alcohol (IPA) A v Methane Sulphonyl Chlorid de v Methanol v Methyl Iso Butyl Ketone (M MIBK) v Methylene Dichloride (MDC C) v Mix Xylene y v N- Heptane v N-M N Meth thyll Pyrr P olidone lid (Nm N p) v Ortho Xylene y v Propylene Glycol (Pg )Usp / Tech e v Sodium Metal v Te ert Butanol v Tetrahydrofuran (THF ) v Toluene o v Trieth r yl Orthoformate (TEOF O ) v Trieth r ylamine v Trimeth r yl Orthoformate (TM MOF ) PAINT & COAT TING INDUSTR RIES v 2-Ethy yl Hexyl y Acryla y te ((2EH HA)) v 2hydroxyethyl Methacrylate t (HEMA) v Acetone v Acrylic Acid v Adipic Acid v Bisphenol-A v Butyl Acetate v Butyl Acrylate Monomer (B BAM) v Butyl Glycol / Cellosolve v Butyl Carbitol v Direthylene Glycol (DEG) v Epichlorohydrine v Ethyl Acetate

v Ethyl Acrylate (EA) v Iso Butanol v Isopropyl Alcoh hol (IPA) A v Metha Acrylic Acid (MAA) v Methanol v Methyl Acrylate e (MA) v Methyl Ethyl Ketone (MEK ) v Methyl Iso Buty yl Ketone (MIBK) v Methyl Metha Acrylate (MMA) v Mix Xylene y v Mono Ethylene e Glycol (MEG ) v N-Butanol v Ortho Xylene y v Phthalic Anhydride v Propylene Glycol (PG) (TECH) v Styrene Monom mer v Titanium Dioxid de Ru le v Toluene o

LEAT THER INDUS STRIES v Melamine l i v Methanol v Maelic Anhydride v Phenol v Paraformaldhyde v Phthalic Anhydride AGROCHEMICAL L /PESTISIDES INDUSTRIES v Cyclohexanone e v Di Acetone Alcohol o v Di Ethylene Gly ycol (DEG ) v Di Methy yl Form mamide ((DMF)) v Di Methyl Sulph hoxide (DMSO) v Iso Propyl Alcho ol (IPA) A v Methanol v Mono Ethylene e Glycol (MEG) v N-Methyl Pyrrolidone o (NMP) v Phosphoric Acid d 85% Tech/F e ood v Propylene Glycol (Te echnical Grade) v Toluene o PACKAGING IND DUSTIRES v Butyl Acetate v Di Acetone Alcohol o

604, 6th Floorr,, Runwal R Square, L.B.S. Marg, Opp. V Ve eena Nagar, Mulund (West), Mumbai-400080, Maharashtra, India. |

v Ethyl Acetate v Iso Propyl Alchohol (IPA) A v Methanol v Methyl Ethyl Ketone (MEK) v Methyl Iso Butyl Ketone (MIBK) v Mp Diol v N-B Butanol v N-P Propanol v N-P Propyl Acetate v Tolu o uene

PAPE ER & PRINTING INKS INDUSTR RIES v Buttyl Acetate v Buttyl Glycol/ Cellosolve v Ethyl Acetate v Iso Propyl Acetate v Iso Propyl Alcohol (IPA) A v Methyl Ethyl Ketone (MEK) v N- Propanol v N- Propyl Acetate v NN Butanol t l v Tita anium Dioxide Anatase/ Ru le SPECIALITY C CHEMICALS & RESIN INDU USTREIS v 2-E Ethyl Hexyl Acrylate (2EHA) v 2 Hydroxyethyl Methacrylate (HEM MA) v Acrrylamide v Acrrylic Acid v Adiipic Acid v Buttyl Acrylate Monomer (BAM) v Ethyl Acrylate (EA) v Iso Phthalic Acid v Maelic Anhydride v Metha Acrylic Acid (MAA) v Methyl Acrylate (MA) v Methyl Metha Acrylate (MMA) v N-B Butyl Metha Acrylate (NBMA) v Phthalic t Anhydride v Styrene Monomer v Vinyl Acetate Monomer (VAM) A

Regular Available in n B and Ex-Bhiwandi Bulk

Tel: 022-69059999 / 022-2 Te 25619999 Email: info@stellarexim.in n / siddharth@stellarexim.in Web: www.stellarexim.in |

5

Adi Metchem Privatee Limited t

PRODUCTS

RHODIUM

S LV SIL VER

l Bis(Benzonitrile Dichlorop palladium(II) l Dichlorobis(Acetonitrile)Palladium(II) a l Bis(Acetylacetonato)Palladium(II) palladium l Tris(Dibenzylidecetone)Dip

ack l Rhodium Bla l Rhodium(III)) Chloride l Rhodium Oc ctanoate Dimer l Rhodium (II)) Acetate, Dimer l Ammonium Hexachlororhodate(III) ( ) l Hydrido T Teetrrakis 1triphenylphosphine)

l Silver Metal Power l Silver(I)Chloride l Silver(I) Nitrate l Silver(I) Oxide l Silver(I) ( ) Iodide l Silver(I)Fluoride l Silver Bromide l Silver Acetate l Silver Carbonate l Silver Lactate

( ) (O)Chlorofor m l Bis(Triphenyl Phosphine) Dichloropalladium(II) l Palladium Acetate,Trimer Or O Palladous Acetate,Trimer l Diactatebis(Triphenyl Phos sphine) Palladium(II) l Dichloro-Bis(Triphenal Pho osphine) Ruthenium(II) GOLD l Gold Power l Gold(I) Chloride l Ammonium Tetrachloroau urate(III) l Hydrogen T Teetrachloroauraate (III) l Gold (I) Iodide

PLATINUM l Platinum Black l Platinum (IV) Oxide Adam’s s Catalyst l Chloroplatinic Acid Hydrog gen

Hexachloroplatinate (IV) Hydrate H l Ammonium Tetrachloropla atinate (II) l Dinitrodiammine Platinum (II)Platinum ‘P’ Salt l Platinum (IV) Chloride PA P ALLADIUM l Palladium Black l Palladium(II) Oxide l Palladium Chloride l Palladium (II) Nitrate Soluttion l Te Tetraamminepalladium Chhloride l Palladium Acetate,Trimer Or O Palladous

Acetate 6

Rhodium(I) RUTHENIU UM l Ruthenium Black B l Ruthenium (III) ( Chloride l Ammonium Chloror uthenate l Ruthenium(IV) Oxide Hydrated l Ruthenium(III)Acetate l Ruthenium Nitrosyl N Nitrate Solution S l Potassium Pentachloror ythenate l Ruthenium (IV) ( Oxide Anhydrous l Ruthenium Red Powder

IRIDIUM l Iridium Blackk l Iridium Chloride Hydrate l Iridium (IV) O Oxide l Carbonylchlo oridobis

(Triphenylphhosphane)Iridium(I) l Cycloocta-1,5-Diene)(Pyridine)

(Tricyclohexxylphosphane)Iridium(1+) Hexafluoridoophosphate(1 ) l Chlorobis(Cy yclooctene)Iridium(I) Dimer l Methoxy(Cyclooctadiene)Iridium(I) Dimer l 1,5-Cyclooc , y ctadiene-Iridium(I) ( ) Chloride Dimer

C COBAL LT T l Cobalt(III) Hydroxide l Cobalt(III) Nitrate l Cobalt(III) C Oxide O l Chloropentamminecobalt Chlo oride

N NICKEL l Nickel(II) Chloride l Nickel(II) Oxide , Nickel Monoxide ,

Oxonickel l Nickel Hydroxycarbonate l Nickel(II) Nitrate , Nickelous Nitrate N l Nickel(2+) Diacetate l Nickel(II) Hydroxide l Nickel Arsenide(II) l Nickel Antimonide l Nickel Arsenide l Raney Nickel l Nickel(II) Oxide l Nickel Sulphate/Solution

12-Samrat Ind. Area, Nrr.. Saatyanarayan Waay Bridge, Gondal Road, Rajkot (Gujarat) 360 004.

Jitendra Chauhan : 9328533777 Email: adimetchem@gmail.com l Web: www.adimetchem m.com

.$ . $1&+$1 5$6$<<$ $1 672&.,67 ,03257(56 2) &+(0,&$/6 62/ /9 9(176 (;&,3,(176

$87+25,=(' ',675,%8725 6,/,&21 ',2;,'( $(526,/ $(526,/ 3+$50$ $(526,/ 9 9 3+$50$ $(526,/ 3+$50$ $(523(5/ 3+$50$ $(526,/ 5 3+$50$

$87+25,=(' ',675,%8725 625%,72/ ,3 %3

$87+25 5,=(' 5(6(//(5 ,62 3523</ $/ /&2+2/ ,3$ 3$ ,3 %3 863 3

&$/&,80 6,/,&$7 $7( =(23+$50 =(23+$50 5;&,3,(176 )0

)$7 $77< $/&2+2/ *LQRO &HW\O $OFRKRO *LQRO 6WHDU\O $OFRKRO *LQRO 7$ 7$ &HWRVWHDU\O $OFRKRO *LQRO /DXU\O 0\ULVW\O $OFRKRO 685)$&7$ 7$176 $26 /LTXLG 3DVWH 3RZGHU 1HHGOH 6/6 /LTXLG 3DVWH 3RZGHU 1HHGOH 6/(6 /LTXLG 3DVWH )$7 $77< $&,'6 6WHDULF $FLG +\VWULF 'LVWULF 7H 7H[WULF 7H 7H[WULF [ 6SO /XEVWULF +\WLWUH /DXULF $FLG 0\ULVWLF $FLG 'LVWLOOHG &RFRQXW )DWW\ $FLG 5HJXODU 2OHLF $FLG /XEROLF ( 2OHLF $FLG /RSRXU (PXOVROLF (FR ,QGROLF 3XUH 2OHLF

$87+25,=(' ',675,%8725 0(7+</(1 1( &+/25,'( 0'&

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

$GGUHVV QG )ORRU =(67 %XVLQHVV 6SDFHV 1HDU 'RVKL 1XUVLQJ KRPH 0* 5RDG *KDWNRSDU ( 0XPEDL 7H 7 HO )D[ 0RE (PDLO NUDVD\DQ#JPDLO FRP :HE ZZZ NDQFKDQUDVD\DQ FRP

(08/6,)<,1* :$ :$;(6 *LQRO (: 1RQ ,RQLF *LQRO (: 6 $QLRQLF *LQRO (: 8QUHN 1RQ ,RQLF *LQRZD[ *LQRQLF &6$ &0 *LQRQLF &6$ *LQRQLF 6 6WHDUHWK *LQRQLF / /DXUHWK (67(56 *LQFRO ,33 ,VRSURS\O 3DOPLWDWH *LQFRO ,30 ,VRSURS\O 0\ULVWDWH *LQFRO &3 &HW\O 3DOPLWDWH *LQFRO 3(*'6 3(* GL VWHDUDWHH *LQFRO (*06 (WK\OHQH *O\FRO 0RQR 6WHDUDWH *LQFRO (*'6 (WK\OHQH *O\FRO 'L 6WHDUUDWH *LQFRO *06 6( *O\FHURO 0RQR 6WHDUDDWH *LQFRO (+3 (WK\O +H[\O 3DOPLWDWH

%/(1'6 *LQDPL[ &%7 *LQDPL[ &%3

/$%6$ $FLG 6OXUU\

7

8

9

+*)(*')*&'%*))$(&&#'"*%!!& !""(#%!!(!*""

(

0/.-,+*)).(,'&.%$#."! * ,+*)).( 0-#"- ", ".(,' *(.!

0-#"- ", ".(,' . $ ."!

0-#"- ", -(",&. $#,' )/-# ,+- ."!

0-#"- ", -(",&. $#,' . .#.,+- ."!

0 - #*), )(- ), ".( 0 - #*), )(- ), $ *$"

( . # (- , $ $)( #. -, $ ,' - - , . #! *(* -#,+- - , $ .-, (.., $ +*""/- ", $ - .#".(, $ $##- #,+-( , $ $##- #, .-%, $ ."-( ", $ (. . , $

( 0-%%( # 0 $ . , ( *#" 0 $ ., )(- )

( ( (%$%#"%! " #" ! " " # #" " " " #" ! " #" #"

10

( 0-#"- ", $ ,' #"$-# , %($ -# * )(- $-#! .)$ .(, $ ,' -$)$ , - - , #"$-#! ($ , $ ,' -$)$! .(-#$* , $ ,' #"$-# , /$#. . , )$-#!

-) / * $, $ ,' #" #. $- ,0* - . $, 0* )(-!

0* -#"- -#)($, $

11

MFG: ANIMAL, CAT TTLE, AQUA & P POULTR T Y FEED SUPP PLEMENTS / ADDIT TIVES MANUFAC TURING G SPECIALITY Choline Chloride 60%Cereaal Base Choline Chloride 60%Corn n Base Choline Chloride 50%Silica Base Choline Chloride 50%Corn Base Choline Chloride 75%Liquiid Choline Chloride 70%Liquid d Choline Chloride 60%Liquid d Choline Chloride 97-98%Pu ure Di-Calcium Phosphate (Dccp) Tri-Calcium Phosphate (Tcp) Monocalium Phosphate (M Mcp) Toxin Binder (Datox) Phytase 5000 u/Granularr/Powder Cocktail Enzymes Mono Sodium Phosphate Vitamin Premix

MINEERALS Hydrated d Lime P ecipit Pr i i ataed d Silic Sili a Bentonite Powder Quick Lim me Dolomite Powder Dextrosee Monohydrate Salt (Sodium Chloride) Table Salt Industriaal Salt Iodised Salt S Copper Sulpha S te Zinc Sulp phate Zinc Oxid de Ferrous SSulphate (Crysal/Powder) Cobalt Su ulphate

MANUFAC TURING G SPECIALITY Choline Chloride75/90/60 Liquid For Oil Driling

AG RO PRODUCTS Rice Ddgs Rice Bran Rice Bran Oil D Oil Ri De Rice B Bran Soyabeen Oil Rice Gluten Chickpeas Groundnut Meal Soyabeen Meal Co onseed Meal Rapeseed Meal Cocopit Powder Cereal Maize Maize Bran Powder Wheat Bran Powder Rice Flour Corn Flour Corn (Yelloow Maize) Soybean Meal Soya Protein Powder Soya Protein Isolate Broken Rice Wheat Grains

OTHER PRODUCTS Acidifier Formic Acid Bronopol Humic Acid Mono Sodium Glutante Magnesium Sulphate Manganese Sulphate Sodium Bi Carbonate Sodium Humate Sodium Perborate Sodium Percarbonate Calcium Propionate Calcium Carbonate Calcium Sulphate Calcium Chloride Di Amonium Phosphate Potassium Nitrate Potassium Chloride

VITTA AMINS Vitamin-A 1,00,000i.U Vitamin-E 50% Vitamin D 600/50,000 I.U Vitamin Ad3 1000/200 Vitamin-Ad2 Vitamin-A 98.5%Liquid

AMINO ACIDS

FISH MEAL POWDER

Dl-Methionine F.G.99% L-Lysine (Hcl) L-Theronine F.G.98.5% L-Tryptophan 98.5% Chlortetracycline 15% Tylosin Phosphate 10% Tiamulin Funerate 10%

Steam Sterilized Fish Meal Sun Dry Fish Meal Aquaculture Fish Meal 60+ Protein Fish Meal Powderr

ENZ YMES Phytase 5000 Granules Xylanase Alkaline Protease Beta Glucanase Cellulase Lipase Neutral Protease Pec nase Cocktail Enzyme Enzymes With Probio cs

DRY FISH F O R POULLTTR RY Dry Jawla Fish Bhel Kuta Mix Dry Fish Sun Dry Fish

SHRIMP MEAL POWD DER Shrimp Head Powder Steam Shrimp Meal Powder Shrimp Meal Powder Steam Jawla Fish Powder

FISH OIL

OTHER FISH PRODU UCTS Castor Meal Organic Manure Fish Manure Meat Bone Meal Bone Meal

FLAVOURS V & AROMA CHEMIC CALS AND OILS HERBAL POWDER RS CONTRACT MANUFACTURING CAN BE B DONE IF REQUIRED Contact Us: 101 Neelkanth Apartment, A F.p No. 284, Opp. Ram Maandir Extn. Road, Opp. Janki Mata Mandir, Vaazira N Naka, Borivali West, Mumbai, Maharashtra - 400091, India Mob: Harish S. Anandpara: A 91-9820048309 | Sagar H. H Anandpara: 91-9930160151 Email: harishanandparra@yahoo.in / sagaranandpara007@ @gmail.com / info@sdaproducts.com Web: www w .sdaproducts.in, www.indiamarrt.com/sdaproducts

12

13

0'.10 '&.)& 0 &/ 0 &* &.*3'&, 1 ' 0 )20.&, & 0*). ) * 0 ). ) * * ) *10 &, /0.08'& ')+&, / ') 0*&/&, / 2!9 *). ) , * ) *0 )' /&0 &, /&(0'. ) 2 )/&- /) . &/), .08'& ')+&, 0 ). ,0 )/&- &,0 * &/ '-.1 ,0+&, / 0,)0* ) ) 3 &, * ) *10 &, 2) ,0/&, 1 ' 8 &*0 &, 1 ' & ), - ) &* 0 ),0+)' . '' * $ 6 " 6 : 6 9 *). ) , ' 0 ,*&, ' *0 * 0* '0*0,). ) *

!" #$% &

' () *& &+&, ' () -'. &/ '). 0 &/ 1 ' ') 0*&/&, ')20.&, - &,0* *1'3 ) 0'0 &, *1'3. /,& )'), *13'. /,& )'), 0 *0* *). )')' - &,0* )2& ')20 &, 1 ' , &(&')' 1 ' ) . 0+)' . '' * 4%56 7%56 0 . 0+)' )/&- -.0*0/&, - 0 0* * .*) 3 &, -'.10* )/&- (0'. )0* *0 -') &, 1 ' * &,0 &, 1 ' *) 0 &*&,& &* 0* * 0(). ) * (0'. )& 0 &/ (&/08'&.*&, () *&)2 *&, 13/ ) ) &/

!"# $$ ! # " % # & ! " ! ' & "( ( % $ #"

14

MARU UTI PETROCHE EM ISO 9001:2015 cer fied

“We take pride in offering you, Only the BEST” ” SOL LV VENTS l

l

l

l

l

l

l l

l l

l l

l l

l l

l l

l

l

l

l l

l l

l l

“W We Access to Futuree” CHEMICAL L INTERMEDIA AT TES l

l

l

l l

l l

l l

l l

l l

l l

l l

l l

l l

l l

l l

SPECIALITY Y CHEMICALS l l

l l

l l

l

l

l

l

l

l

l l

l l

l l

l l

l l

l l

l

l

l

l l

l l

l

Authorised Distributor of Ethyl E Acetate for

Pure Ma aterial l No Shor rtage l Q i k Delivery Quick D li l

Head Office: 508-510, Goyal Trade Cente er, Opp. HDFC Bank Ltd., Shantivan, Borivali (E), Mumbai-400066 Warehouses: Silvassa, Bh hiwandi, V Va api, Nagpur, Indore, Haridwar, Guwahati

Contact: 9223250911 / 72 218742627 / 7715947888 / 9323150911 Email Id: marutipetroch hem@gmail.com, info@mlunias.com 15

16

ZZZ \DNVK SKDUPD FRP P

17

AT ROMINE DERIVATIVES BROMINE & BR

TALLYYST PHASEE TRANSFER CAATTA etra Butyl Ammonium Bromide (TBAB) Te T

Liquid Bromine (BR) 1-Bromo-3-chloroprropane (1,3 BCP) 4 % in water (HBR 48%) Hydrobromic Acid 48 l in Glacial acetic acid 3 Hydrobromic acid 33% l (HBR 33%) 6 % in water (HBR 62%) Hydrobromic Acid 62 l ( N-Propyl Bromide (NPBR) l NBBR) N-Butyl Bromide (N l Iso Propyl Bromide (IPBR) l de (EDBR) Ethylene Di Bromid l R) Ethyl Bromide (EBR l (NHBR) h B id / 1 Bromohexane Bromide lB H Hexyl l R) Allyl Bromide (ABR l BR) Pentyl Bromide (PB l de (NBS) N Bromosuccinimid l Hydantoin (DDH) D 1,3-Dibromo - 5, 5 Dimethyl l ane (1,3-DBP) 1,3- Dibromo Propa l 1, 4- Dibromo Butane (1,4-DBB) l owder / Sodium Bromide Sodium Bromide Po l BR) Solution 45% (NAB 52% (CABR 52%) S Calcium Bromide Solution l

l

l

l

Tri Ethyl Benzyl Ammonium Chloride (TEBAC)

l

etra Butyl Ammonium Hydrogen Sulphate (TBAHS) Te T

l

Ethyl Tri Phenyl Phosphonium Bromide (ETPPBR)

l

Cetrimide (CT)

l

Strong Cetrimide Solution (CT SOL)

l

Phenyl Tri Methyl Ammonium Chloride (PTMAC)

l

etra Butyl Ammonium Iodide (TBAI) Te T

l

Tetra Butyl Ammonium Hydroxide 40% Solution Te (TBAOH)

l

etra Ethyl Ammonium Bromide (TEAB) Te T

l

PAB) etra Propyl Ammonium Bromide (TPA Te T

l

Benzyl TriButyl Ammonium Chloride (BTBAC)

l

etra Butyl Ammonium Chloride (TBAC) Te T

l

Cetyl Pyridinium Chloride (CPC)

l

Benzalkonium chloride 50% (BKC 50% / 80%)

l

INTERMEDIAATES & SPECIALITY CHEMICCALS

M COMPOUNDS LITHIUM Lithium Hydroxide Monohydrate (LIOH)

2-Cyanoacetamide (CAD)

l

N, N- Diisoprropylethylamine (DIPEA)

l

l

owder / Lithium Bromide Solution Lithium Bromide Po date / Chromate base (LIBR) 55% (Plain / Molybd

l

Meta Bromo Nitro Benzene (MBNB)

l

owder / 40 % Solution Lithium Chloride Po (LICL) b (Plain / Chromate base)

l

Tri-n-Butyl Amine (TNBA)

l

( Lithium Carbonate (LC)

l

noacetate (MCA) Methyl Cyan

l

nhydrous (LS) Lithium Sulphate An

l

(CBB) B Cis -Bromo Benzoate

l

Lithium Nitrate (LN))

l

Tosylate (CTS) Cis To

l

Lithium Molybdate - Powder & Solution (LIMO)

l

2 -Amino - 3, 5- Dibromobenzaldehyde (ADBA)

l

A) Lithium Acetate (LA

l

A A) PA 2,2 - Dibromo - 3 – Nitrilopropionamide (DBNP

l

BROMO OTBN (B-OTBN)

Lithium Stearate (LIIS)

l

earate (LHS) Lithium Hydroxy Ste

l

l

d Pacifiic 0rganics Pvt Limited

g , N-4, Addl.. M.I.D.C., Anand Nagar Ambernatth (E) - 421 506, Dist. Thane, (MH), INDIA. T :0251-2621525 , 2620464, 2620415, Fax : 2620416 3224 67890, +91 93211 65565 M :+91 93

1:2015 ISO 14001:2015 & ISO 45001:2018 CERTIFIED COMPANYY 1:2015, ISO 9001

QM 003

EM 004

ul Rajpurohit / Mr. Chetan Satpute Mr. Rahu

OHSMS 001

CLICK TO DOWNLOAD PDF

m, info@paccificorganicsltd.com @pacificorganicsltd.com chetans@ acificorganicsltd.com rahulr@pa www.pacificorganicsltd.com

18

AGR ENTE ER PRISE E S is an Indiia baased d distriibu on n compaany estab liisheed in 1991 1 . Eve er sin ce our in cep o on , we e ar e p er fo ormin g con si sten tl y and o e erin g standard qu uality produ ucts to our clients.

We e h ave evol ved as on e of th e l eadin g supplier s of or ganic and in or ganic ch emical s caterin g to a number of dom es cc and in te ern a o on al clien tss. Th e comp an y curr en tlly ser ves clien tss acr oss br oad sp ec trrum of indu strries r an gin g fr om ph arm aceu ccal , agr och emical s, coa n n gs, p ain t,, d yes, prin n ng in k,, cosmee ccs, pl as cc & se ver al o th er indu strial ver ccal s.

PRODUCT ACETONE BENZENE ISOPROPYL ALCOHOL

MIX XYLENE PHENOL TOLUENE

1,2,3-TRICHLRO BENZENE 1,2,4-TRICHLORO BENZENE 2,3-DICHLORO NITROBENZENE 4-CHLRO BUTYRYL CHLORIDE ANILINE OIL CHLORINATED PARAFFIN CHLORO SULPHONIC ACID DASDA ISONOANOYL CHLORIDE META DICHLORO BENZENE 70% META NITRO CHLRO BENZENE META NITRO TOLUENE META TOLUDIDINE MONO CHLORO BENZENE

NITROBENZENE ORTHO DICHLORO BENZENE ORTHO NITRO CHLORO BENZENE ORTHO NITRO TOLUENE ORTHO TOLUDINE PARA NITRO CHLORO BENZENE PARA NITRO TOLUENE PARA TOLUDINE PIVALOYL CHLORIDE SODIUM NITRATE SODIUM NITRITE VALERYL CHLORIDE VINYL SULPHONE ESTER INDL. NITRO CELLULOSE

WE ARE OFFERING PRODUCTS DIRECTLY FROM MANUFACTURERS:

Chemieeorganiic Pvt. Lttd..

Steel Autthority of In ndia Lttd.

GRN Cellulose e P vt. L td.

Raashtriya Isspaat Nigam Ltd. Registered Office 1132 / 33, Hubtown Solaris, Prof NS Phadke Marg, Opp. Telli Galli Signal, Andheri (East), Mumbai – 400069

Ta a ta Stteel BSSL Lttd.

Jiindal Steel & P o we er L td.

Haaldia Peetrochemicals Lttd.

Deeepak Pheenooliics Ltd Tel: +91 22 6911 1111 (100 Lines) Email: sales@agr11.com Web: www.agr11.com Follow us:

19

20

21

22

ALKYL AMINES CHEMICALS LTD l Acetonitrile l Butyl Amines l Di Ethyl Amine (DEA) l Di Methyl Amine

(DMA) l Di Methyl Amine HCL l Mono Ethyl Amine 70% l Mono Isopropyl Amine

70% l Mono Methyl Amine

RCF

MANUFACTURERS OF ORGANIC HALIDES

l Ammonium Bi Carbonate

l 1,3 Dibromopropane l 1,4 Dibromobenzene l 1,4 Dibromobutane l 1,6 Dibromohexane l 2 Bromoethylbenzene l 2 Bromosuccinamide l 2 Bromo-4-fluroacetanilide l 2 Bromo-2-

(ABC) l Di Methyl Acetamide l Di Metyl Amine l Di Methyl Formamide l Formic Acid l Methanol l Mono Methyl Amine l Sodium Nitrate l Sodium Nitrite l Tri Methyl Amine

(MMA) l Tri Ethyl Amine (TEA) l Tri Methyl Amine (TMA) l 2 Ethyl Hexyl Amine (2

EHA) l Propyl Amines-Mono

And Di Propyl Amines l PMEDA l Triethyl Amine HCL l Ter ary Butyl Amines l Dimethylamino Propylamine (DMAPA) l DBU l DIPEA l DIPA

DIAMINES AND CHEMICALS LTD l Di Ethylene Tri Amines

(DETA) l Monoethanolamine (MEA) l Ethylene Diamine (EDA) l Piperazine 68% l Piperazine Anhydrous

SHREE SULPHURICS PVT LTD l Thionyl Chloride l Sulphur Dioxide l Sulfuryl Chloride l Sodium Sulphite l Sodium Meta bi sulphite

ADITYA BIRLA THAILAND l Di Sodium Phosphate l Mono Sodium Phosphate l Potassium Meta Bi

Sulphite l Sodium Acid Pyro

Phosphate l Sodium Hexa Meta

Phosphate l Sodium Meta Bi Sulphite l Sodium Sulphite l Sodium Tri Poly

Phosphate l Tri Sodium Phosphate

AAK KAMANI PRIVATE LIMITED l Soybean Oil l Linseed Oil l Corn Oil l Sunflower Oil l Coconut Oil l Hydrogenated Vegetable

l Sa ower Oil l High Oleic Sunflower Oil

(HOSO) l Soybean Lecithin l Medium Chain

Triglycerides USP (MCTOil)

Oil (HVO)

BROMIDE & CHLORIDE : l Allyl Bromide l Cyclohexyl Bromide l Cyclopentyl Bromide l Dectyl Bromide l Lithium Bromide l N-Hexyl Bromide l N- Octyl Bromide l Iso Propyl Bromide l N-Propyl Bromide l Sodium Bromide

l Pyridine Hydro Bromide

(PHBR) l HBR 33% in Ace c Acid l Bromo Benzene

methylpropionylbromide l 2 Bromo-4-fluoroaniline l 3 Bromonitrobenzene l 4 Bromoanisoe l 4 Fluoroanisole l Benzoylchloride l Benzylchloride l Bromoace c acid l Bromoacetonitrile l Bromobenzene

l Bromo OTBN l Cetylchloride l Ethyl,4-bromobutyrate l Ethylene dibromide l HBr 33% in ace c acid l Lauroylchloride l Meta Bromoaniline l Meta Bromoanisole l Methoxyacetylchloride l N-Butylchloride l N-Hexylchloride/bromide l N-Octylchloride/bromide l N-Pentylchloride/bromide l N-Propylbromide l Phenylacetyl chloride l Pivaloylchloride l Tert Butylbromoacetate l Valerylchloride

MANUFACTURERS OF INORGANIC HALIDES l Hydrobromicacid l Phosphorous oxychloride l Phosphorous pentachloride l Phosphorous trichloride

l Potassium bromide l Sulphuryl chloride l Thionyl chloride

PRODUCTS: l Ace c Acid l Acetyl Acetone l Adipic Acid l Alpha Methyl Styrene l Ascorbic Acid l Chloro Acetyl Chloride l Chloro Benzenes l Citric Acid l Cyclohexane l Decanol l Di Acetone Alcohol l Di Methyl Carbonate l Di Methyl Sulfoxide l Do Decanol l Ethyl Chloro Formate l Formic Acid (85/99%) l Heptane l Hexane l Hydrazine Hydrate 80% l Hydrogen Peroxide l Hydroxylamine Sulphate l Isobutanol l Isophorone l Isopropyl Alcohol l Lactose l Methoxy Acetyl Chloride. l Methyl Chloro Formate l Methyl Cyclo Hexane l Methyl Ethyl Ketone (MEK) l Methyl Iso Butyl Ketone

(MIBK)

l Methylene Di Chloride l Monoethylene Glycol (MEG) l Morpholine l N Hexanol l N Octanol l N Pentanol l N-Methyl-2-Pyrrolidone l Ortho Phenylene Diamine

(OPDA) l Phosphoric Acid 85% l Phosphorous Oxy Chloride l Phosphorous Pentachloride l Phosphorous Trichloride l Propionaldehyde l Propylene Glycol l Pyridine l Sodium Benzoate l Sodium Gluconate l Sodium Sulphide Yellow

Flakes l Sodium Thiocyanate l Sodium Tungstate l Solvent C-IX l Sulpholane l T G Urea l Ter ary Butanol l Tetra Hydro Furan l Tri Ethyl Ortho Formate l Tri Methyl Ortho Formate l Tri-N-Butyl Amine l Xanthun Gum

l Tert Butyl Bromoacetate l Chloroacetyl Chloride l N-Hexyl Chloride l Pivaloyl Chloride l N- Octyl Chloride

KRISHNA SOLVECHEM LTD. Corporate Office: B-503, Sahyog, S. V. Road, Kandivali (West), Mumbai – 400067. Maharashtra. INDIA. Tel: 9320529869 Email: marketing4@kscl.co.in l Web: www.kscl.co.in

23

24

PRODUCT LIST l Acebrophylline

l Desvenlafaxine Succinate

l Hydrochlorothiazide

l Nortriptyline Hcl

l Alprazolam

l Dex Rabeprazole Sodium

l Hydroxychloroquine Sul.

l Ofloxacin

l Amisulpride

l Dextromethorphan Hbr

l Hydroxyzine Hcl

l Olanzapine

l Amitriptyline

l Diazepam

l Indapamide

l Olmesartan Medoxamil

l Amlodipine Besylate

l Diclofenac Sodium

l Indion-204/234/214/244/254/

l Omeprazole Magnesium

l Amoxapine

l Dicyclomine Hcl

l Ondancentron Hcl / Base

l Aripiprazole In

l Diluted Nitro Glycerine [10%]

l Atorvastatin Calcium

l Diluted-Isosorbide-5

l Atropine Sulphate

Mononitrate [40/50/80%] l Domperidone Ip l Domperidone Maleate l Dothiepin Hcl l Doxofylline l Drotavarine l Duloxetine Hcl l Ebastine l Enalapril Maleate l Es-Citalopram Oxalate l Etizolam l Etodolac l Etoricoxib l Febuxostat l Fexofenadine Hcl l Flavoxate l Fluconazole l Flunarizine Di l Fluoxetine Hcl l Flupentixol Di Hcl l Fluvoxamine Maleate l Fusidic Acid l Gabapentine l Glibenclamide l Gliclazide Ip l Glimepiride l Glipizide l Haloperidol

294/414/454 l Iron Iii Polymaltos 34% l Ketoconazole l Ketorolac Trom [Tab / Inj l l Labetalol Hydrochloride l Lamotrigine l Levetiracetam l Levocetrazine Di Hcl l Levofloxacin Hemihydrate l Levosulpiride l Loratidine l Lorazepam l Lornoxicam l Losartan Potassium l Mebeverine Hcl l Melitracin Hcl l Mesalamine (Mesalazine) l Metaxalone l Metformin Hcl #100/80/60 l Methoxsalen l Methylcobalamine l Metoprolol Succinate l Metoprolol Tartrate l Minoxidil l Mirtazapine l Modafinil l Montelukast Sodium l Mosapride Citrate Dihydrate Ip l Nebivolol Hcl l Nitrazepam Ip

l Baclofen l Betahistine Di Hcl l Chlordiazepoxide l Chlorpromazine Hcl l Chlorthalidone l Cilnidipine l Cinnarizine Ip l Ciprofloxacin l Citalopram Hbr. l Citicoline Sodium Ip l Clidinium Bromide l Clobazam l Clomipramine Hcl l Clonazepam l Clopidogrel Bisulphate l Clozapine Ip l Cyproheptadine l Desloratadine

Health is Wealth

l Pantoprazole Sodium l Paroxetine Hcl l Phenobarbitone [Plain/Sod] l Pioglitazone Hcl l Pregabaline l Propranolol Hcl l Quetiapine Fumarate l Rabeprazole Sodium l Ramipril l Risperidone l Rosuvastatin Calcium l S-Amlodipine Besylate l Serratiopeptidase Granules l Tapentadol Ip l Telmisartan l Terbinafine Hcl l Terbutaline Sulphate l Thiocolchicoside l Tizanidine Hcl l Tolperisone Hcl l Topiramate l Tranexamic Acid l Trifluperazine Hcl l Trihexyphenidyl Hcl l Trioxsalen l Venlafaxine Hcl l Xylometazoline Hcl l Zolpidem Tartrate

765 FLY - EDGE, 808 - 8th FLOOR, OFF. S.V.ROAD, NEAR KORA KENDRA FLY OVER, BORIVALI - WEST, MUMBAI - 400092.

Tel.: 022-28019252, 28059252 l Mob.: 9869060346 / 9869825228 Email: logistics@aril-pharmaceuticals.com | Website: www.arilpharmaceuticals.com 25

ISO 9001:2015 & 14001:2015 Certified Company PHARMA DYES DAIRY BIO CHEMICAL FOOD

Manufacturer of Inorganic Chemicals

Product Names AMMONIUM ACETATE AMMONIUM CARBONATE AMMONIUM CHLORIDE AMMONIUM FORMATE AMMONIUM OXALATE AMMONIUM SULPHATE MONO AMMONIUM PHOSPHATE DI AMMONIUM PHOSPHATE CALCIUM ACETATE CALCIUM CHLORIDE 75%, 85%, 95% TRI CALCIUM PHOSPHATE FERRIC CHLORIDE HEDP ACID HEDP DI SODIUM HEDP TETRA SODIUM MAGNESIUM SULPHATE MANGANESE SULPHATE PHOSPHORIC ACID 85% POTASSIUM ACETATE POTASSIUM CHLORIDE POTASSIUM SULPHATE MONO POTASSIUM PHOSPHATE DI POTASSIUM PHOSPHATE TRI POTASSIUM PHOSPHATE SODIUM ACETATE SODIUM ACID PYRO PHOSPHATE SODIUM DIACETATE SODIUM HEXA META PHOSPHATE SODIUM META BI SULPHITE SODIUM OXALATE MONO SODIUM PHOSPHATE DISODIUM EDTA DI SODIUM PHOSPHATE TRI SODIUM PHOSPHATE SODIUM THIO SULPHATE (HYPO) SODIUM TRI POLY PHOSPHATE TETRA POTASSIUM PYRO PHOSPHATE TETRA SODIUM PYRO PHOSPHATE TETRA SODIUM EDTA ZINC ACETATE ZINC CHLORIDE ZINC SULPHATE ZINC SULPHATE-PHARMA GRADE

ELECTROPLATING LEATHER PAINT TEXTILE PAPER

Grades CRYSTAL PURE LUMPS TECHNICAL CRYSTAL CRYSTAL-MONOHYDRATE TECHNICAL TECHNICAL TECHNICAL ----FUSED / LUMPS ------40% SOLUTION 60% LIQUID 270-330 CV

-----POWDER / FLAKES PURE: 99% ----------PURE:99% PURE PURE:99% ANHYDROUS POWDER ANHYDROUS ANHYDROUS 90% POWDER 500-650 CV

HEPTAHYDRATE 32% MN FOOD GRADE -------TECHNICAL TECHNICAL TECHNICAL TECH. ANHYDROUS ------TRIHYDRATE ------CRYSTAL TECHNICAL TECHNICAL: 63% SO2 CRYSTAL MONOHYDRATE / DIHYDRATE ------DIHYDRATE DODECAHYDRATE PENTAHYDRATE TECHNICAL TECHNICAL TECHNICAL ------DIHYDRATE TECHNICAL: 80% HEPTAHYDRATE: 21% HEPTAHYDRATE: 22.6%

MONOHYDRATE ------ANHYDROUS PURE PURE PURE PURE ANHYDROUS ANHYDROUS ANHYDROUS PURE ANHYDROUS PURE (P205:68%) -----ANHYDROUS ANHYDROUS PURE ANHYDROUS ANHYDROUS ANHYDROUS PURE PURE ----PURE ANHYDROUS ANHYDROUS: 98% MONOHYDRATE: 33% MONOHYDRATE: 36%

1/3, Kandhari Colony, 2nd Road, Chembur (E), Mumbai - 400071, Maharashtra, India Phone: 9867252610 / 8655064852 / 8655002610 | Mobile: +91 90220330847, +91 9867252610 Email: sales@vinipul.com, enquiry@vinipul.com, umang@vinipul.com, vipul@vinipul.com Website: www.vinipul.com

26

27

28

0$18)$&785(5 2) ,%& +0 +'3( '5806 06 '5806

z 0(',80 z %8/. z +'3( 06 z ,%& WLJƌĂŵŝĚ W ŝĚ dĞ dĞĐŚŶŽƉůĂƐƚ Ś ů ƚ /ŶĚŝĂΖƐ / Ěŝ Ζ ŽŶĞ ŽĨĨ ƚŚĞ ƚŚ ůĞĂĚŝŶŐ ů Ěŝ ŵĂŶƵĨĂĐƚƵƌĞ Ĩ ƚ

ŽĨ ,DͲ, W ĚƌƵŵƐ ƌĂŶŐŝŶŐ ĨƌŽŵ ϮϬ ůƚƌ ƚŽ ϮϱϬ ůƚƌ ;/^K ϵϬϬϭ ŽŵƉĂŶLJͿ DĂŶƵĨĂĐƚƵƌŝŶŐ :ĞƌƌLJ ĐĂŶ͕ ^ƋƵĂƌĞ :ĞƌƌLJ ĐĂŶ͕ ZŽĐŬĞƚ dLJƉĞ͕ &Ƶů dŽƉ ƌƵŵƐ Θ ŽŶƚĂŝŶĞƌƐ͕ ZŽƵŶĚ ŽŶƚĂŝŶĞƌƐ͕ EĂƌƌŽǁ KƉĞŶ dŽ DŽƵƚŚ ƌƵŵƐ Θ ĂƌƌĞůƐ

ZK h /E' D/> ^d > ZZ >

DĂŶƵĨĂĐƚƵƌŝŶŐ ĨƌŽŵ ϭϬϬй ƉƌŝŵĞ ŐƌĂĚĞ ǀŝƌŐŝŶ ŵĂƚĞƌŝĂůͲĨŽŽĚ ŐƌĂĚĞ ,DͲ, W

ϭϬ >ŝƚĞƌƐ Θ Ϯϯϱ >ŝƚĞƌƐ ^ ĂƌƌĞů ŵĂŶƵĨĂĐƚƵƌĞĚ Žŵ ϭϴ ' ĂŶĚ ϮϬ '͕ ŽƐĞ ĂŶĚ ŽƉĞŶ ŵŽƵƚŚ ƉƉƌŽƉƌŝĂƚĞ ĨŽƌ ,ĂnjĂƌĚŽƵƐ EŽŶ ,Ănj ĐŚĞŵŝĐĂůƐ͕ ŽĚ ŝŶĚƵƐƚƌŝĞƐ͕ ů ŝŶĚƵƐƚƌLJ ĞƚĐ͘

/ŶͲŚŽƵƐĞ ůŽŐŝƐƟĐƐ ĨŽƌ ƟŵĞůLJ ĚĞůŝǀĞƌLJ ;ŽǁŶ ŇĞĞƚ ŽĨ ƚƌƵĐŬƐͿ ^ƚƌĂƚĞŐŝĐĂůůLJ ^ƚ ƚ ŝ ůů ůůŽĐĂƚĞĚ ƚ Ě D DƵůƟƉůĞ ůƟ ů tŽƌůĚ ůĂƐƐ DĂŶƵĨĂĐƚƵƌŝŶŐ &ĂĐŝůŝƟĞƐ

^ƉĞĐŝĂů ^ƚƌƵĐƚƵƌĞ &Žƌ ,ŝŐŚ WĞƌĨŽƌŵĂŶĐĞ

hE ĂƉƉƌŽǀĞĚ ĂŶĚ ĞdžƉŽƌƚ ǁŽƌƚŚLJ DĂŶƵĨĂĐƚƵƌŝŶŐ ŵŽƌĞ ƚŚĂŶ ϭ͕ϱϬ͕ϬϬϬ ƉĞƌ ŵŽŶƚŚ ĚƌƵŵƐ ŽĨ ϮϭϬͬϮϯϱ ůŝƚĞƌƐ ĐĂƉĂĐŝƚLJ

"

:+ : +< 86

&XVWRPHU &KRRVHQ DQG SUHIIH HUUHG 3\UDPLG PDNH RI ,%& PDQXIDFWXUHG RXW RI SULPH YLUJLQ PDWHULDO PDWFKLQJ LQWHUQDWLRQDO VSHFL¿FDWLRQ UREXVW LQ GHVLJQ ZLWK JOREDO FROOHFWLRQ DQG UHFRQGLWLRQLQJ VHUYLFHV

ͻ ƵƐƚŽŵŝnjĂƟŽŶ ͻ ƚŚŝĐĂů ƵƐŝŶĞƐƐ WŽůŝĐŝĞƐ ͻ džĐĞůůĞŶƚ YƵĂůŝƚLJ ͻ ƚŚŝĐĂů ƵƐŝŶĞƐƐ WŽůŝĐŝĞƐ ͻ WƌŽĚƵĐƚ ^ĞĐƵƌŝƚLJ ͻ WƌŽŵƉƚ ĞůŝǀĞƌLJ ͻ ^ƚĂŶĚĂƌĚ ĞƐŝŐŶ ͻ ^ƵƉƉůLJŝŶŐ ƵůŬ KƌĚĞƌƐ ͻ dĞĂŵ ŽĨ džƉĞƌƚƐ ͻ dƌƵƐƚͲǁŽƌƚŚLJ ͻ hE ƉƉƌŽǀĞĚ ͻ tŽƌůĚͲĐůĂƐƐ &ĂĐŝůŝƟĞƐ ͻ tŝĚĞ ZĂŶŐĞ ŽĨ WƌŽĚƵĐƚƐ

0IJ RI ,%& +0 +'3( 3ODVWLF 'UXPV 06 %DUUHOV

2I¿FH 1R QG )ORRU 6KDK 7UDGH &HQWUH 5DQL 6DWL 0DUJ 0DODG ( 0XPEDL 7HO z (PDLO \DVKEDUUHOV#S\UDPLGWHFKQRSODVW FRP z :HE ZZZ S\UDPLGWHFKQRSODVW FRP z )DFWRULHV 6LOYDVVD %KDUXFK

29

30

31

32

33

M Manuf acturer e s of Nut Nutr utraceuticals, Prese errvatives a and d Speciality Spe Chem micals www.preservativesindia.com We make Pr P eser s vativ ves that preserve your urr Reputa e tion Topical Ingredien e ts Allantoin Sallitoin n 2-Hydroxy Ethyl Salicylate / Glycol Salic cylate Salime li g EGMS EG GMS Trolamine Salicylate Salipharm TS Wintergreen Oil Methyl Salicylate Dimethyl Isosorbide Salibide DMI Climbazole Salizole Piroctone Olamine Salimine Capryloyl Salic cylic Acid Salicap CSA Sodium Ascorbyll Phosphate Salivite C-SAP

Anti Bacterial e s 2-Hydroxybenzzoic Acid Salicylic Acid Sodium Salicy ylate Salisod Chlorhexidine Gluconate 20% Sol. Salidine 20% Chlorhexidine Hydrochloride Salidine HCL

Excipients

Nutraceuticals Gluconates Zinc Gluconate Magnesium Gluconate Calcium Gluconate Lactates Zinc Lactate Magnesium Lactate Calcium Lactate Sodium Lactate Orotates

Sunscreens

Zinc Orotate Magnesium Orotate Calcium Orotate Citrates Zinc Citrate Magnesium Citrate Calcium Citrate Acetates Zinc Acetate Magnesium Acetate Calcium Acetate

Chlorhexidine Acetate Salidine ACT

Manganese Acetate

Phenoxyethanol Saliethanol li th l

Zi PCA Zinc

Undecylenic Acid Saliguard UA

Sodium PCA

5/44 TTa ardeo A/C Market, Ta Tardeo Main Road, Mumb bai - 400 034.

Email: sales@salicylates.net, corporate@salic a ylates.net TTe el.: +91-2 22-23514413 / +91-22-23513868 34

35

.(6+$9 +,&+(0 35,9$7( /,0,7(' ZZZ NHVKDYKLFKHP FRP

.(6+$9 %,2&+(0 35,9$7( /,0,7(' ZZZ NHVKDYELRFKHP FRP

6285&(6

352'8&76

0$1$/, 3(752&+(0,&$/6 /7'

3523</(1( */<&2/ 3* , 3 ))* 863 ', 3523</(1( */<&2/ '3* )5 7(&+

.$6<$3 6:((71(56 /7'

625%,72/ , 3 863 /,48,' */8&26( , 3 863

.2/,%$ 32/0/(. $6726$1

/$&726( 0(6+

+,&& /7' &+,1$

7&&$ *UDQXODU 7DEOHW 6',& *UDQXODU 7DEOHW

.816,/ 6,/,&21 ,1'8675< .25($

.816,/ )6 )80(' 6,/,&$

0'. &+(0,&$/6 397 /7'

.25.(0 ,3 863 )80(' 6,/,&$

+8$/,1* ,1'8675< +. &203$1< &+,1$

+86,/ &2//2,'$/ 6,/,&21 ',2;,'(

0'. &+(07(; 397 /7'

0'. &2//2,'$/ 6,/,&21 ',2;,'(

352'8&76 /,67 &,75,& $&,' 0212+<'5$7( $1+<'5286

5(),1(' */<&(5,1(

0$/(,& $1+<'5,'(

;$17+$1 *80 0(6+

3523</(1( */<&2/ &+,1$

3 ( *

,62 3523</ $/&2+2/ ,3$

&$/&,80 */8&21$7( , 3 7(&+1,&$/

62',80 &,75$7( ,3 863 %3

:+(< 3527(,1 &21&(175$7( ,167$17

%521232/

62',80 &$5%2;<0(7+</ &(//8/26( &0&

&217$&7

1DUHQGUD .RWKDUL _ (PDLO PXPEDL#NHVKDYKLFKHP FRP 0DGKDY .RWKDUL _ (PDLO PDGKDY#NHVKDYELRFKHP FRP $UXQ 0RKDWD _ (PDLO DUXQ#NHVKDYKLFKHP FRP

36

080%$, $ :LQJ 0LWWDO &RPPHUFLD 2)) 0 9 5RDG 0DURO $QGKHUL (DVW 0XPEDL 7HO /LQHV

1(: '(/+, 5J 7UDGH 7RZHU % 1HWDML 6XEKDVK 3ODFH 3LWDPSXUD 1HZ 'HOKL ± LQGLD

+$5,':$5 8775$.+$1' (DVW *XUXED[ 9LKDU 'DNVK 5RDG -DJLWSXU .DQNKDO +DULGZDU 8WWDUNKDQG

%$'', +,0$&+$/ 35$'(6+ .KDVUD 1R 9LOODJH ±0DONXPDMUD %DGGL + 3

0'. &+(0,&$/6 397 /7' &KHPLFDO 3ODQW ' FK 'DKHM ,QGXVWULDO $UHD 3KDVH 'DKHM 'LVW %KDUXFK *XMDUDW

7(*$1 7(;2)$% 397 /7' 7HFKQLFDO 7H[WLOH 3ODQW %ORFN 1R 9LOO ± 3LSRGDUD 7DO±PDQJURO 1HDU .LP &KRNGL 2SS ,RFO 3HWURO 3XPS 6XDUW *XMDUW

$SUD ,QQRYDWLYH 3YW /WG ´6SHFLDOL]LQJ LQ WKH DFWLYLW\ RI ,PSRUW 0DUNHWLQJ DQG 'LVWULEXWLRQV RI &KHPL FDOV ZLWK D FHQWUDOO\ ORFDWHG RIÀFH LQ 0XPEDL DQG FRQYHQLHQWO\ ORFDWHG ZDUHKRXVHV LQ %KLZDQGL $QNOHVKZDU 6XUDW &DWHULQJ WR UHTXLUHPHQWV DFURVV LQGXVWULHV ZLWK FXVWRPHU IRFXV DV D VLQJOH PLQGHG REMHFWLYH WKDW LQ VXUHV \RX

JHW WKH EHVW SRVVLEOH FRPPHUFLDO VHUYLFHV µ

,QGXVWULHV ZH FDWHU 3DLQWV 5HVLQV 3KDUPDFHXWLFDOV $JUR &KHPLFDOV ,QVHFWLFLGHV 3HVWLFLGHV (PXOVLRQV

2UJDQLF ,QRUJDQLF &KHPLFDOV /HDWKHU 7H[WLOH ,QGXVWU\ 3ULQWLQJ 3DFNDJLQJ )RXQGDU\ &KHPLFDOV

³$9$,/$%/( 5(*8/$5/< $7 &203(7,7,9( 35,&(6 ,1 %8/.

7$1.(5 /2$' ,17$&7 '5806 &$5%28<6

35,1&,3$/6 6833/,(56 *RGDYDUL %LRUH¿QHULHV /WG (WK\O $FHWDWH $FHWDOGHK\GH

5&) /WG 0HWKDQRO 00$ '0) )RUPLF $FLG

*1)& /WG $FHWLF $FLG *ODFLDO 0HWK\O )RUPDWH )RUPLF $FLG (WK\O $FHWDWH 7HFKQLFDO *UDGH 8UHD 7*8

352'8&76 ,03257(' ',675,%87(' $520$7,&6 $FHWRQLWULOH 7ROXHQH 0L[HG ;\OHQH 2UWKR ;\OHQH

(67(56 (WK\O $FHWDWH %XW\O $FHWDWH 0HWK\O )RUPDWH

.(721( '(5,9$7,9(6 $/,3+$7,&6 $FHWRQH 0HWK\O (WK\O .HWRQH 0HWK\O ,VR %XW\O .HWRQH &\FORKH[DQRQH &\FORKH[DQH 1RUPDO +H[DQH &+/25,1$7(' 62/9(176 (WK\OHQH 'L &KORULGH 0HWK\OHQH 'L &KORULGH

$&,'6 $/&2+2/6 $1' (7+(56 $FHWLF $FLG *ODFLDO )RUPLF $FLG 'L 0HWK\O )RUPDPLGH '0) (WK\O $OFRKRO 0HWKDQRO 1 %XWDQRO (WK\O +H[DQRO 3KHQRO ,VR 3URS\O $OFRKRO 'L ,VR 3URS\O (WKHU 'L $FHWRQH $OFRKRO 7HUWLDU\ %XWDQRO 1 +HSWDQH )RUPLF $FLG

02120(56 6W\UHQH 0RQRPHU 9LQ\O $FHWDWH 0RQRPHU %XW\O $FU\ODWH 0RQRPHU (WK\O $FU\ODWH 0RQRPHU 0HWK\O 0HWKD $FU\ODWH */<&2/6 'L (WK\O *O\FRO 0RQR (WK\O $OFRKRO %XW\O &HOORVROYH (WK\O &HOORVROYH %XW\O &HOORVROYH $FHWDWH

&RUUHVSRQGLQJ $GGUHVV WK )ORRU 'DODPDO +RXVH -DPQDODO %DMDM 5RDG 1DULPDQ 3RLQW 0XPEDL ,QGLD

5HJLVWHUHG $GGUHVV 6DL &KDPEHUV QG )ORRU 1DUVKL 1DWKD 6WUHHW .DWKD %D]DU 0XPEDL ,QGLD 7HO Z (PDLO LQIR#DSUDLQQRYDWLYH LQ

:DUHKRXVH $GGUHVV 3ORW 1R $\\DSSD ,QGXVWULDO (VWDWH 3DQGHVDUD 6XUDW *XMDUDW ,QGLD

$1,/ %$-$5,$

'LUHFW (PDLO DQLO#DSUDLQQRYDWLYH LQ

9,5$- %$-$5,$ 'LUHFW (PDLO YLUDM#DSUDLQQRYDWLYH LQ &+,5$* %$-$5,$ 'LUHFW (PDLO FKLUDJ#DSUDLQQRYDWLYH LQ :( +$9( 12 $5*80(17 :,7+ &203(7,7256 :+2 &+$5*( /(66 7+(< 5($/,=( :+$7 7+(,5 352'8&7 6(59,&( ,6 :257+

37

Add: F-24, Sez Phase-1, Lal Gate, sector 3, Pithampur Dist. - Dhar (454774), MP, India.

Mobile: 9754731000 | Eamail: jasmina@balajisnh.com

Manufacturer of: v Dexamethasone v Dexamethasone Sodium Phosphate v Betamethasone Sodium Phosphate v Betamethasone Dipropionate v Betamethasone Valerate v Beclometasone Dipropionate v Budesonide v Clobetasol Propionate v Hydrocor sone Acetate v Hydrocor sone Hemisuccinate

38

v Prednisolone Acetate v Mometasone Fuorate v Methylprednisolone v Methylprednisolone Acetate v Methylprednisolone Hemisuccinate v Triamcinolone Acetonide v Triamcinolone VITAMINS v Methylcobalamin v Hydroxycobalamin

MARUTI INDUSTRIES Manufacturer of Active Pharma Ingredients (APIs)

ISO 9001 : 2015 Approved Company

GMP Certified Company Registered Address : Plot No. 1032/4. Phase - II, GIDC Panoli, Dist. Bhar uch, Gujarat - 394116 M. : 91-9712575758 | Email : sales@mar utiindustries.in

Active Pharma Ingredients (APIs) Meglumine (N-Methyl-D-Glucamine)

D-Threo-Ritalinic Acid

Flupir tine Maleate

Rivaroxaban

Etoricoxib

Pregabalin

Ritalinic acid

Nebivolol Hydrochloride

Amlodipine

Advance Bulk Drug Ingredients Dibenzo[b,f][1,4] Thiazepine-11(10H)-one

4-(4-aminophenyl) morpholin-3-one

2-Methoxy-5-Sulfamoyl Methyl Benzoate

2-[(2S)-oxiran-2-ylmethyl]-1H-isoindole-1,3(2H)-dione

2-Methyl-10H-thieno [2,3-b][1,5] benzodiazepine-4amine Hydrochloride

(3aR,4S,7R,7aS)-rel-Hexahydro-4,7-methano-1H-isoindole1,3(2H)-dione

2-Amino-5-methylthiophene-3-carbonitrile

P-Toluenesulfonylurea

We are well experienced & specialized in carr ying out “HYDROGENATION” of speciality & pharma product by using all types of Catalyst (Raney Ni, Pd/C, Pt/C, RH etc)

39

• EXPORTERS • IMPORTERS • MANUFACTURERS • STOCKISTS CHEMICALS • BOROSIL / RIVIERA GLASSWARES • SCIENTIFIC INSTRUMENTS • SARTORIUS /PALL / MILLIPORE MAMBRANE FILTERS • PHARMA RAW MATERIAL • WHATMAN FILTER PAPERS • HPLC SOLVENTS / COLUMNS. Authorised Stockists: METALAB / SHANTI SCI. INDUSTSRIES • JAYANT / SHITAL SCL. INSTRUMENTS • THOMAS BAKER CHEMICALS LTD. • SHIMADZU BALANCES • 3 M SOLUTIONS • MAHEK INDUSTRIES Dealers / Stockists : SDFCL• MERCK • RANBAXY • QUALIGENS • ACROSS • LANCASTER • WHATMAN • HIMEDIA We Stock & Supply : Chemicals and Bio- Chemicals for Research and Industry Manufactured by Merck (Germany ), BDH (UK), Sigma (USA) , Aldrich (USA), Difco & Oxoid Culture Media , Lancaster (UK), ICN (USA).

Chemicals : Glaxo , E-merck, BDH, SRL -SD's , Ranbaxy, Loba - Chemie Spectrochem, Hi - Media.

Sartorius (German) / Pall (UK) / Millipore Membrane Filter Papers, Prefilteres and Filtration Assemblies, Filter Pads, all sizes with or without hole as per required sized, Filter Cartridges.

Whatman Filter Papers, Thimbles, Chromatography Sheets and Glass Microfibre Filters for Enviornment and Pollution Control Testing. Laboratory Sealing & Parafilm.

SARTORIUS BOROSIL WATER

ESTD.1979

PALL REMI HYPERSIL

MILLIPORE TEMPO ZORABAX

WHATMAN METALAB J&W

TLC/ HPTLC / Gas Chromatography Equipments and Spares, GC/ HPLC Grade Chemicals, Phases, Supports, Columns etc.

Top/Hamilton (USA), SGE, Micro Syrings Reference Standards.

Pharmaceutical Raw Materials, Solvents ( Bulk & Small Packing).

Precoated TLC, Plates Merck (Germany) for TLC/HPTLC. Certified Reference Material (Standards). Ethanol for UV & HPLC /AR 99.95% China /Hayman (UK) & Merck (Germany) Borosil / Riviera Glasswares, Glass Assemblies upto 200 Ltr. Hydrometers, Hygrometers Silicawares, Proceleinwares, Tefton items, Tarson Plasticwares, Thermometers. (with certificate for ISO 9000) Scientrific Instruments of Imported and Reputed Indian make, Quartiz Cells, Refractometers.

SHIMADZU DHONA H. P.

VITROSIL PATHAK SGE

ZEAL TOP COLUMNS

ERMA LABOMED HAMILTON

KIRAN TRADERS

14/A, DEVKARAN MANSION COMPOUND, PATHAKWADI, PRINCESS STREET, MUMBAI - 400 002.

TEL .: 022-2201 4039 / 022-4011 3132, MOBILE: +91 8082191974, EMAIL: kirantraders1979@gmail.com

List Of APIs ANTIHISTAMINE Bilastine Fexofenadine HCL ANTI-RESPIRATORY DISORDER Bromehexine HCL Ambroxol HCL ANAESTHETIC Benzocoine Lidocaine ANTI INFLAMMATORY Mesalazine Meloxicam Etoricoxib ANTI HYPERTENSION Metoprolol Succinate Amlodipine Besylate Prazosin

List Of Intermediates ANTICOAGULANT Apixaban ANTI FUNGAL Fluconazole Voriconazole Sertaconazole TREAT HIGH CHOLESTERO; / HEART FAILURE Fenofibrate Chlorthalidone ANTIDIABETIC Sitagliptin Phosphate PAIN MEDICATION Ketoprofen VITAMINS P-Amino Benzoic Acid LAXATIVE Docusate Sodium

Name Of Intermediate Meta Bromo Benzaldehyde Meta Phenoxy Benzaldehye Tetra Butyal Ammonium Bromide Trifluoroacetic Acid Isopropyl Easter 2,3-Diamino Pyridine 3-Bromo-N,N-Dimethylaniline Isonipecotic Acid Methyl Isonecotate Azacyclonal Meta Bromo Nitro Benzene Benzyl Phylephrine Hydrochloride Meta Phenoxybenzyl Alcohol 2-Amino-3,5-Dibromobenzaldehyde Ethyl Benzoate Acetyl Hydrate Benzhydrol 4-Hydroxycomarins 2,3 Lutidine 3,5 Lutidine Meta Bromo Anisole Meta Bromo Phenol

CAS No. 3131-99-8 39515-51-0 1643-19-2 400-38-4 452-58-4 16518-62-0 498-94-2 2971-79-1 115-46-8 585-79-5 71786-67-9 13826-35-2 50910-55-9 93-89-0 1068-57-1 91-01-0 1076-38-6 583-61-9 591-22-0 2398-37-0 591-20-8

Name Of Intermediate Meta Bromo Aniline Meta Anisidine Meta Amino Benzoic Acid Mannich HCL 2-(4-(4-(4-(Hydroxydiphenyl methyl)-1-Piperidine)-1Oxobutyl) Phenyl)-2,2-Dimethyl acetic Acid Methyl Easter Methyl2-(4-(4-ChlorobutNOYL) Phenyl)-2-Methylpropionoate Alpha, Alpha Dimethyl Phenyl Acetic Acid 4-(Cyclopropyl-Oxo-Methyl) – Alpha, Alpha Dimethylphenyl acetic Acid 3-(Trifluoromethyl)-5,6,7,8Tetrahydro-[1,2,4]Triazolo [4,3-A] Pyrazine HCL BOC-®-3-Amino-4-(2,4,5Trifluoro-Phenyl)-Butyric Acid 4-Bromobenzyl Alcohol 4-Bromobenzaldehyde 2-Piperidin-4-YL-1HBezoimidazol 2-Ethoxyethyl-4-Methyl benzenesulfonate 4,5-Dihydrooxazole Bilastine

CAS No. 591-19-5 536-90-03 99-05-8 42036-65-7

154477-55-1 154477-54-0 826-55-1 162096-54-0 762240-92-6 486460-00-8 873-75-6 1122-91-4 38385-95-4 17178-11-9 202189-77-3

Plot No. 1101, G.I.D.C., Ankleshwar, Bharuch, Gujarat – 393002, India. | Mob: +91 94285 11112 Website: www.suryalifesciences.com | Email: shikha@suryalifesciences.com, marke ng@suryalifesciences.com

40

Mr. Kamlesh Doshi

9325352677 9222241417 PRODUCT LIST

: DEALERS IN : PHARMACEUTICALS RAW MATERIALS, VITAMINS, FINE CHEMICALS, SOLVENTS, ESSENTIAL OIL & FOOD COLOURS

PARSHWA PHARMA CHEM

IS A CONVENIENCE STORE / SOLUTION FOR ALL API / CHEMICAL / BULK DRUG / SOLVENT’S REQUIREMENTS

WE CAN PROVIDE ANY TIME ANY QUALITY ( SMALL / BIG ) OTHER THEN ABOVE AS PER YOUR VALUABLE REQUIREMENTS.

l ACCECLOFENAC l ALBENDAZOLE l ALLOPURINOL l AMBROXOL HCL l ATOMOXETANE HCL l BROMHEXINE HCL l CLOTRIMAZOLE l CIPROFLOXACIN HCL l CHLOROQUINE PHOSPHATE l CHLORZOXAZONE l CROSS CARMILOSE SODIUM l CLOBETASOLE l DICLOFENAC POTASSIUM l DICLOFENAC SODIUM l DICYCLOMINE HCL l DROTAVERINE HCL l DMR l DEFLAZACORT l DOMPERIDON l ERYTHROYCIN STERATE l ENROFLOXACIN l FERROUS ASCORBATE l FERROUS ASCORBATE DC GRADE l FOLIC ACID l FLUCONAZOLE l GLYCERINE l GLIMIPRIDE l GRISOFULVIN l IPA

l IVERMECTINE l KETOCONAZOLE l LACTOSE l LEVOCETRIZINE HCL l LISINOPRIL l L-LYSIN l LORATIDINE l MCCP l METHYL COBALAMINE l METHYL FOLATE CALCIUM l METFORMIN HCL l METRONIDAZOLE l MAIZ STARCH POWDER l NIACINAMIDE l NIMUSULIIDE l ORNIDAZOLE l OFLOXACIN l PARACETAMOL l PENTOPRAZOLE SODIUM l POVIDON IODIN l PROGESTERONE l PREGABALIN l SUCRALFATE l THIAMINE HCL l TERBUTALINE SULPHATE l TRIFLUPERAZINE HCL l TRANEXAMIC ACID l VITAMIN A ACETATE

Chlorzoxazone USP- Samarth l Serra opep dase- Enzyme

Registered Add: A/06, Shivshakti Apt., Sangeetawadi, Shiv-Mandir Road, Dombivli (E), Thane-421201, Maharashtra Office Add: Office No. 220, Commerce Plaza, Near Godrej Showroom, Manpada Road, Dombivli (E) - 421201., Thane-421201, Maharashtra

Office: 7900001075 / 9323613209 | Email: doshikamlesh84@gmail.com

41

AD Pharma a ch h em m P vt Lttd (ISO 9001:2015 & 14001:2015 Certified Company)

API / Agro Intermediates & Fine Chemicals

Cas No.

N-Bromo Succinimide (NBS) N-Butyl Bromide (NBB) Tetra Butyl Ammonium Bromide (TBAB) Tetra Butyl Ammonium Hydrogen Sulphate (TBAHS) Tetra Butyl Ammonium Iodide (TBAI) Tri Ethyl Benzyl Ammonium Chloride (TEBAC) Phenyl Tri Methyl Ammonium Chloride (PTMAC) 4-Bromomethyl-2-Cyanobiphenyl (Bromo OTBN) Ethyl Tri Phenyl Phosphonium Bromide (ETPPBr) Methyl Tri Phenyl Phosphonium Bromide (MTPPBr) Iso Propyl 2-Bromo Iso Butyrate (IPBIB) Di Ethyl Bromo Malonate (DEBM)

128-08-5 109-65-9 1643-19-2 32503-27-8 311-28-4 56-37-1 138-24-9 114772-54-2 1530-32-1 1779-49-3 51368-55-9 685-87-0

Contact Manufacturer

42

Unit 1 : G-39/9, MIDC, Waluj, Aurangabad - 431136, Maharashtra Unit 2 : A-86 MIDC, Paithan, Aurangabad - 431107 Maharashtra Mobile : +91 9326149185 l Email : adpharmachem@gmail.com

PRODUCT

PKG.

MAKE

PRODUCT

PKG.

MAKE

Acesulfame k FCCV Alpha Lipoic Acid Ascorbic Acid (Vitamin C Plain) Aspartame 20 / 60 / 100 / 300 Mesh / Granuler Azithromycin Caffine Anhydrous Ciprofloxacin Cyanocobalamin (Vit B12) D-Calcium Pantothenate DL-Alpha Tocopherol Doxycycline Hcl DryVitamin A-Acetate 500 CWS DryVitamin A-Acetate 325 CWS Dry Vitamin D3 100 GFP FOS L55 FOS L55+ FOS L95 FOS P95 Griseofulvin

25kg 25kg 25kg 25kg

Anhui Jinhe Tohope Shandong Luwei / CSPC Sinosweet / G. Sweet

Levamisole Hcl Levofloxacin Hemihydrate

25Kg 25Kg

25lg 25kg 25kg 100Gms/1Kg 20/25Kg 5Kg 25 Kg 1Kg 25Kg 25Kg 25Kg 25Kg 25Kg 20Kg 20Kg

Dongfeng / Guobang Cspc Aarti Kingvit / Hebei Huarong BASF BASF Hebei Dongfeng Piramal BASF BASF Tata Chemical Tata Chemical Tata Chemical Tata Chemical Inner Mongolia

Lucarotin 30 M Mannitol Mannitol (Perlitol 200 SD) Metronidazole Metronidazole Benzoate Neomycin Sulphate Neotame Oxytetracycline Hcl PVPK Tech Grade PVPK 30 Pyridoxine (B6) Riboflavin (B2) Sucralose Sucralfate Vitamin A – Palmitate 1.7 MIU Vitamin E Acetate 98% Vitamin D2

5Kg 25Kg 25Kg 25Kg 25Kg 1/20bou 1Kg 25Kg 25Kg 25 Kg 25Kg 10Kg 1/10/25Kg 25Kg 5Kg 5Kg / 25Kg 50GMS

Guilin Shanghyu Jingxin / East Asia BASF Qingdo Brigtmoon Roquette Huanggang Hubei Hongyuan Yichang Sanxia Wuhan Hebei Shengxui BOAI NKY BOAI NKY Jianxi Tianxin BASF Kanbo / Jubang Zhejiang Haisen BASF BASF Jiangxi Gannan

We offe er Fructo-oligosaccharides

P 95

1X 20

Fructo-oligosaccharides

L55+

1 X 25

Fructo-oligosaccharides

L55

1 X 25

Fructo-oligosaccharides

L 95

1 X 25

G-2 Om Mayureshwar Co-Op. Housing Society Limited, L. T. Road, Dharamdas Marg, Babhai Naka, Opp. Dwara Hotel, Borivali (West), Mumbai - 400 092. Tel. No.: 8655448030 | Email: novachemie1@gmail.com

NEW BRANCH AT

BARODA

API PRODUCT LIST l Amoxicillin Sodium Sterile l Aceclofenac l Albendazole l Alpha Beta Arteether l Ambroxol Hcl l Amlodipine Besilate l Ampicillin Plain/Comp/Sterile l Artemether l Artesunate ( Oral & Injectable ) l Azithromycin Dihydrate l Beclomethasone Dipropionate l Betamethasone Di Propionate l Betamethasone Sodium Phosphate l Betamethasone Valerate l Brinzolamide l Bupropion Hcl l Caffeine Anhydrous l Carisoprodol l Cefixime Trihydrate Compoacted l Cefalexin Compacted l Cefadroxil l Cefpodoxime Proxetil l Ceftriaxone Sodium Sterile l Cefoperazone Sodium Sterile l Celecoxib l Cetirizine Dihydrochloride

l Chlorzoxazone l Chymotrypsin l Ciprofloxacin Salts l Citicoline Sodium l Clarithromycin l Clobetasol Propionate l Clopidogrel Bisulphate l Cloxacillin Plain/Comp/Sterile l Colloidal Silicon Dioxide l Dapoxetine Hcl l Deflazacort l Dexamethasone Sodium Phosphate l Dextromethorphan Hbr l Diclofenac Salts l Dicloxacillin Sodium Sterile l Dicyclomine Hcl l Diethyl Carbamazine Citrate l Di Dihydro Artemesinin l Diloxanide Furoate l Dimenhydrinate l Diphenhydramine Hcl/Base l Doxophylline l Enrofloxacin l Erythromycin Estolate l Erythromycin Ethyl Succinate l Erythromycin Stearate l Esomeprazole Mg. Trihydrate

l Etoricoxib l Febuxostat l Fenbendazole l Fenofibrate l Ferrous Ascorbate/Dc Grade l Finasteride l Flucinolone Salts l Fluconazole l Fluticasone Propionate l Folic Acid l Furosemide l Glimepiride l Glucosamine Hcl l Glucosamine Sulphate Potassium Chloride. l Glucosamine Sulphate Sodiumchloride. l Hydrocortisone Salts l Irbesartan l Ketoconazole l Levetiracetam l Levocetirizine Hcl l Levofloxacin Hemihydrate l Levosulpiride l Lornoxicam l Luliconazol l Lumefantrine l Mefenamic Acid

l Meropenem Sterile l Mesalamine l Metformin Hcl l Methyl Prednisolone Acetate l Methylcobalamin l Metoclopramide Hcl l Metoprolol Succinate l Metoprolol Tartrate l Metronidazole Salts l Miconazole Nitrate l Mometasone Furoate l Montelukast Sodium l Moxifloxacin l Niacin l Niacinamide l Nimesulide l Nitazoxanide l Norfloxacin l Ofloxacin l Olmesartan Medoxomil l Ondansetron Hydrochloride l Ornidazole l Pancreatin l Paracetamol l Phenazone l Phenytoin Base/Sodium l Picosulfate Sodium l Pioglitazone Hcl

l Pipercillin + Tazobactum Sodium Sterile (8:1) l Praziquantel l Pregabalin l Propyl Gallate l Quinine Salts l Risperidone l Rosuvastatin Calcium l Roxythromycin l Secnidazole l Serratiopeptidase Plain /Coated l Silver Sulfadiazine l Sulbactum Sodium Sterile l Tamsulosin Hcl l Tapentadol l Telmisartan l Teneligliptin Hbr l Tetracycline Hcl l Tolnaftate l Tolfenamic Acid ( Oral & Injectable ) l Tricholine Citrate l Trypsin l Vildagliptin l Vitamin B1 Hcl / Mono l Vitamin B12 (Cyanocobalamin) l Vitamin B2 (Riboflavin) l Vitamin B2 5 Phosphate l Vitamin B6 (Pyridoxol 5 Phosphate) l Vitamin C ( Plain & Coated )

Note : All Products Available in IP / BP / EP / USP / JP Forms.

43

SADHANA ENTERPRISES Dealers And Importers In Pharmaceuticals Raw Material, Chemicals & Solvents Product List Aceclofenac Ip Albendazole Ip Ambroxol Hcl Ip Amisulpride Ip Benfothiamine Ih Benzocaine Ip Betahis n Di Hcl Ip Bromohexine Hcl Ip Bupropion Hcl Ip Chlorphenramine Maleate Ip Chlororomazine Ip Chromium Picolinate Usp Dapoxi n Hcl Ip Dextromethorphen Hbr Ip Diacerene Ip

Diclofenac Diethylamine Ip Dycylomine Hcl Ip Diethylcarbamazine Citrate Ip Dil azem Hcl Ip Divalporex Sodium Ip Domperidon Bp Dutestride E zolam Jp Fluconazole Ip/Usp Flu casone Di Propionate Ip Folic Acid Ip Furazolidone Ip Gliclazide Ip Glimipride Ip Hyosin Butyl Bromide Ip

Irbesertan Usp Ima nib Mesylate Ivermec n Ip Levosalbutamol Sulphate Ip Levosulpride Ihs Lornoxicam Ih Methylcobalamin Ip Meman ne Hcl Metronidazole Ip Metronidazole Benzoate Ip Minoxidil Ip Mitrazipine Ip Mupirosin Usp Mupirosin Ip Naproxen Usp

Niacinamide Ip/Bp Ondensetron Hcl Ip Pantaprazole Sodium Ip Phenylephrine Hcl Ip Pregabalin Ip Procyclidine Hcl Ip Silver Sulphadiazine Usp Sulphacetamide Sodium Ip Sodium Valporate Ip Tadalafil Ip Tamsulosin Hcl Ip Trihexyphenidyl Hcl Ip Ursodeoxicholic Acid Ip Valporic Acid Ip Vitamin A Acetate Ip Voglibose Ip

Add: J-47/602, Poonam Sagar Complex, Near Allahabad Bank, Miraroad (E), Thane - 401 107, Maharashtra (India) Tel.: 022-28100190 / 28100191 | Email: sadhanaenterprises77@gmail.com

SANDEEP MEHTA: +91 9322334989 / +91 9322403205

44

SPECIALITY CHEMICALS

PHARMACEUTICALS ENZ ZYMES

l Or tho Phthalaldehyde

l Ve eg Pancreatain(Ip/Bp/U Usp)

l Glycolic Acid

l Animal Pancreatain(Ip/B Bp/Usp)

l 4-Chlorothymol

l Lipase

l Cinnamyl Chloride

l Serratiopeptidase

l Para Chloro Benzoyl Chloride

l Amylase

l Para Chloro Benzyl Cyanide

l Protease

l Para Hydroxy Benzaldehye l Ortho T To oluic Acid

l Tr ypsin

l Meta To Toluic Acid

l Pepsin

l Para To Toluic Acid

l Bromelain

l 3,5 Dimethyl Benzoyl Chloride

l Papain

l Sodium Borohydride Powder

COSMETICS ENZYMES l Lipase l Protease

l Lactase l Chymotr ypsin l Pectinase

INTERMEDIA AT TES S

CAS NO

END USE

Ethyl 1-(4-methoxyphenyl)-7-oxo-6(4-(2-oxopiperidin-1-yl))phenyl)4,5,6,7tetrahydro-1h-pyrazolo[3,4-c]pyridine3-carboxyalate.

3-CHLORO-5,6-DIHYDR RO-1(4-NITROPHENYL)-2-(1 1H)-PYRIDINONE 2-(2-Hydroxyphenyl)-4H-1, 3-benzoxazin-4-one (+/-)-3-carbamoylmethhyl)-5methylHexanoicAcid 4-Chloro4-HydroxyBenzophenone ParaChloroBenzopheno one (R)1-[1-(4-chlorophenyyl) phenylmethyl]piperazine

503614-91-3

APIXABAN

536760-29-9

APIXABAN

1218-69-5

DEFERASIROX

181289-15-6

Pregabalin

4201-78-3 134-85-0 130018-88-1

Finofibrate Levocetirizine Cetirizine Levocetirizine

5-NitroSalicylicAcid

96-97-9

Formamidine Acetate 2-Bromo-3-Chloropropiophenone (+)Chloro phenyl glycine methyl ester tar tarate salt (D-(+)-Methyl-(2-thiennylethamino)2chlorophenyl)acetate hyydrochloride 4-BromophenylAceticA Acid Ethyl 2-Chloroacetoaceetate N.O-Dimethylhydroxylamine Hydrochloride R-(+)-N-Benzyl-1-phennylethamine

3473-63-0 34911-51-8 141109-14-4

Mesalamine/5-Amino Salicylic Acid Itraconazole Bupropion Clopidogrel Bisulfate

141109-19-5

Clopidogrel Bisulfate

1878-68-8 609-15-4 6638-79-5 38235-77-7

4-Nitrobenzenesulfonyl chloride

56553-60-7

N-Butyl Nitril Phthalide

544-16-1 87-41-2

Bilastine/Macitentan Apixaban Isoniazid Chemical Synthesis for Pharma compound Foscmprenavirr,,Dar unavir and Amprenavir New Generation nitrating agents Pharma Intermediates

l Diastase

l Amylase

l Alpha-Galactosidase

l Cellulase

l Nattokinase

Address: 211- B Wing ,Cr ystal Plaza ,Opp Infinity Mall Link Raaod,Andheri(W).Mumbai-400054 Phone: +91 9920082277 | Email: sales@asielchempharma.com,asielchempharm ma@gmail.com | Web: www.asielchempharma.com

! $ &" $ !

$ " ($ĺ $ ĺ

0DQXIDFWXUHUV ,PSRUWHUV RI $3,¶V %XON GUXJV DQG ,QWHUPHGLDWHV 77Ĺ Ѷ|_ lĺ -mv-|_ !o-7ķ -@-um-]-uķ &ĺ ĺ Ŋ ƑƔƐƏƏƐ Ŋ

(ob1; ş )_-|v -rr Ĺ ƳƖƐŊѶƖƔѶƑƔƏƕƓƓķ ƳƖƐŊƖѶƒƕƓƕƒƒƓѶ l-bѴ Ĺ u-ঞr v_rŠ -_ooĺ1ol Ň );0 Ĺ ĺu-ঞr v_rĺbm

1ঞ ; _-ul-1; ঞ1-Ѵ m]u;7b;m|v Ő ĺ ĺ ĺő @;ubm]Ĺ

! ĺ ĺ ! $ $ ĺ ĺ ƐƏƏѷ " ! -vv -|;ub-Ѵ -11ou7bm] |o ĺ ĺ ƑƏƑƑ &Žƌ ŶLJ ZĞƋƵŝƌĞŵĞŶƚƐ͕ WůĞĂƐĞ ŽŶƚĂĐƚ ŽŶ ďŽǀĞ ĞƚĂŝůƐ 45

DIPTI CHEMICALS AND PHARMACEUTICALS API l Ce listat ODMF l Linaglip n DMF l Ledipasvir Co Povidine l Sofosbuvir l Tenofovir Alafenamide Fumarate ODMF l Tofaci nib Citrate l Velpatasvir Co Povidine

ONCOLOGY PRODUCTS l Abiratone Acetate l Bosu nib l Enzalutamide l Erlo nib Hcl l Gemcitamine HCL l Ibru nib ODMF l Ima nib Mesylate l Olaparib l Palbociclib l Pazopanib l Ventoclax

INTERMEDIATES Amisulpride Intermediate l 2 Methoxy 4 amino 5 ethylsulphonyl benzoic acid CAS NO 71675 87 1 Carprofen, Ketoprofen, Darifinacin Intermediate l 2 Cyclohexene 1 one CAS NO 930 68 7. ( For Export Only)

Dapagliflozin, Empagliflozin, Bexagliflozin Intermediate l 2 Chloro 5 bromo benzoic acid CAS NO 21739 92 4

Fingolimod Intermediate l N Octyl benzene CAS NO 2189 60 8 Linaglip n Intermediate l 3 Methyl Xanthine l 8 Bromo 3 Methyl Xanthine CAS NO 93703 24 3 l 8 Bromo 3 methyl 7 but 2 ynyl Xanthine CAS NO 666816 98 4 l 2 (Chloromethyl) 4 Methyl Quinazoline CAS NO109113 72 6 l R 3 Boc Aminopiperidine CAS No : 309956 78 3 l Ortho Cyano Benzyl Bromide ( For Export Only ) l (2 R 4S) 5 (Biphenyl 4 yl) 4 (tert butoxycarbonyl amino)

2 methylpentanoic acid CAS NO 1012341 50 2

O ce : 53, Highway Avenue, Sai Kripa Complex, Kashigoan, Mira Road 401107 Email : info@dip pharma.com, dip farma@gmail.com l Mobile No : 8448085663 / 9930305464 Works : 124/15 GIDC Nandesari Vadodara 391340 Gujarat

46

47

SHRIYA PH HARMA A & SUR RGIICA AL IMPORTERS & AGENTS: BULK DRUGS / CHEMICALS / SOLVENTS PRODUCT LIST l ACEBROPHYLLINE l ACECLOFENAC BP/IP l ALPHA LIPOIC ACID USP 28/30 l AMBROXOL l AMOXYCILLIN TRIHYDRATE BP/IP COMP l ATROVASTATIN CALCIUM IP l AZITHROMYCIN IP/EP/USP l BACLOFEN IP l BETAHISTINE DI HCL IP l BROMHEXINE HCL BP/IP l CARBIDOPA IP l CEFIXIME TRIHYDRATE IP (COMPACTED) l CEFTRIAXONE SODIUM STERILE USP/IP l CEFUROXIME AXETIL AMORPHOUS IP l CHLORZOXAZONE USP l CITICOLINE SODIUM IP l D-BIOTEEN USP/EP l DEFLAZACORT l DICYCLOMINE HCL IP/BP

l ESCITALOPRAM OXALATE IP l ETODOLAC IP l ETORICOXIB IP l FAROPENEM SODIUM l GLICLAZIDE BP/IP l ISOXSUPRINE HCL IP l LEVO SALBUTAMOL SULPHATE IP l LISINOPRIL USP l LOSARTAN POTASSIUM IP/USP l LULICONAZOLE IP l MEFENAMIC ACID IP/BP l METFORMIN HCL IP / BP l METHYL COBALAMINE I.P l METOPROLOL SUCCINATE USP/IP l MONTELUKAST SODIUM IP l NADIFLOXACIN IP l OFLOXACIN IP l ORNIDAZOLE IP l OXACEPROL

l PANTAPRAZOLE SODIUM IP l PARACETAMOL IP l PAROXETINE HYDROCHLORIDE HEMIHYDRATE IP l PREGABALIN I.P. l PROCHLORPERAZINE MALEATE IP l QUETIAPINE FUMARATE IP l RANOLAZINE l ROSUVASTATIN CALCIUM IP l SALBUTAMOL SULPHATE l SALBUTAMOL SULPHATE IP/BP l SULTAMYCILLIN TOSYLATE l TELMISARTAN IP/EP/USP l TENELIGLIPTIN l TERBINAFINE HYDROCHLORIDE EP/ USP/BP l TERBUTALINE SULPHATE IP. l TICAGRELOR l TRANEXAMIC ACID IP l URSODEOXYCHOLIC ACID IP/EP. l VILDAGLIPTIN

43, Hanifabai Manzil, Room No. 18, Ground Floor, Kapad Bazar, Mahim, Mumbai – 400 016 Tel.: 24472816 | Fax: 24472817 | Mobile: 9323766144 Email: shriya97@hotmail.com / shriya@mtnl.net.in

48

49

SCAN ME...

DOWNLOAD BROCHURE

Manufacturers & Exporters

PRODU UCT LIST HERBAL EXTRACTS '&%$#"%!% #%& % '& % & & % & '& $" %& % '& % & % '& & % & '&! !! & % & '&! $ !& % & '&! ! & %& % & '& & # $ & % &

'& % % & % &

PERSONAL CARE EXTRACTS '&% & %& % '& #% & % '& % %& % '& & % '&! & %& % '&! % $&$ & % '&# $ $& % '& & & % '& & % '& & %

ESSENTIAL | NATURAL OIL’S '&% & '&% !% & '& % &$ & '& % $& '& % $ & '& & '&$%"& % & '& & '& $ % & '& %& &

INGREDIENTS '& & & '& % & # % '& '&! & " '& '& & '& %$$ &$ % '& &! '&$ & " '& % & &% %

R-322, M.I.D.C., T.T.C. Industria al Estate, Rabale, Navi Mumbai, Maharashtra - 400701. India Web.:www.global-merchants.in E-Mail: sales@global-merchantts.in | Phone no.: +91 75065 06197

50

INdIAN PlATiNUM PVT. LTd.

Manufacturing & Exporting Superior Quality Prevous Metal Chemicals, Compounds of Rhodium, Gold, Silver, Palladium, Platinum, Iridium, Osmium, Ruthenium, Indium, Bismuth, Molybdenum Etc.

SILVER

Silver Chemicals Silver Bars Silver Nanoparticles Silver Carbonate Silver Acetate Silver Chloride Silver Chromate Silver Oxide Silver Sulphate Silver Triflate Silver Lactate Silver Sufadiazine Silver Trifluroacetic Acid Silver Nitrite Silver Nitrate AR / LR Silver Sulfate Silver Nitrate Crystal Silver Iodide Silver Bromide Silver Iodate Indium Compounds l Indium Sulphate l Indium Chloride l Indium Phosphate l Indium Nitrate l Indium Oxide Cerium Salts / Cerium Chloride / Lanthanum Salts l Ammonium Cerium Sulphate l Ammonium Cerium Nitrate l Cerium Acetate l Cerium Sulphate l Cerium Hydrate l Cerium Sulfate Hydrate l Cerium Oxide l Lanthanum Nitrate l Lanthanum Chloride l Lanthanum Phosphate

Bismuth Salts Compounds l Bismuth Nitrate l Bismuth Oxychloride l Bismuth Carbonate l Bismuth Citrate l Sodium Bismuthate AR/LR l Bismuth Sulphite l Bismuth Subsalicylate l Bismuth Oxide Industrial Chemicals

l Styphnic Acid l Phenyl Mercuric Acetate l Peracetic Acid l Lead Acetate l Methyl Pyruvate l Phosphotungstic Acid l Acid Fuchsin l Hexachloro Patinic Acid l Picric Acid l Resorcinol l Lead Nitrate l 5 Sulphosalicylic Acid l Ethyl Pyruvate l Pyruvic Acid l Sodium Molybdate l Sodium Tungstate l Ammonium Molybdate l Phosphomolybdic Acid l Sodium Pyruvate l Raney Nickel

Metal Powders

l Silver Metal Powder l Moly Trioxide l Gold Metal Powder l Platinum Metal l Rhodium Metal Powder l Copper Metal Powder

Copper Salts l Copper Sulphate l Copper Nitrate l Copper Acetate l Copper Citrate

Regd. Off.: 401, Aashiya, Narsi Chhaya, J.V.P.D. Scheme, 18, Swastik Society, N.S. Road No. 2, Ville Parle (W), Mumbai - 400056 Tel: 9322395199, 26171279 Mob: 98920 63766 Email: indianplatinum@gmail.com Web: www.palladiumchemicals.com

51

HRITIK CHEMICALS PVT. LTD. Unit No. 1301-1304, 13th Floor, ‘B’ Wing, Dhanashree Heights, Bldg. No. 42, Azad Nagar 2, O . Veera Desai Road, Andheri (West), Mumbai- 400053 Tel: 022-67115900 | Email: pharma@hri kchemical.com; enquiry@hri kchemical.com

AVAILABLE REGULARLY FOLLOWING CHEMICAL & SOLVENTS AVAILABLE BOTH IN TANKER’S & DRUM l Acetic acid l Acetone l Acrylonitrile l BAM l Benzene l Butyl Acetate l N-Butanol/ ISOButanol l Chloroform

l DEG l DMA 40% l EDC l Ethyl Acetate l Iso-Propyl Alcohol l MDC l MEG l Methanol

ALL FOLLOWING COMPOUNDS l MIBK l Mixed Xylene l MMA 40% l N-Propanol l Ortho Xylene l Phenol l Styrene l Toluene l VAM

l All Bromine Compounds l All chlorine Compounds l All Corrosion Inhibitors l All Acetophenone Compound l All Pyridine Derivatives l All Water Treatment Chemicals l All Oil FieldChemicals

l All Polyacrylic Acid (PAA,Dispersant) l All Mud Cake Cleaners l All Amines l All Quinoline Derivatives l All ISO Phathalic Derivatives l All Iodine &It’s Salts l All Piperidones

l All Piperazine Compounds l All Phenol Based Compounds l All Napthols l All Eco-Friendly Defoamers l All High Temperature Deflocculant

AVAILABLE BOTH IN DRUMS & BAG PACKING l Ammonium persulphate l Acetic Acid l Acetophenone l Acetonitrile l Acetyl acetone (INT) l Acetyl Chloride l Acrylamide l Acrylic Acid l Acrylonitrile l Adipic Acid l Allyl Alcohol l Allyl Chloride l Aluminium Chloride l Ammonium Acetate l Amino ethyl ethanol amine l Diethanol Amine l Ammonium Persulphate l Benzene l Boric Acid l Borax l Benzoic Acid l Benzyl Alcohol l Benzylamine l Bisphenol A l Bromine l 1 Bromo-5-chloropropane l N-Bromosuccinimide (INT) l N- Butanol l N-Butyric ACID l Tert-Butanol l Butyl Acetate l N-Butyl methacrylate l Caproic Acid l Carbon Black l Carbon disulphide l 5-Chloro 2 nitroAniline l Dimethyl Sulphoxide

l 1,4-Dioxane l Formic Acid l Glycerine l Glycine l Gamma Butyrolactone l Glyoxal- 40 % l N-Heptane l Hexamine l Hexylene Glycol l Hydrobromic Acid l Hydrogen peroxide l Hydro Quinone l 2-Hydroxyethyl Methacrylate l Hydroxylamine Hydro Chloride l Hydroxyl Amine Sulphate l Imidazole l Indium Sulphate l Iodine l Iso Butanol l Iso Butyraldehyde l Iso Butyroyl Chloride l Iso Butyric Acid l Iso phorone l Iso Phoronediamine l Iso Phthalic Acid l Isopropyl Acetate l Isopropyl Ether l Maleic Anhydride l Malonic Acid l Malononitrile l Mefenamic Acid l Methactylic Acid l Methane Sulphonic Acid l Methanol l Methyl Acetoacetate l Methyl Acrylate

l Methyl Iso Butyl Ketone l Methyl Methacrylate l N-Methyl-2-Pyrrolidone l 2-Methyltetra Hydrofuran l Morpholine l Neopentyl Glycol l Nitromethane l Oxalic Acid l Poly Phosphoric Acid l Para Tertiary Octyl Phenol l Paraffin Liquid l Paraformal Dehyde l Phthalic Anhydride l Pentaerythritol l Perchloro Ethylene l Phenol l Phenyl Chloroformate l Zinc Sulphate Monohydrate l Caustic Soda Flakes l Chloroacetyl chloride (INT) l Caustic Potash Flakes l Chloroform l Chromic Acid l Citric Acid l Citric Acid monohydrate l M-cresol l O-cresol l P-cresol l Cyano Acetic Acid l Cyclohexane l Cyclohexanone l Cyclohexyl Amine l Dimethyl amino ethanol l Diethyl Amine l Diacetone Alcohol l Dichloromethane l Dicyandiamide

l Dicyclohexylamine l Ethyl Acrylate l N,N-dicyclohexyl Carbodiimide l N,N-diethylamine l Diethylene glycol l Diethylene Trimine l Diethyl Ether l Diethyl Malonate l Diethyl Sulphate l Methyl Cyano Acetate l 1,3-Difluoro Benzene l Diisopropylamine l N,N-Dimethyl Acetamide l Dimethyl Amine l Dimethyl Carbonate l N,N-dimethyl Formamide l Dimethyl Malonate l Phosphoric Acid l Phosphorous Oxychloride l Potassium Carbonate l N-Propanol l Propionic Acid l Gluteraldehyde- 50 % l N- Methyl Piperazine l Propylene Glycol l Pyridine l Quinoline l Resorcinol l Sodium Metabisulphite l Sodium Methoxide l Sodium Nitrite l Sodium Sulphate l Sodium Thiocyanate l Sorbic Acid l Soda Bicarbonate l Stearic Acid l Styrene

l Methyl Magnesium Chloride In THF l 2 Methyl THF l N-methyl piperazine l N-propanol HCL l 1,2,4- Triazole l TEA HCL l Tolyltriazole l Diethylene Triamine Pentamethylene Phosphonic Acid

(DTPMPA, DTPMP, DETPMPA) l Polyamino Polyether Methylene Phosphonic Acid (PAPEMPA) l Benzalkonium Chloride(BKC50% & BKC80%) l Drilling Fluid Biocide l Bactericides – Aldehyde/Amine/Nana

INTERMEDIATES & SPECIALITY CHEMICALS l Anisole l All Fire Retardant Chemicals l All Picoline l 2 Aminopyridine l All Benzoate l 4 Bromo Aniline l Benzoylmetronidazole l Bromo Chloro Propane l Corrosionin Inhibitors l 2 Chloro Acetonitrile

l 4 Cynopyridine l Diphenyl Acetic acid l 4 DMAP l DMA HCL l Ethyl Acetate HCL l IPA HCL l Para Hydroxy Benzaldehyde l Lithium Aluminium Hydride l Mem Chloride l 3 Methyl Xanthine l Methanolic HCL

l Succinic Acid l Sodium Persulphate l DL-Tartaric Acid l L-Tartaric Acid l Tetra Butyl Ammonium bromide l Tetrahydrofuran l Thioacetic Acid l Thionly Chloride l Thiophenol l Toluene Diisocyanate l Titanium Dioxide All grede l p-toluene Sulphonyl Chloride l O-Toluic Acid l P-Toluic Acid l Tolyltriazole l Tri-N-Butyl Amine l Trichloroisocyanuric Acid l Trietanol Amine l Triethyl Amine Hydrochloride l Triethyl Orthoformate l Trimellitic Anhydride l Trimethyl Amine l Trimethyl Chlorosilane l Trimethyl Orthoformate l Trimethyl ortho acetate l Triphosgene l Ortho Chloro benzaldehyde l Urea l Vanadium Pentoxide l m-Xylene l O-Xylene l Xylene Mixed l D-Xylose l Zinc Chloride l Zinc Borate

ALL FOLLOWING FORMATES l Ethyl Formate l Methyl Formate l Benzyl Chloro Formate l Phenyl Chloro Formate l Sodium Formate l Ammonium Formate

WE ALSO SUPPLY ALL CHEMICAL & SOLVENT IN DRUMS AND TANKER 52

PIONEER IN GRIGNARD REAGENTS Exclusive Suppliers Of Isopropyl Magnesium Chloride - Lithium Chloride Complex 4 - Fluoro Phenyl Magnesium Bromide Allyl Magnesium Bromide

Methyl Magnesium Bromide

Allyl Magnesium Chloride

Methyl Magnesium Chloride

Cyclohexyl Magnesium Chloride

Isobutyl Magnesium Bromide

Ethyl Magnesium Bromide

n-Butyl Magnesium Bromide

Ethyl Magnesium Chloride

n-Butyl Magnesium Chloride

Ethynyl Magnesium Bromide

n-Propyl Magnesium Bromide

Isopropyl Magnesium Bromide

t-Butyl Magnesium Chloride

Isopropyl Magnesium Chloride

Vinyl Magnesium Bromide

(z)-1- Propenyl Magnesium Bromide

Vinyl Magnesium Chloride

Solvent Based Reactions & Distillation Facility In Reactor Ranging From 0.16kL to 8.5kL & Temp -25℃ to 250℃

Contact: Azeocryst Organics Pvt Ltd. www.azeocryst.com MR. N.S BHIRUD

MR. MOHIT PHALAK

+91 - 98690 01672 / 88790 77780 nandubhirud@azeocryst.com

+91 88790 77787 / 902961 9810 mohitphalak@azeocryst.com

1-G, Siddhivinayak Chambers, Opp. M.I.G Club, Gandhinagar, Bandra East, Mumbai-400051 53

Deepak Fertilisers & Petrochemicals P Corporation Ltd. Auth horised Reseller for:

Isopropyl Allcohol (Tanker Ta r & Drum) Grade - T Te ec chnical / IP / BP / USP / CC / EP

Eth hyl Acetate Isoophorone Hexyllene Glycol Acetone MIBK

Dii-Acetone Acetone Phenol M Methanol Sodiium Nitrite Sodium Nitrate DMF Formic Acid 85% Regularly A Avvaailable with Cenvat in Bulks B (High Seas / Bond Transfer) Ex-Bhiwan ndi <;:98769;:965 <;:987438 <;:98743672618 <;:361638;061 <;/83.838 <;/18-9,63+;*4)582 <;/(7'1;:987-78 <;/(7'1;&-2%6741 <;/(7'1;&8114$411##8 <;&-($769;*47-$, <;&-($769;"45-;!1- 8$; /-+ <;&,1424 42 <;&67269;:965;:3,'524($ <;&67269;:965; 434 <;&'914,8 -38 <;&'914,8 -341 <;&'914,8 -3438 <; // <;

<; * <; 6 :987438 <; 6 7,'1;: 638 <; * <; ! <; "0 <; 69,1424,'5263 <; 7,'1;:987-78 <; 7,'1838; 69,142658 <;!42 -158,'58; <;!42 69;:965; <; 11''982638 <; & ; '5249,14269;:965 <; '524+83;*824 658; <; '524 '1- 638;"(1 -78 <; $4;/(7-341 <; $4 ,42438 <; $4 24 '1;:194,41

<; -27-269;:965; /-+ <; -9769;:965; /-+ <; & <; <; <; 81- 638 <; 87,-341 <; / <; 6 '1838 <; :; 87,'1; 87,-92'1-78 <; 434;&,1424;/83.838 <; 42 ,41638 <; /: <;3 8 7-38 <;3 *24 -3-1 <; *24 '1;:987-78 <;097-341; <;027,4 '1838 <;0 -169;:965

<;*-2- 42 -158,'58; <;* ; ; ; <;*,8341 <;*,4$ ,4269;:965; <;*47-$$6( ;&-2%43-78 <;*24 '1838; 11''941 <;" /" <;"45-;:$,; /-+ <;"456( ; 672-78 <;"456( ; 672678 <;"42%6741 <;" ** <;"7'2838; 434 82 <;"(1 ,4369;:965 <; <; ! <; 41(838 <; 2687,'1- 638 <; :

Contact:

Khushbu Dye Chem C Pvt. Ltd. Gala No. 99, 2nd Floor, New Unique Indl. Estate, Opp. Jawahar Talkies, Dr. R.P. Road, Mulunnd (W), Mumbai 400 080.

Tel.l : +91-22-67102828 / 67103838 / 669822266 / 66982277 / 25929595 Web : www.khushbudyechem.com Contact Person: MR. ASHOK DAND (Director) Mob.: +991-9821110150 / 9223433143 Email : info@khushbudyechem.com MR. VIRAL DAND Mob.: +991-9821454191 / 9773222422 Email : viral.dand@khushbudyechem.com MR. DHAWA WAL LAP PA ASIA Mob.: +991-7208022278 / 8013334222 Email : dhawal.lapasia@khushbudyechem.in

Our Braanch: ANKLESHW WAR Contact Person: MR. Yash Salot Mob.: +91-92235532926 Email : kdcplank2017@gmail.com & kdcplank@redifffmail.com

KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU

KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHB K U KHUSHBU KHUSSHBU KHUSHBU

KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUS SHBU

KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUSHBU KHUS SHBU 54

AVAILABLE

Caproic Acid (C-6) Caprylic Acid (C-8) Capric Acid (C-10) Lauric Acid (C-12) Myris c Acid (C-14) Palmi c Acid (C-16) Stearic Acid (C-18) Oleic Acid (C-18.1) Dis lled Coconut Fa y Acid Hydrogenated Palm Stearin Hydrogenated Technical Oil Hydrogenated Soya Oil For Quality, Regular Supply & Compe ve Prices Contact: Sunil Goenka

Siddharth International Green House, 2nd Floor, Green Street, Fort, Mumbai 400 023.

Phone: 022-22662136 / 22663119 l Mobile: 9820026621 Email: sales@siddhint.com l Web: www.siddhint.com 55

56

DEALING IN : PHARMACEUTICAL RAW MATERIALS, CHEMICAL, INORGANIC CHEMICAL, INTERMEDIATE WAREHOUSE : GALA NO. 19 & 20, 1ST FLOOR, GHAR NO. 1055, BHATIYA COMPLEX, PURANA VILLAGE, BHIWANDI 421 302.

Address : SHOP NO.4, GORAI DISHA CHS LTD., L.T. ROAD, GORAI 2, PLOT NO. 50, OPP. SHANTIDHAM ASHRAM, BORIVALI (W), MUMBAI 400 092.

• Email : info@hapenterprise.com • 022 28677670 / 71 / 72 • Mob. : 9324265877 / 9324517446

ACTIVE PHARMACEUTICAL INGREDIENTS v ACECLOFENAC v ALLOPURINOL v AMITRIPTYLINE v AMLODIPINE BESILATE v ARIPIPRAZOLE v ARTEMETHER v ATROVASTATIN CALCIUM v BACLOFEN v BENFOTIAMINE v BENZOCAINE v BETAHISTINE DI HCL v BROMHEXINE HCL v CALCITROL v CALCIUM DOBESILATE v CARBAMAZEPINE v CARVEDILOL v CELECOXIB v CETIRIZINE DI HCL v CHLORPHENIRAMINE MALEATE v CHONDROITIN SODIUM v CILNIDIPINE v CINNARIZINE v CITICOLINE SODIUM v CLOBETASOL PROPIONATE v CLOMIPHENE CITRATE v CLOMIPRAMINE HCL v CLOPIDOGREL BISULPHATE v CLOTRIMAZOLE v CLOZAPINE v CYCLOBENZAPRINE HCL v CYPROHEPTADINE v DAPOXETINE HCL v D-BIOTIN v DEFLAZACORT v DESLORATADINE v DESVENLAFAXINE SUCCINATE v DEXAMETHASONE PLAIN /SODIUM v DEXTROMETHORPHAN HYDROBOMIDE v DIACEREIN v DICLOFENAC DIETHYLAMINE v DICLOFENAC POTASSIUM v DICLOFENAC SODIUM v DICYCLOMINE HCL v DOTHIEPIN HCL v DOXEPIN HCL v DOXYLAMINE SUCCINATE v DULOXETINE HCL v DUTASTERIDE v EBASTIN v EPERISONE HCL

v ESCITALOPRAM OXALATE v ETHAMSYLATE v ETODOLAC v ETORICOXIB v FEBANTEL v FEBUXOSTAT v FENOFIBRATE / MICRONISED v FEXOFENADINE v FLUCONAZOLE v FLUNARIZINE v FLUPENTIXOL HCL v FOLIC ACID v FUROSEMIDE v FUSIDIC ACID v GABAPENTIN v GLICLAZIDE v GLIMEPIRIDE v HYDROXYZINE HCL v IMIPRAMINE HCL v INDOMETACIN v ISOTRETINOIN v ITOPRIDE v IVERMECTIN v KETOPROFEN v LABETALOL v LACOSAMIDE v LAMOTRIGINE v LEFLUNOMIDE v LEVO SALBUTAMOL SULPHATE v LEVOCETIRIZINE HYDROCHLORIDE v LEVOSULPRIDE v LINAGLIPTIN v LINEZOLID v LOPERAMIDE v LORATADINE v LORNOXICAM v LOSARTAN POTASSIUM v LULICONAZOLE v LUMEFANTRINE v METOCLOPRAMIDE v METOPROLOL SUCCINATE/ TARTRATE v MINOXIDIL v MIRTAZAPINE v MONTELUKAST SODIUM v MOXIFLOXACIN v MUPIROCIN v MEBEVERINE HCL v MEFENAMIC ACID v MECLIZINE v MELATONIN

v MELITRACEN HCL v MELOXICAM v MESALAMINE v METADOXINE v METFORMIN HCL v METHYLCOBALAMINE v METHYLPREDNISOLONE v NIACINAMIDE v NIFEDIPINE v NIMESULIDE v NORTRIPTYLINE HCL v OLANZAPINE v OLMESARTAN MEDOXOMIL v ONDANSETRON v PANTOPRAZOLE SODIUM v PAROXETINE HCL v PHENYLEPHRINE HYDROCHLORIDE v PIOGLITAZONE HCL v PIROXICAM v PREGABALIN v PROGESTERONE v PYRANTEL PAMOATE v QUETIAPINE FUMRATE v RACECADOTRIL v RIBOFLAVIN SODIUM PHOSPHATE v ROSUVASTATIN CALCIUM v S - AMLODIPINE v SERTACONAZOLE NITRATE v SILDENAFIL CITRATE v SMX / TMP v SODIUM FUSIDATE v SULFASALAZINE v SULPHADIAZINE v TACROLIMUS v TADALAFIL v TAMSULOSIN HCL v TELMISARTAN v TENELIGLIPTIN v TICAGRELOR v TOLPERISONE v TOPIRAMATE v TORSEMIDE v TRANEXAMIC ACID v TRIFLUOPERAZINE HCL v TRIHEXYPHENIDYL HCL v TRIMETAZIDINE v VENLAFAXINE HCL v VILDAGLIPITIN v VITAMIN C PLAIN & COATED v VITAMIN E 50%

57

PANCHSHEEL ORGANICS LIMITED (W.H.O GMP Certified Company) Add: 137-138 Hubtown Solaris Prof. N.S.Phadke Marg, Opp.Teli gali, Andheri (East), Mumbai-400069.

Ph: 022-68634200 /4214/4213/4212/4219/4218 l Fax No.: 022-22063929 Email: poltd@panchsheelorganics.in l Web: www.panchsheelorganics.com / www.panchsheelorganicsltd.com

API PRODUCT LIST l ACAMPROSATE CALCIUM l AMIODARONE l ATOMOXETINE l BACLOFEN l BISOPROLOL FUMARATE l CANDESARTAN l CARBAMAZEPINE l CARNOCISTEINE l CHLORDIAZEPOXIDE l DENATONIUM BENZOATE / SACCHARIDE l DIL TIAZEM l DISULFIRAM l DOBUTAMINE l DOPAMINE HCL l DOXYCYCLINE MONOHYDRATE l DUTASTERIDE l ESLICARBAZEPINE l FLUTAMIDE

l GATLFLOXACIN l GRANISETRON HCL l HYDROQUINONE l HYDROXYPROGESTERONE CAPROATE l HYDROXYZINE HCL l IMIPRAMINE HCL / PAMOATE l IRBESARTAN l LAMOTRIGINE l LEFLUNOMIDE l LITHIUM CARBONATE l LOMEFLOXACIN HCL l L- THYROXINE SODIUM l MELATONIN l MERCAPTOPURINE l NAPHAZOLINE / NITRATE l NEOSTIGMINE METHYL SULFATE l NITROFURANTOIN MONO / ANHYDROUS

l NITROFURAZONE l OXCARBAZEPINE l PERINDOPRIL ERBUMINE l PHENAZONE l PIRFENIDONE l PRAMIPEXOLE DI HCL l PRAZIQUANTEL l PROPYLTHIOURACIL l PYRIDOSTIGMINE BROMIDE l RUTIN l SODIUM CROMO GLYCATE l THALIDOMIDE l TOLFENAMIC ACID l TORSEMIDE l TRIAMTERENE l VERAPAMIL l VITAMIN K 1 l XYLOMETAZOLINE HCL l ZINC BACITRACIN

* AVAILABLE AS PER LATEST PHARMACOPEA & CUSTOMER SPECIFICATIONS

HORMONES & STEROIDS l ADRENALINE BITARTRATE l CYPROTERONE ACETATE l DESOGESTREL l DROSPIERENONE l ESTRADIOL / VALERATE / PHENYL l PROPIONATE / BENZOATE l ETHINYL ESTRADIOL

l FINASTERIDE l HYDROCORTISONE ACETATE l L-THYROXINE SODIUM l LEVONORGESTREL l NANDROLONE PHENYL PROPIONATE/ DECANOATE l NORANDRENALINE BITARTRATE

l NORGENTAMINE l NORGESTREL l NORTHISTERONE / ACETATE l PREDNISOLONE ACETATE / METHYL PREDNISOLONE ACETATE l TESTOSTERONE ENANTHENTE / DECANOATE/ CYPIONATE / UNDECANOATE / METHYL

NUTRACEUTICALS & HEALTHCARE l BETASTEROL l CHONDROITIN SULFATE l DOCOSAHEXANOIC ACID (DHA ) VEG POWDER l EICOSAPENTAENOIC ACID (EPA ) POWDER l GAMMALINOLENIC ACID (GLA ) POWDER l GINSENG POWDER / EXTRACT . l ISOTRETINOIN l L-ARGININE L ASPARTATE

l LYSINE MONO ACETATE l OMEGA 3 FATTY ACID POWDER l PHYTOMENADIONE PREMIX l PHYTOSTEROL AND OTHER ESTER l TRETINOIN / MICROSPHERES l VITAMIN E 50% ( PHARMA GRADE ) l VITAMIN K2-7 ( MENAQUINONE ) l ZINC MONOMETHIONINE

* THE ABOVE PRODUCT LIST AS PER THE LATEST PHARMACOPEIA 58

59

MANUFACTURERS & EXPORTERS OF INORGANIC & OTHER METAL SALTS ALUMINIUM NITRATE BARIUM NITRATE COBALT NITRATE CALCIUM ACETATE CALCIUM NITRATE COPPER ACETATE COPPER CARBONATE COPPER NITRATE COPPER SULPHATE CHROMIUM ACETATE

CHROMIUM CHLORIDE CHROMIUM NITRATE FERRIC NITRATE FERRIC SULPHATE LEAD NITRATE MAGNESIUM NITRATE MAGNESIUM ACETATE MAGNESIUM CHLORIDE MANGANESE ACETATE MANGANESE CARBONATE

MANGANESE CHLORIDE NICKEL ACETATE NICKEL CARBONATE NICKEL NITRATE POTASSIUM NITRATE SODIUM THIOSULPHATE ZINC ACETATE ZINC CARBONATE ZINC SULPHATE ZINC NITRATE

AND OTHER METAL SALTS COSMIC CHEMICALS

EMPEEF CHEMICALS PVT LTD.

Manufacturing Unit K-20, MIDC,Tarapur, Boisar Western Railway Dist. Palghar- 401506, Maharashtra, INDIA Tel: 0091-22- 28911481

Manufacturing Unit T- 114, MIDC,Tarapur, Boisar Western Railway Dist. Palghar- 401506, Maharashtra, INDIA Tel: 0091-22- 28958550

MUMBAI OFFICE: 12,Veena Apts, Opp. Bhagwati Hospital, S.V.P. Road, Borivli (W), Mumbai - 400 103, INDIA Tel no. 0091-22- 28911481 / 28958550 /35525803 Fax No. 091 - 22 - 28934619 E-Mail: costpr@mtnl.net.in / cosmicvjb@hotmail.com Web Site: http://www.cosmicchemicals.com

Contact Person: Mr Jagannath Bhandary Mobile: 9324619871 / 8806467677 60

61

62

Corp. Office: Ground Floor, Usha Building, S. V. Road, Near Nanavati Hospital, Vile Parle (West), Mumbai-400056, Maharashtra.

Tel: +91(022) 26104647 / 25188195 Mobile: +91(0) 9768456789 / 9768312345

Email: info@siddhambikaimpex.com

Authorised Distributor of Worlds Largest Producer of

Lactulose Concentrate 67% USP From Fresenius Kabi Austria You Can also contact us for: 1) Opthalmic API 2) Anti Cancer API 3) Excepients 4) Vitamins

Fresenius Kabi Austria is one of the leading lactulose suppliers, with more than 40 years of experience in its production and distribution. We supply lactulose in liquid and crystalline form manufactured at two production sites in Linz, Austria, and in Vicchio, Italy.

For more information on our Lactulose product portfolio and services, please contact our Indian Distributor.

Regd. Office: Shri Muni Suvrat Complex, F-209, 2nd Floor, Phase-1, Rehnal Village, Bhiwandi – 421 302, Thane, Maharashtra.

63

64

Admin O : Unit No 12, 1St Floor, Neminath Indl Estate No. 6, Navghar, Vasai East, Dist Palghar- 401210 TEL : 91-250-2390032 / 2390989 Email: sales@oxfordlabchem.com, info@oxfordlabchem.com Web: www.oxfordlabchem.com / www. oxfordlabfinechem.com

MANUFACTURERS OF WIDE RANGE OF LABORATORY CHEMICALS l ACRIDINE ORANGE l AGAR AGAR

( FOR MICROBIOLOGY )

l AGAROSE l ALCIAN BLUE 8 GX l ANTHRONE LR/ AR l AZUR A & B l BASIC FUCHSIN l BILIRUBIN l BIOLOGICAL BUFFERS l CARMINE l CHOLESTEROL l CRYSTAL VIOLET

(GENTIAN VIOLET )

l ERIOCHROME BLACK T l ERIOCHROME CYANINE R l ETHIDIUM BROMIDE AR l FIELD STAIN A l FIELD STAIN B l GOLD CHLORIDE

(24% AND 49% )

l HEMATOXYLIN STAIN

CERTIFIED

l IMMERSION OIL l IODINE MONOBROMIDE l LEISHMAN STAIN

l MERCURIC CHLORIDE

l PLATINUM CHLORIDE

l MERCURIC IODIDE RED

l POTASSIUM BROMIDE IR

l MERCURIC SULPHATE

l POTASSIUM

l MERCURY AMMONIATED

l POTASSIUM IODATE LR/AR

LR/AR LR/AR LR/AR LR/AR

l META PHOSPHORIC ACID

STICKS

l METAL SALTS LR/AR

GRADES

l METHYL ORANGE l MUREXIDE l N-1 NAPHTHYL ETHYLENE

DIAMINE DIHYDROCHLORIDE LR/AR

l N, N –DIMETHYL –P-

PHENYLENEDIAMINE OXALATE AR

l NEOCUPROINE l N-PHENYL ANTHRANILIC

ACID

l PALLADIUM CHLORIDE

(59-60% PD )

l PHENYL MERCURIC

ACETATE

l PHENYL MERCURIC

NITRATE

(40% PT )

SPECTROSCOPY

CHLOROPLATINATE

l POTASSIUM IODIDE LR / AR l POTASSIUM TELLURITE l PYRONIN B l PYRONIN G (Y) l RESAZURIN SODIUM SALT l SAPONIN l SILVER DIETHYL

DITHIOCARBAMATE

l SILVER METAL SALTS l SILVER NITRATE LR/ AR l SILVER SULPHATE LR/AR l SODIUM ARSENATE LR/AR l SODIUM ARSENITE LR/AR l STAINS & INDICATORS l THIOMERSAL l THYMIDINE l WRIGHT STAIN l XYLENE CYANOL FF l XYLENOL ORANGE

WE ACCEPT ALL EXPORT ORDERS AND OEM LABELLING 65

66

Committed for Quality Services Since 1957

Office no :- 45, 3rd Floor, Pheerbhoy Building, Dawabazar, 89, Princess Street, Mumbai - 400002.

Tel.: 022-6637 9219 Mob.: ( ) 093222 11535 / 079771 80631 Email: bshahandsons@gmail.com Website: www.shahandassociates.co.in LIST OF ESSENTIAL OILS Aleovera Gell / Powder Ajwain Oil/Thyme Oil Almond Oil Sweet /

Bitter Anise Oil Basil Oil Camphor Castor Oil Clove Oil Clove (Rectified) Citronella Oil Cinnamon Oil

Caraway Oil Capsicum Oleoresin Camphor Oil Cardmom Oil Cypress Oil Cajiput Oil Cumin Seed Oil Cedarwood Oil Davana Oil Dill Oil Eucalyptus Oil Eucalyptol

ENZYMES Protease Amylase Glucoamylase Alphagalactosidase Lipase Cellulase Lactase Invertase Fungal Diastase IP Pepsin IP Bacterial Alpha Amylase Neutral Protease Pectinase Pancreatin IP Papain IP

Euginol Fennel Seed Oil Ginger Grass Oil Geranium Oil Garlic Oil Iso Borneol Flakes Jasmine Oil Jojoba Oil Juniper Berry Oil Lime Oil Lemon Oil Lemon Grass Oil

Voglibose IP

Diclofenac Potasium I.P

Calcium Folinate IP/USP

Serratiopeptadiase I.P

Ormeloxifene IP

Encoated

Cabergoline IP/USP Serratiopeptidase IP

VITAMIN ACTIVES

Niacinamide

L-Methylfolate Calcium

Tamsulosin

Vitamin K2 [MK4]

Adapalene

Delta Tocotrienol

Lulicanazole

Pyridoxine Cyclic Phosphate

Nimusulide

Pyridoxal-5-Phosphate

Ibuprofen

Pyridoxamine di Hydrochloride

Clotrimazole

Calcium Folinate

Vitamin E Vitamin A 1.7 Bromhaxine Ambroxol Ferrous Ascorbate

API Valganciclovir USP

Lavender Oil Linseed Oil Menthol Methol Crystal Nutmeg Oil Neem Oil Orange Oil Olive Oil Patchouli Oil Pine Oil Lr. Peppermint Oil Palmrosa Oil

Calcium Propionate Diclofenac Sodium I.P

Acetylsalicylic Acid / Asprin

ANTIOXIDANTS / NUTRACEUTICALS Pyrroloquinoline quinone (PQQ) EN-Q10 (Ubiquinol Acetate) Grape Seed Extract Ginseng Extract

Rose Oil Rosemarry Oil Sesame Oil Spearmint Oil Turpentine Oil Turmuric Oil Terpineol Thymol Crystal Tea Tree Oil Vetivert Oil Winter Green Oil Wheat Germ Oil Green Tea Extract Gama Oryzanol ResArgin Pterostillbene ResCu (Bioavailable Curcumin) Pine Bark extract Co-enzyme 010 Resveratrol Bilberry extract Mulberry Extract (1% DNJ) Alpha GPC s-Equol y-Glutamyl Cysteine ResArgin

PROBIOTICS Lactobacillus Species Bifidobacterium Species Streptococcus Species Bacillus clausii Saccharomyces boulardii

Methyl Paraben Sodium I.P.

Papain USP (50000 USP/mg)

Methyl Salicylate I.P. / B.P. / USP

Papain x / 2x / 4x / 5x / 8x

Beta Carotine 20 % and 30 %

Octyl Salicylate

Propyl Paraben I.P.

Bromelain 2400 GDU

Papain 1:350 BPC

Propyl Paraben Sodium I.P.

DHA 10 % And 20 %

Papain Refined

Ruthoside

Homosalate

Papain I.P.

Salicylic Acid I.P. / B.P / USP

Lutein Powder 10 %

Papain LG 200

Sodium Salicylate I.P.

Lycopene 6% 10 %

Papain USP/NF

Trypsin BP / USP

Methyl Paraben I.P.

Papain USP 6300

Trypsin Chymotrypsin Mix (6:1)

I.P. / B.P / USP

67

Delivering Quality Products

Import & Trading | Pharmaceu cal Raw Material & Chemicals PRODUCT LIST

Aspartame FCC/USP Acesulfame K Alpha Lipoic Acid Azithromycin IP / USP Aceclofenac IP Artemether INT Ph. / USP Amoxycillin IP Ambroxol HCl IP Benfothiamine Bees Wax Biotin BHA / BHT Cross Povidone Caustic Soda Flakes Caustic Potash Flakes Citric Acid Mono Citric Acid Anhydrous Clotrimazole IP/BP/USP Calcium D Pantothenate Ciprofloxacin IP / USP Cefixime IP / USP Cefpodoxime Proxetil IP Cefuroxime Axetil IP Clindamycin Phosphate /HCl Cloxacillin Sodium IP Clarithromycin IP Colours - Food Colours - Pharma Di Propylene Glycol (DPG) Domperidone IP Diclofenac Sodium IP/ BP Diclofenac Potassium IP/ BP Dextromethorphane Hydrobromide (DMR) DiCalcium Phosphate (DCP) DMF Erythromycin Stearate IP Fluconazole IP / USP Folic Acid IP Glycerine CP / IP / USP HPMC-E-5 HPMC-E-15 HPMC-K-100M Hyoscine Butyl Bromide IP / BP Iso Propyl Alcohol (IPA)

Ibupprofen IP / BP Levofloxacin Hemihydrate IP Lumefantrine IH / USP Levoctrizine HCl IP Linseed Oil Levoctrizine HCl IP Light Liquid Parafin (LLP) Methylene Chloride (MDC) Mannitol Ip / BP / USP / Ph.eur Methylcobalamine IP Niacinamide IP / BP Neotame Ornidazole IP Ofloxacin IP Paracetamol IP / BP PVPK-30 PG- Tech PG- USP Polysorbate 80 Pantaprazole Sodium IP Piracitam IP Quinine Sulphate USP Quinine HCl BP Quinine Di-HCl BP Sucralose USP Sucralfate JP / USP Sorbitol 70 % IP Soda Ash Telmisartan IH / IP Vitamin A Palmitate 1.7 Miu Vitamin A Acetate Powder Vitamin AD3 Vitamin C Plain IP Vitamin C Coated IP Vitamin B1 Mono (Thiamine Mononitrate) Viramin B1 HCl Thiamine Hydrochloride) Vitamin B2 (Riboflavin) Riboflavin 5 Phosphate Sodium IP Vitamin B6 (Pyfidoxine HC l) Vitamin B12 (Cyanocobalamine ) Vitamin D3 Vitamin E Liquid (DL-Alpha Tocopherol) Vitamin E Powder 50 % Xanthan Gum (200 Mesh)

C-32 Aditya Villa, Near Prabhuta Hall, B/h SBI Bank, Ramakaka Temple Road, Channi, Vadodara - 391740, Gujarat (India). M: +91-9426985832 | Email: contactus@malayenterprise.in 68

PRODUCT LIST: CORE PRODUCTS: l Hydroquinone (HQ) l Tert-Butylhydroquinone (TBHQ) l Propionic Acid l Butylated Hydroxyanisole (BHA) l Butylated Hydroxytoluene (BHT) l Tert-Butylcatechol (TBC) l Iodine

ACIDS: l Ace c Acid l Acrylic Acid l Adipic Acid l Benzoic Acid l N-Butyric Acid l Citric Acid - Anhydrous (CAA) l Citric Acid - Monohydrate (CAM) l 2-Ethylhexanoic Acid (2-EHA) /

Octoic Acid l Formic Acid 85% l Formic Acid 99% l Isobutyric Acid l Lac c Acid 80% l Lac c Acid 88% l Oxalic Acid l Phosphoric Acid 85% - Food Grade l Phosphoric Acid 85% - Technical

Grade

l Methylene Chloride (MDC) l Propylene Glycol (PG) - Technical

Grade l Tetrahydrofuran (THF) l Toluene l mixed-Xylene l Ortho-Xylene

SPECIALTY CHEMICALS: l Acetophenone l Ac vated Carbon l Amprolium l Anisole l Ascorbyl Palmitate (AP) l Benzotriazole l Butylated Octylated

Diphenylamine (BODPA) l Tert-Butylchloride (TBC) l Calcium Propionate (CP) - Feed

Grade l Calcium Propionate (CP) - Food

Grade l Catechol l Chloranil l Chloro Acetyl Chloride (CAC) l Dicyandiamide (DCDA) l Diortho Tolylguanidine (DOTG) l Di tert-Butylhydroquinone

(Di-TBHQ)

l Sulphamic Acid l Sorbic Acid

SOLVENTS:

l Etamsylate l Ethyl Vanillin l Glycerine l Glycerol Monostearate (GMS) -

Non-Self Emulsifying (NSE) Grade l Acetone l n-Butanol l Tert-Butanol (TBA) l Chloroform l Cyclohexane l Cyclohexanone l Dimethyl Formamide (DMF) l Dimethyl Sulfoxide (DMSO) l Ethyl Acetate l 2-Ethylhexanol (2-EH) / Octanol l Isopropyl Alcohol (IPA)

l Glycerol Monostearate (GMS) -

Self Emulsifying (SE) Grade l Glycerol Monooleate (GMO) l Isopropyl Myristate (IPM) l Isopropyl Palmitate (IPP) l Maleic Anhydride l Methylene Diphenyl Diisocyanate

(MDI) l Mono Methyl Ether of

l Paraformaldehyde 96% l Polyols l Polypropylene Glycol (PPG) l Polysorbate 80 (Tween 80) l Sodium Formate l Sodium Propionate - Food Grade l Sodium Selenite l Stearic Acid l Toluene Diisocyanate (TDI) l Tolyltriazole l Vanillin l Xanthan Gum

METALLIC SALTS: l Cobalt Sulphate l Copper Sulphate l Ferrous Sulphate l Manganese Sulphate l Potassium Iodate l Potassium Iodide l Zinc Oxide l Zinc Sulphate

AROMA CHEMICALS: l Benzyl Isoeugenol l Caryophyllene l Caryophyllene Acetate l Clove Oil (Bud) l Clove Oil (Leaf) l Dihydro Eugenol l Dimethyl Hydroquinone (DMHQ) l Eucalyptol l Eucalyptus Oil l Eugenol l Eugenyl Acetate l Green Patchouli Absolute l Isoeugenol l Isoeugenyl Acetate l Methyl Eugenol l Methyl Isoeugenol l Patchoulol l Tabac Dodecane

Hydroquinone (MEHQ) l Paraformaldehyde 91%

And many more products....

Contact Details:

CHEMSTAR GLOBAL PRODUCTS LLP 601 Nestor Court, 6th Floor, Baji Prabhu Deshpande Marg, O S.V. Road, Kamala Nagar, Vile Parle (West), Mumbai - 400056, Maharashtra, India. | Landmark: Next to Vinayak CHS Telephone: +91 22 26100790 | Email: apurva@chemstarglobal.co.in Apurva Jhaveri: +91-9920366780 69

READY STOCK ALPHA AMYLASE (1:2000) IP BROMELAIN 2400 GDU BROMELAIN 1200 GDU D CHIRO INOSLTOL HCL/DASE FOLIC ACID IP/BP/USP FUNGAL ALPHA AMYLASE DIASTASE 1:2000 IP FUNGAL DIASTASE 1:2000 IP FUNGAL DIASTASE 1:5000 IP HYALURONIC ACID LACTIC ACID BACILLUS 150 BILLION CFU/GM LACTIC ACID BACILLUS 300 BILLION CFU/GM LACTIC ACID BACILLUS 6 BILLION LACTIC ACID BACILLUS 6000 BILLION

LACTULOSE CONCENTRATE USP LIGNOCAINE BASE USP PANCERATIN (IP) PEPSIN (1:3000. IP) PAPAN IP PROBIOTIC BLEND 1 TO 200 BILLION CFU RUTOSIDE TRIHYDRATE SERRATIOPEPTIDAS E/C SERRATIOPEPTIDASE PLAIN POWDER TRYPSIN TRYPSIN CHYMOTRYPSIN MIX (6:1) L- GLUTATHION REDUCED

JAKSON PHARMA 4, Gr, Flr, Bhatru Chhaya Niwas, 83 A, Gokhale Road, Opp Chatwani Baug, Vile Parle (east), Mumbai- 400057 Piyush J.kamdar: 9768311111 / 9322223592, Harsh P. Kamdar: 9167646425 Landline: 022-26101753 Off Mob: 83569-50980/42623 Email: jakson.pharma@gmail.com, jaksons_1960@yahoo.com

70

71

72

73

501, Sanjar Enclave, Above Mahindra Showroom, Opp. Milap PVR, S. V. Road, Kandivli (W), Mumbai - 67.

Tel: +91 22 4011 3538, 2865 1412, 4005 8604 | Email: sohyoglifesciences@gmail.com

Dhruvil Parekh : +91 99304 61006, +91 9372073783 Product List

m ALPHA LIPOIC ACID USP m ASCORBIC ACID IP m AZITHROMYCIN m BIOTIN USP m CLINDAMYCIN PHOSPHATE m DOXYCYCLINE HYCLATE IP m FENBENDAZOLE VET BP

m LEVAMISOLE IP m METHYLPREDNISOLONE IP m NIACINAMIDE m PARACETAMOL IP m SODIUM ASCORBATE m SUCRALOSE

WE DEAL IN ALL KINDS OF API'S AND CAN MATCH CUSTOMERS REQUIREMENTS WITH COMPETITIVE PRICES

ISO 9001:2015 Certified Company

Manufacturers & Exporters of Pharmaceutical Excipients CELLULOSE ACETATE PHTHALATE (CAP / CELLACEFATE) IP/BP/USP/EP (U.S. DMF AVAILABLE) CAS NO. 9004-38-0

Applications Film Coating Tablets

HYPROMELLOSE ACETATE SUCCINATE (HPMCAS) USP (U.S. DMF IN-PROCESS) CAS NO. 71138-97-1

Enteric Coating of Tablets

HYPROMELLOSE PHTHALATE (HPMCP / HPMC PHTHALATE)

Sustained Release

IP/BP/EP/USP (U.S. DMF AVAILABLE) CAS NO. 9050-31-1

Delayed Release

CELLULOSE ACETATE

Pellet Coating Material

BP/EP/USP (U.S. DMF IN-PROCESS) CAS NO. 9004-35-7

CELLULOSE ACETATE TRIMELLITATE CAS NO. 52907-01-4

POLYVINYL ACETATE PHTHALATE (PVAP) USP (U.S. DMF IN-PROCESS) CAS NO. 34481-48-6

Our Plant is FDA (India) & cGMP Certified

Plot No. C-467/468 T.T.C Industrial Area, Pawane MIDC, Navi Mumbai-400705.INDIA. Ph:+91-22-27631692 / 20874696 Fax:+91-22-27621696 / 20874697 Email: sales@gmchemie.com Web: www.gmchemie.com 74

Food Colours, Lake Colours and Pearl Pigments Attn.: Pharmaceutical, Capsules, Tablets, Cosmetics & Edible Product Manufacturers and Exporters ALLURA RED LAKE AMARANTH LAKE BRILLIANT BLUE FCF LAKE CARMOISINE LAKE CHOCOLATE BROWN HT LAKE ERYTHROSINE LAKE FAST GREEN FCF LAKE FAST RED E LAKE INDIGO CARMINE LAKE PONCEAU 4R LAKE QUINOLINE YELLOW LAKE TARTRAZINE LAKE SUNSET YELLOW FCF LAKE BLENDED LAKES APPLE / PEA GREEN / BLACK / BROWN LAKE IRON OXIDE (RED / YELLOW / BLACK / BROWN ) Also available D & C Colours and D & C Lakes Like Green 5, 6 / Violet 1,2 / Yellow 7,8 / Red 4,6,7,17,19,21,22,27,28,30.33,36.

Available Pearl Pigments in various shades

DISTRIBUTORSHIP / DEALERSHIP / AGENCY INQUIRIES SOLICITED

An ISO 9001-2015, WHO-GMP, HACCP, KOSHER & HALAL Certified Company

Manufacturers & Exporters of Lake Colours & Food Colours D-14/5, TTC Ind. Area, Near Reconda Village, Turbhe, Navi Mumbai - 400 705. INDIA Ph. (+91) 93231 32280 / 91371 79278 | Mobile - (+91)-70216 73493, 93230 87138 E-mail:- colours@standardcon.com | web: www.standardcon.com

-$<680 %,27(&+

K&&/ Z ^^͗ ͬϬϮ ŚĂŶĚƌĞƐŚ EĂƌŵĂĚĂ͕>ŽĚŚĂ ,ĞĂǀĞŶ ͕ ŽŵďŝǀĂůŝͲ ĂƐƚ ͕ ŝƐƚƌŝĐƚͲ dŚĂŶĞ ϰϮϭϮϬϰ ;/E / Ϳ͘ ŽƌƉŽƌĂƚĞ KĸĐĞ͗ ϯϳϰ ͕^ĞĐƚŽƌͲϭ 'ŚĂŶƐŽůŝ ͕ EĂǀŝͲŵƵŵďĂŝͲϰϬϬϳϬϭ ;/E / Ϳ ͘DĂŝů͗ ŝŶĨŽΛũĂLJƐƵŵďŝŽƚĞĐŚ͘ĐŽŵ z DŽď͗ ;нϵϭͿ ϵϮϳϬϮϬϵϱϴϰ͕ ;нϵϭͿ ϴϮϳϱϬϱϯϰϵϰ z tĞďƐŝƚĞ͗ ǁǁǁ͘ũĂLJƐƵŵďŝŽƚĞĐŚ͘ĐŽŵ

E/D > & /d/s ^ /KEKW,KZ Ed/ K / / >

z E/ Z /E ϴй н DKE E^/E ϴй

z E Z ^/E ϮϬй z DKE E^/E ϮϬй z ^ >/EKDz /E ϭϮ й z D hZ Dz /E ϭй

z E/ Z /E ϴй н

, D/ > Ed/ K / / > z >KW/ K> Ϯϱй z ZKy Z^KE ϮϬй z ZK E/ /E ϭϬй z KYh/E d ϲй z / > hZ/> Ϭ͘ϱй Ed/ K / / > KD /E d/KE z E/ Z /E ϴй н E Z ^/E ϴй

D hZ Dz /E Ϭ͘ ϴй z E/ Z /E ϭϲй н

D hZ Dz /E ϭ͘ϲй

'W ^z^d D/ d/E' z Kyzd dZ z >/E ϮϬй z ,>KZd dZ z >/E ϭϱй ; d Ϳ 'W Ed/Dz KW> ^D > z Zzd,ZKDz /E ϭϬй z /d,ZKDz /E ϭϬ͕ ϮϬй z dz>s >K^/E d Zd Z d Ϯϱй z d/ Dh>/E ,z ZK' E &hD Z d ϭϬй z dz>K^/E W,K^W, d ϭϬй

'W 'hd d/E' z EZ Dz /E ϴй z s/> Dz /E ϭϬй EKE 'W z D ϭϬй z &> sKDz /E ͬ D ZDz /E ϰй͕ ϴй z , >Yh/EK> ϭϮ͘ϱ й Θ ϲϬй z ^K /hD hdzZ d z >/E KDz /E ϭϭй z ^^ Ed/ > K/> 'Z Eh >^ z s/Z/E/ Dz /E ϭϬй z DK^ ; D EE EͲ z /E /dZ /E ϭϬй K>/'K^ , Z/ Ϳ WKt Z

tĞ ĐĂŶ ƉƌŽǀŝĚĞ Ăůů ƚŚĞ ĂďŽǀĞ WŽƵůƚƌLJ ĂŶĚ ŶŝŵĂů &ĞĞĚ ĚĚŝƟǀĞƐ ŝŶ WŽǁĚĞƌ ĂŶĚ 'ƌĂŶƵůĞƐ ďŽƚŚ͘ ŶLJ ŽƚŚĞƌ ĐŽŵďŝŶĂƟŽŶ Žƌ ƉƌŽĚƵĐƚ ƌĞƋƵŝƌĞĚ͕ ǁŝůů ďĞ ĐƵƐƚŽŵŝƐĞĚ ĂƐ ƉĞƌ ĐƵƐƚŽŵĞƌΖƐ ƌĞƋƵŝƌĞŵĞŶƚ͘ 75

MERU CHEM PVT. LTD. The Chemical Hub

Office: 313, Ramgopal Ind. Estate, 3rd Floor, Dr. R. P. Road, Opp. Jawahar Talkies, Mulund (West), Mumbai – 400 080.

Tel.: 022-67105940 / 66711229 / 25691517 | Mob.: 098201 96391 / 092234 32507 | CIN NO: U24100MH2009PTC191266 Email: meruchempltd@gmail.com / infomeruchempltd@gmail.com | Website: www.chemical-supplier.net

MTBE- Methyl Tert Butyl Ether & META XYLENE - MITSUBISHI GAS CO. LTD. Product List

AUTHORIZED AGENT OF VINATI ORGANICS LTD FOR MTBE DRUMS & TANKERLOAD l Acetic Acid l Acetone l Acetonitrile l Ammonium Chloride l BKC 50% / 80% l Benzaldehyde l Benzoyl Chloride 99% + Purity l Benzyl Acetate / Alcohol / Chloride l Butyl Acetate / Alcohol l Calcium Carbonate / Chloride / Sulphate l Calcium Propionate l Caustic Potash Flakes / Pellets l Caustic Soda Flakes / Prills / Pellets l Citric Acid Mono / Anhydrous l Cobalt Sulphate / Chloride l Crude Glycerine 80% / Refined Glycerine l Cyclohexonone / Cyclohexane l Dicalcium Phosphate l Di Ethyl Ether l Di Ethyl Sulphate l Di Iso Propyl Ether l Di Methyl Formamide l Emulsifire 2.5/6/9.5/10/20 Mol l l Epichlorohydrine l l Ethyl Acetate l l Ethyl Aceto Acetate l l Ethyl Butyl / Methyl / Phenyl Acetate

l l Ethyl Butyl / Methyl / Phenyl Carbitol l l Ethyl Butyl / Methyl / Phenyl Cellosove l Ethyl Butyl / Methyl / Phenyl Glycol l Ethyl / Methyl Chloroformate l Ferric Chloride Anhydrous l Ferrous Sulphate (Crystal / Powder) l Formaldehyde 37% l Formamide l Formic Acid 85% & 99% l Hydrobromic Acid 48% l Hydrogen Peroxide - 35%/ 50% l Hydroquinone l Iso Butanol l Louryl Alcohol 2.5/3/6/7/9/Mol l Magnessium Oxide l Manganese Sulphate l Meta Xylene l Methyl Aceto Acetate l Methyl Methacrylate l Methyl Tert Butyl Ether (MTBE) l Mono Calcium Phosphate l Mono Ethylene Glycol l Mono Sodium Phosphate l Octyl Phenol 8 / 10ml l Oxalic Acid 99%/ 96%

VQ DOCUMENTS SUPPORT AVAILABLE.

76

l Paraformaldehyde 91% / 96% l Phenol l Phosphoric Acid 75% / 85% (Technical & Food Grade) l Piperidine l Piprazine Anhydrous l Poly Ethylene Glycol (200/400/600/1000/1500/4000/6000) l Potassium Carbonate Powder / Granular l Potassium Iodate / Iodide l Pott. Bicarbonate- China l Propylene Glycol Tech / Food Grade l Pyrldine l Sodium Acetate / Benzoate / Citrate l Sodium Propionate l Sodium Thiosulphate l Sorbitol Liquid l Sulphur (Powder) l Sulphuric Acid l Tri Calcium Phosphate l Tri Sodium Phosphate l Tween-80 (Polysorbate 80) / Tween-20 l Xantham Gum l Zinc Oxide / Sulphate

Laboratory Solutions India SOLE DISTRIBUTOR OF: ETHANOL AR 99% (UNDENATURED) & ALL OTHER GRADES PACKING SIZE 500 ML / 25 LIT. / 200 LIT. State Excise License Holder (All India) Importers of:

Changshu Hongsheng Fine Chemical (China) ETHANOL AR 99.9% 500 ML

(U.K.) ETHANOL 100% PREMIUM GRADE AR / HPCL / EP / BP / USP 500ML

(Germany) 1.00983.0511 ETHANOL GR/ACS EMURE 500 ML 1.11727.500 ETHANOL GRADIENT GRADE HPLC 500 ML

(U.K.) ETHANOL AR/ACS 500ML

ETHANOL 200 PROOF (500ML) ACS / USP / EP / BP / JP / FCC / GMP WORLD GRADE

Add: Earth Baug CHS., 116, Shamaldas Gandhi Marg, O ce No. C/506, Princess Street, Mumbai – 400 002.

Cantact: Himanshu Rach: 9833125242 Email: labsolind@gmail.com

304, Western Edge I, Above Metro Store, W E Highway,Borivali (E), Mumbai 400066 EMAIL: emco@emcochemicals.com, WEB: www.emcochemicals.com TEL: 91-22-42433333 I FAX: 91-22-42433366 I Factory : G.I.D.C., sachin-Surat, Pin code - 384230

PRODUCT LIST 2-METHYL-5-NITROANILINE

SODIUM BOROHYDRIDE

PARA ANISIDINE

ACRYLIC ACID

ETHYL CYANO ACETATE

PHOSPHORIC ACID - FOOD GRADE

ALPHA NAPHTHOL

ETHYLENE DIAMINE (EDA)

P-HYDROXY BENZOIC ACID

ALUMINIUM CHLORIDE (ADITYA BIRLA)

GUM ROSIN(W/W)

PROPYLENE GLYCOL- TECH/USP

ANILINE

MALEIC ANHYDRIDE

SALICYLIC ACID (SUBLIM / TECH)

ANTHRAQUINONE

META AMINO PHENOL (MAP)

DIMETHYL ACETAMIDE

BETA NAPTHOL

SODIUM METAL

SODIUM HEXAMETA PHOSPHATE 68% (SHMP)

D-TARTARIC ACID/L(+) TARTARIC ACID/DL-TARTARIC ACID

METHYL ACETO ACETATE (MAA)

SODIUM NITRITE

DI CYANDIAMIDE (DCDA )

ORTHO CHLORO BENZOIC ACID

SODIUM SULPHIDE 60% YELLOW FLAKES

DI METHYL FORMAMIDE (DMF)

ADIPIC ACID

PARA TOLUIC ACID

DIETHANOLAMINE (DEA)

METHYL CYANO ACETATE(MCA)

SULPHANILIC ACID

DIETHYLENETRIAMINE (DETA)

MONO ETHYL AMINE 70%

TETRA SODIUM PYRO PHOSPHATE

EDTA PURE ACID/2NA/4NA

MONOETHANOLAMINE

THIOUREA

EPICHLORO HYDRINE

NONYL PHENOL ETHOXYLATE (NAP) 9.5%

TRIETHANOLAMINE

77

KAMLESH ENTERPRISE D/003, Vijay Park Iraniwadi, Kandivali west, Mumbai-400067 Rajesh Goradia- Mob: 9820019738/9223433306 Email:kamlesh_enterprise@yahoo.com / Rajeshgoradia@gmail.com

PRODUCT LIST l Emulsifier 4.5(Alphox 100)

l Poly Ethylene Glycol (Peg 200)

l Emulsifier 9.5(Alphox 200)

l Poly Ethylene Glycol (Peg 400)

l Emulsifier 30(Alphox 500)

l Poly Ethylene Glycol (Peg 600)

l Benzoic Acid 99% Tech Grade

l Poly Ethylene Glycol (Peg 4000)

l Butyl Cellosolve

l Poly Ethylene Glycol (Peg 6000)

l Butyl Carbitol

l Poly Ethylene Glycol (Peg 1500)

l Castor Oil 40 (Castrox-200)

l Polysorbate 80 (Sorbox -80 / Twin-80)

l Cetomacrogol 1000(Cetodet 500)

Ethoxylate l Propylene Glycol l Toluene (Bulk) l Methyl Ethyl Ketone (Bulk) l Butyl Acetate (Bulk) l Ace c Acid (Bulk)

l Ethyl Carbitol (Igtol 12016 E) l Ethyl Cellosolve(Igsol 12026 E) l Ethyl Cellosolve Acetate (Igace 6701 E) l Methyl Cellosolve l Maleic Anhydride

Akshar Chemicals India Pvt Ltd. F-8, Ground Floor, Avtari Industries, Hatkesh Udhyog Nagar, Mira-Bhayander Road, Miraroad (East), Thane-401107 Mobile: 9833878293 / 9987744529 l Email: aksharchem.mum@gmail.com / info@aksharinterna onal.in Website: www.aksharinterna onal.in

Product List l Acetonitrile (ACN)

l Fromic Acid

l Naphthalene Powder / Balls

l Acid Slurry (Labsa)

l Sodium Sulphate

l Benzene

l Castor Oil

l Polyvinyl Alcohol (PVA)

l Benzyl Alcohol

l Tetrahydrofuran(THF)

l Coco Diethanolamie (CDEA)

l Dimethyl Formamide (DMF)

l TRO (Turkey Red Oil)

l Sodium Tripolyphosphate (STPP)

l Toulene

l Caus c Soda Prills & Flakes

l Trisodium Phosphate (TSP)

l Soda Ash (Sodium Carbonate)

l Ace c Acid

l Sodium Lauryl Ether Sulfate (SLES)

l Sodium Bicarbonate

l Sodium Laureth Sulfate (SLS)

l Potasium Bicarbonate

l Acid Thickner

l Sodium Benzoate

l Soap Noodles

l Xanthan Gum

l Tansparent Soap Base

l DEG (Diethylene Glycol)

l Alpha Olefin Sulfonates (AOS)

l Nitro Benzene

l Pine Oil

l O-Di Chloro Benzene

l Ortho Nitro Chloro Benzene (ONCB)

l Cocamidopropyl Betaine (CAPB)

l P-Di Chloro Benzene

l Para Nitro Aniline (PNA)

l Alphox 200

l Mono Chloro Benzene

l Gum Rosin (Grade-WW / N / K)

78

l Phosphoric Acid l Isopropyl Alcohol (IPA) l Ethyl Acetate l Acetone l O-xylene l Tri Chloro Benzene l Silica Gel l Formaldehyde l Para Nitro Chloro Benzene (PNCB)

SIDDHIVINAYAK PHARMA ETHYL OLEATE BENZYL ALCOHOL / BENZOATE / ZINC PYRITHIONE CHLORPHENIRAMINE MALEATE / DEX CPM COLLIDAL SILLICON DIOXIDE (EQ AEROSIL) PERMITHRIN / PHENOLPHTHALEIN LP MEDIUM CHAIN TRIGLYCERIDE (MCT OIL) ALL TYPE OF FLAVOUR / COLOUR / WAXES / OILS LACTIC ACID / S.S.G / M.C.C.P CETIRIZINE DI HCL IP / FUROSEMIDE IP TRICLABENDAZOLE / BRONOPOL IP ADAPALENE / NEPAFENAC (STERILE & MICRONISED) INDOMETHACIN BP / CABERGOLINE INDAPAMIDE IP / IVERMECTIN IP VET METOPROLOL SUCCINATE / MOMENTASONE FUROATE IP NICORANDIL / VOGLIBOSE / PHENAZONE IP ARACHIS OIL / LINSEED OIL / CALCIUM LACTATE AVOBENZONE / BENZOPHENONE (OXYBENZONE) B.H.A / B.H.T / PROPY GALLET / D.C.P. / T.C.P. COLOUR ERYTHROSIN / BRILLANT BLUE / PONCEAU 4R PANCREATIN I P COLOUR QUINOLINE YELLOW / SUNSET YELLOW / TARTRAZINE CHOLINE CHLORIDE (FEED) / PHARMA

DIVAPROEX SODIUM / SODIUM VALPORATE D.H.A (VEG) / GINSENG POWDER / EXTRACT EMULSIFYING WAX / PEG / TWEEN-60-80 H.P.M.C / ETHYL CELLULOSE / H.P.M.CP IRON OXIDE RED / YELLOW / BLACK LIVER / YEAST EXTRACT POWDER / HONEY MAGNESIUM STEARATE / CROSS CARMOLOSE SODI MAIZE STARCH / SORBITOL / LIQUID GLUCOSE MANITOL / XANTHAN GUM / P.V.P.K.-30 N-ACETYL-CYSTIN / L-ARGININE (L-SERIES) OCTINOXATE (OCTYL P-METHOYCINNAMATE)(O.M.C) P.G. / GLYCERIN / I.P.A / M.D.C / B.H.A / B.H.T / GUAR GUM PROTIN LIQ. / POWDER55-60% / 75-80% SIMITHICON / CETOSTRYLALCHOL / STRYLALCOHOL SODIUM / POTASSIUMHYDROXIDE PALLETS SODIUM SACCHARINE / B.H.A / B.H.T / GUAR GUM VITB1 / B2 / B6 / B12 / D3 / D3 STABILISED METHYL FOLATE CALCIUM (MAXFOL) TRETINOIN USP CAMPHOR USP / BP METHYLCOBALAMINE IP / JP

A-102, Gharkul Bldg., Missquitta Cross Lane, Azad Road, Vileparle (E), Mumbai - 400057.

Tel No. - 022-26123411/ 65276034 Mobile No. - 9322593515 / 9323128870 Email: siddhivinayakpharma@yahoo.co.in / siddhivinayakpharma@hotmail.com

H K ENTERPRISE

(ESTD 1973)

108 , SAI JYOT NEEPA CHS , JUNCTION OF S N ROAD & S L ROAD, MULUD WEST, MUMBAI- 80. l O ce NO : 022 2562 2600 / 2700 KIRTI SHAH : 9223 43 2600 l HARDIK SHAH : 9223 29 2600 l ANKIT SHAH : 9223 26 2600 Email id : hkenterprise1973@gmail.com

We are the regular STOKIEST of M/s V V F ( INDIA ) Ltd. OUR STRENGTH: FATTY ACID AR / RU BBER GRA ADE l STEARIC ACIID ( REGULA /43-4 45 % / 65 5% / 90 % ) CERI NE ( IP / BP / CP / USP / BU ULK / l GLYC RTED ) FSSSAI / IMPOR LEI C ACID ( INDI AN / IMP OR RTED) l OL CO FATTY ACID ( D CFA ) l DI STILLED COC l DI STILLIED SOYYA FATTY ACID l CAPRI C ACID l CAPR YLI C ACID l CAPRI C CAPR YLI C ACID l CAPR OIIC ACID l L AURI C ACID l PALME TI C ACID l M YRI STI C ACID 0% l S O AP N O OD L E S l SL E S 70

lME GlDE GlMIBK lMEK AN ONE l CYCLOHE XA ANE l CYCLOHE XA l ACE TONE BUTANOL l N .B l OCTANOL l BUTYEL ACETATE l ETHYL ACETATE l ACETIC ACID P.A A. l I.P l DI-ACETONE l ACETONITRIL l TOLUENE l MEHANOL

SOLVENTS : ( BULK / DRUM )

FATTY ALCOHOL OL – C 16618 l CETO STEARYL ALCOHO l PURE L AUR YL AL COH OL – C 1 2 14 l L AURYL M YRI STYL ALCOH OL – C 1 21 l CE TYL ALCOH OL – C 1 6 l STEARYL ALCOH OL – C 1 8 l BEHEN YL ALCOH OL – C 22

MONOMERS : l STYRENE MONOMER l V AM l B AM C YL ATTE l 2 E TH YL HE XYL AC lM M AlM A A CR YLI C AC CID l AC l 2 HEM A

OTHERS PRODUCTS : l PHOSPHORIC ACID ( TECH / FOOD GRADE ) l FORMIC ACID ( 85 % / 99 % ) lMDC l ACRYLAMIDE lMDI lTDI lDPG l PROPYLENE GLYCOL (TTECHNICAL / USP) YL AL COH OL l BENZY l SODIUM GLU CON ATE l EP OXY RE SIN l BI SPHEN OL A l SOD A ASH l CAU STI C SOD A FL AKE S l CAU STI C P OTTASH FL AKE S AX l PER AFIN WA UIED PAR AFIN OIIL l HE AVY LI QU UIED PAR AFIN OIIL l LI GH T LI QU R OIIL l CASTOR LIUM JE ELLY l PE TR OL l RUBBER OIL

79

WACKER METROARK CHEMICALS P. LTD/WACKER CHEMIE AG Silicones: 1. Silicone Fluids – 10 Ctsk To 10 Lakh Ctsk 2. Geniosil Vinyl Silanes & Genioplast Polymer Addi ves 3. Silicone Greases 4. Silicone For Car Care & Personal Care Silicone Defoamers/An foams For: 1. Paper And Pulp Industry (Pulpsil Series) 2. Low Foaming We ng Agent (Silfoam Series) 3. Etp And Other Low End Applica ons 4. Metal Working Industry 5. Powder And Liquid Defoamer For Detergent Industry 6. Tex le Applica on 7. Powder And Liquid Defoamer For Agro Industry Silicone Emulsions: 1. Tyre And Dash Board Polish 2. Mould Release A) For Rubber Footwear B) For Eva Footwear C) For Polyurethane Release D) Alumininum Dia Cas ng Release Paints, Coa ng & Construc on: 1. Silicone Resin For Heat Resistant Paints 2. Slip& Mar Addi ve For Solvent Based Paints 3. Hammertone Addi ve For Solvent Based Paints 4. Silicone Addi ve To Make Paints Water Repellent 5. Silicone Binder For Water Based Paints 6. Silicone Based Water Repellents For Natural Stones 7. Powder Based Silicone Water Repellents For Wall Pu y Agro Industry: 1. Silicone Spreader 2. Emulsifiers

80

WACKER CHEMIE INDIA PVT LTD. Vinnol Resins 1. Heat-Sealable Coa ngs For Pharma/Alu-Foil/Paper Packaging 2. Binder For Prin ng Inks Polymer Dispersions For Adhesives 1. Binder For Lamina on Adhesives / Wood Adhesives 2. Binder For Paper Adhesives / Wood Adhesives 3. Binder For Wood Adhesives / Pvc To Mdf 4. Binder For Membrane Press Adhesives Sustainable Paper Adhesive (Paper Solu ons) 1. Barrier Coa ng For Paper

AQUAPHARM CHEMICALS PVT.LTD. Phosphonates: 50 & 60% Hedp Hedp Powder 2 Na / Hedp Powder 4 Na Atmp & Detmp & Edtmp & Hmdtmp Accl–Acetyl Chloride Pci3–Phosphorous Tri Chloride Chela ng Agents For Agro & Aqua Culture Hedo Based Chela ng Agents Polymers: Copolymers Polyacrylate Homopolymer Polyacrylate Comopolymer Ter Polymer Powder Copolymer Poly Maleic Acid Biocide

CLARIANT IGL SPECIALTY CHEMICALS PVT LTD Ethoxylates 1. Nonyl Phenol Ethoxylates 2. Octyl Phenol Ethoxylates 3. Styrenated Phenol Ethoxylates 4. Tridecyl Alcohol Ethoxylates 5. Cetostearyl Alcohol Ethoxylates 6. Cetyl Alcohol Ethoxylates 7. Castor Oil Ethoxylates 8. Polyethylene Glycols 9. Oleyl Amine Ethoxylates 10. Glycerine Ethoxylates THIRUMALAI CHEMICALS LTD 1.Malic Acid 2.Fumaric Acid Other Products Oleo Chemicals 1. Lauryl Alcohols 2. Cetyl Alcohols 3. Ceto Stearyl Alcohol (30:70/50:50/70:30) 4. Stearyl Alcohols 5. Ldma (For Manufacturing BKC) 6. SLES 28% & 70% 7. Perfume Solubilizer Glycerine Glycerine USP/BP/IP/CP/EP

CONTACT DETAILS:

Mr.Anmol Wadhwa: Mobile NO. 9819592146 Mail Id : anmol@arkchemicals.in

PRODUCT LIST Name of product

Pharmacopeia

Therapeu c use

API (HUMAN) COMMERCIAL PRODUCTION

Name of product

Pharmacopeia

Therapeu c use

API (VETERINARY) COMMERCIAL PRODUCTION FENBENDAZOLE CLOSANTEL SODIUM CLOSANTEL BASE OXFENDAZOLE

IP/BP VET /USP/ EP IP/BP VET IN-HOUSE BP VET / EP

TRICLABENDAZOLE

BP VET/EP

ANTHELMINTIC

ALBENDAZOLE OXYCLOZANIDE PYRANTEL PAMOATE

IP/BP/USP BP VET /EP USP/IN-HOUSE

ANTHELMINTIC ANTHELMINTIC ANTHELMINTIC BENZIMIDAZOLE ANTI-HELMINITIC BENZIMIDAZOLE ANTI -HELMINTIC ANTHELMINTIC ANTHELMINTIC ANTHELMINTIC

LOCAL ANAESTHETIC

UNDER DEVELOPMENT

LOCAL ANAESTHETIC

NAME OF PRODUCT META CHLORO PROPIOPHENONE 2-BROMO-3’CHLOROPROPIOPHENONE 1-(2-HYDROXYETHY ) PIPERAZINE

CAS NO. 34841-35-5 34911-51-8

END USE BUPROPION HCL BUPROPION HCL

103-76-4

TRIETHYLENE DIAMINE

CITICOLINE SODIUM

IP/USP

NOOTROPIC

BUPROPION HYDROCHLORIDE

USP

ANTIDEPRESSANT

LIDOCAINE HYDROCHLORIDE MONOHYDRATE

IP/BP/USP/EP

LOCAL ANAESTHEITC

LIDOCAINE

IP/BP/USP/EP

5-HT3 RECEPTOR ANTAGONISTS

GRANISETRON HYDROCHLORIDE

IP/BP/USP

LOCAL ANAESTHETIC

MELOXICAM

IP/BP/USP/EP

ANTI-INFLAMMATORY

PIROXICAM

IP/BP/USP/EP

ANTI-INFLAMMATORY

ALBENDAZOLE

IP/BP/USP

PRILOCAINE

IP/BP/EP/USP

PRILOCAINE HYDROCHLORIDE

BP/EP/USP

ARTICAINE HYDROCHLORIDE

IP/BP/USP/EP

LOCAL ANAESTHETIC

NAME OF PRODUCT BILASTINE BENFOTIAMINE CELECOXIB GLICLAZIDE

CAS NO. 202189-78-4 22457-89-2 169590-42-5 21187-98-4

SITAGLIPTIN PHOSPATE METHYLCOBALAMIN RIVAROXABAN

654671-78-0 13422-55-4 22457-89-2

END USE ANTIHISTAMINES VITAMINB1 ANTIINFLAMATORY (NSAID) HYPOGLYCAEMIC (ANTI-DIABETIC DRUG) ANTIDIABETICS VITAMIN B12 ANTICOAGULANT

UNDER DEVELOPMENT

Corporate O ce: 303, Western Edgwe 1, Western Express Highway Magathane, Borivali (East), Mumbai 400 066 Maharashtra Tel: 22 40160260 /61/62/63/64 Works: Plot No. 411/1 & 412/2, L.I.C. Sector, Silvassa Road G.I.D.C. Vapi 396195 Dist, Valsad, Gujrat, India. Tel: 91 260 2453714/ 91 260 2453567 Mob: +91 8689897373 l Email: enquiry@cheminopharma.com Web: www.cheminopharma.com

81

PRODUCT LIST

Cobalt l Cobalt Chloride l Cobalt Acetate l Cobalt Sulphate l Cobalt Nitrate l Cobalt Oxide l Cobalt Carbonate Nickel l Nickel Chloride

l Nickel Acetate Ace etate

l Chromium Formate

l Nickel Sulphate

Tungsten l Sodium Tungstate l Tungs c Acid l Phospho Tungs c Acid Tin l Stannous Chloride l Stannous Sulphate l Potassium Stannate l Sodium Stannate

l Nickel Nitrate l Nickel Carbonate

Chromium l Chromium Chloride l Chromium Acetate l Chromium Fluoride l Chromium Nitrate

103, Savera, offf. Shimpoli Road, Borivali-west, Mumbai – 400092, Maharashtra, Ind dia Mobile: 9833 251 567, 9167 551 567 Email: gogri.harsh@gmail.com

JAYANT AGRO-ORGANICS LIMITED MANUFACTURERS & EXPORTERS OF CASTOR OIL & ITS PRODUCTS CIN. L24100MH1992PLC066691

Products Castor Oil – Various Grades Including Pharmaceu cal Grades Castor Oil Fa y Acids Hydrogenated Castor Oils & Fa y Acids Dehydrated Castor Oil & Its Fa y Acids Castor Oil Methyl Esters Castor Amides Blown Castor Oils Sebacic Acid 2-Octanol & 2-Octanone (Methyl Hexyl Ketone) Glycerine Regd. O ce : 701, Tower ‘A’ Peninsula Business Park, Senapa Bapat Marg, Lower Parel(W) Mumbai 400 013 India Tel.: +91 22 4027 1300 l Fax: +91 22 4027 1399 l Email: info@jayantagro.com l Website: www.jayantagro.com 82

KEMS RAW PHA ARMA '($/(5 3+$50$&(87,&$/6 &+(0,&$/6 5$: $: 0$7(5,$/ %8/. '58*6 328/7$5< 6833/,0(176 (7&

$1$1' %+$:$1 %$%8 *(18 52$' 35,1&(66 675((7 080%$, 0$+$5$6+75$ ,1',$ $ 3+21( 2 &(//

(PDLO NHPFRFKHP#\DKRR FRP NHPVUDZ#JPD DLO FRP Following Raw Material Bulk Drugs Available From Ready Stock: l Acriflavine l Ac vated Carbon Powder l Aluminium Hydroxide Paste l Aluminium Sterate l Bees Wax l Belladona Green Verdis Paste l Bile Salt l Ca ne Citrate l Calamine Powder l Calcium Carbonate l Calcium D- Saccharate l Calcium Hypophosphite l Cassin Pro n Hydrolystae Powder 60% l Cassine Pro n Hydrolysate Powder 80% l Cellulose Acetate Pthalate l Cerebro Pro n Powder l Choline Chloride Powder 98%/60%/50% l Choline Chloride Solu on 65% l Collodion Flexable Sol. l Crysobinum Powder l Crystal Violet Powder Pure l Dried Aluminium Hydroxide Gel l Dry Yeast Powder

l Emulsifying Wax (Ionic/Non-Ionic) l Extract Belladona Dry Powder l Extract Belladona Green Veredis Paste l Extract Liver (Paste / Powder) l Extract Malt (Powder / Paste) l Extract Stomach (Paste/ Powder) l Extract Yeast (Paste / Powder) l Gama Benzoin Hexa Chloride l Gum Accacia l Gum Guar l Gum Tragacanth l Iodoform l Isolated Soya Pro ne Powder 90% l Lanoline Anhydrous l Light Kaoline l Magaldrate l Magnesium Aluminium Silicate l Magnesium Hydroxide l Magnesium Sulphate l Magnesium Trisilicate l Malt Diastase l Merbromine Powder l Oil Arachies l Oil Castor Bss l Oil Linseed Refine l Oil Neem Refine

l Oil Olive Oli l P Papain i IIp / P Pure l Pap pain Usp / Refine /5x/7x l Parra Amino Benzoic Acid l Parra Chloro Meta Cresol l Pec c ne l Peptone - Gela n / Proteosse l Peptone (Bactro/ Pharma) l Pro oflavine Hemisulphate l Propyl Ga allate l Pro o n Liquid (20% / 30% /60%) l Silv ver Sulphadiazine l Sim methicon 100% l Sim methicon Emulsion 30% l Soy ya Lecthin Powder /Paste l Soy ya Pro n Hydrolysate Powder 60% % l Soy ya Pro n Hydrolysate Powder 80% % l Soy ya Pro n Powder Capsula on Grad de l Sug der gar Pharma Grade l Sulphur Powd l Talcum Powder l Tannic Acid l Tolna ate l Vittamin K 3 Feed / Pharma l Zin nc Acetate Pure

Besides This We Can Also Supply All Kinds Of: EXTRACT HERBS, OLEROSINE, AROMATIC ESSENTIAL OILS, FOOD & PHARMA COLOUR. C /// BISMUTH SALT LT S (CARBONATE E, OXIDE, SUB-NITRATE, CITRATE, SUB GALLATE ETC.) /// CHLORIDE & BROMIDE SALT LT (AMMONIUM.CALCIUM, SODIUM, POT TASSIUM) /// MATELLIC STE ARA AT TE (ALUMINIUM, BARIUM, CALCIUM, ZINC, MAGNESIUM)

CR PHAR RMA A

Proprietor: Chintan Domadia Mobile:- +91 9324211958, +91 9022445757 Email:- sales.crpharma@gmail.com | Website:- www.crpharma.co.in 511, 5th floor, Zest Business Space, M.G.Road, Ghatkopar (East), Mumbai-400077

HARIKA DRUGS REPRESENTATIVE l PROCHLORPERAZINE MALEATE IP/BP/USP (PREMIUM SELLER) l DOXYLAMINE SUCCINATE USP (PREMIUM SELLER) l GLICLAZIDE IP/BP l PROMETHAZINE HCL IP/BP/USP (PREMIUM SELLER) l PROMETHAZINE THEOCLATE IP/BP (PREMIUM SELLER)

OTHER PRODUCTS:l ETORICOXIB IP l OXYCLOZANIDE BP VET l LULICONAZOLE IP l LINEZOLID IP l VILDAGLIPTIN IP

l METHYLCOBALAMIN IP l ALBENDAZOLE IP & USP (PLAIN) l CLOPIDOGREL BISULPHATE IP l LEVOCETIRIZINE HCL IP l DOMPERIDONE IP

l AMBROXOL HCL IP l RIFAXIMIN EP l MONTELUKAST SODIUM IP l BRIVARACETAM IHS l MEFENAMIC ACID IP/BP

*All Prices are Subject to final confirma on and availability of the stock at the me of order.

83

Address: Ajay Industrial Estate, 3rd Floor, O ce No. 306, Anjirwadi, Mazgaon, Mumbai-400 010, Maharashtra, India.

Phone: +91-22-23717140 Email: tejas@relicchemicals.com, info@relicechemicals.com

Manufacturer | Importer | Exporter

Mob: +91-98331 18324, 98701 94496

Manufacturers for Bromo Compounds, Defoamers and Polymers l

1,2,3 Benzotriazole

l

Fabric Seal C (Fire Reardants)

l

N-Butyl Bromide

l

1,4 Dioxane

l

Fabric Seal N (Fire Reardants)

l

Phthalic Anhydride

l

Adipic Acid

l

Fabric Seal S (Fire Reardants)

l

Paper Seal Concentrate (Fire Retardants)

l

Biocides

l

H2S Scavanger

l

Potassium Monopersulfate

l

Bisphenol A

l

Hydroquinone

l

Propylene Glycol

l

Butalated Hydroxy Toulene

l

Isophthalic Acid l

Coal Combus on Catalyst

l

Isopropyl Alcohol

Succinic Acid

l

Defoamers

Tetrabutylammonium Bromide

l

Maleic Anyhydride

l

l l

Diethylene Glycol

l

Mono Ethylene Glycol

l

Tetrabutylammonium Hydrogen Sulphate

l

Dipropylene Glycol

l

Mono Methyl Amine (30%)

l

Tolytriazole

l

Epoxy Resin

l

Mono Methyl Amine (40%)

l

Tri-N-Butylamine

l

Ethyl Acetate

l

N-Bromosuccinimide

l

Wood Seal A (Fire Retardants)

98200 34250 PRODUCT LIST 1,4 - Butanediol Acetic Acid Acetophenone Acrylic Acid Acrylonitrile Adipic Acid Benzoic Acid Bisphenol A Butyl Acrylate Butyl Carbitol Butyl Carbitol Acetate Butyl Cellosolve Butyl Cellosolve Acetate DEG Diethanolamine

84

Dimethyl Formamide Dimethyl Sulfoxide Epichlorohydrin Ethyl Acetate Ethyl Carbitol Ethyl Cellosolve Ethyl Cellosolve Acetate Hexamine Isobutanol Maleic Anhydride MDI MEG Methacrylic Acid Methoxy Propanol Methoxy Propyl Acetate

Methyl Carbitol Methyl Cellosolve Methyl Methacrylate Mix Xylene Monoethanolamine PEG 200/400/600/6000 PPG 400/1000/2000 Propylene Glycol PTMEG 1000/2000 TEG THF Toluene Triethanolamine Vinyl Acetate

Animal Health API PRODUCT NAME Afoxolaner Amitraz Buparvaquone Butaphosphan Carprofen Clorsulon Decoquinate Diminazene Diaceturate

Fenbendazole Fluazuron Flunixin Meglumine Fluralaner Imidocarb Dipropionate Marbofloxacin Nitroxynil N-Ethyl Glucamine

Parvaquone Praziquantel Ractopamine HCI S-Methoprene Toldimfos Sodium Toltrazuril Triclabendazole Xylazine

Animal Health Formulations PRODUCT NAME Amitraz Liquid Concentrate 12.5% Diminazene Diaceturate Granules with Phenazone Decoquinate Premix 6%

Homidium Chloride Tablets Ractopamine Premix 10%

Human Health API PRODUCT NAME Atovaquone

Nitazoxanide

Praziquantel

Product are offered where there is no patent infringement

301, E Square, Subhash Road, Vile Parle (E), Mumbai 400 057, India. (+91 22) 40842222 | info@nglfinechem.com | www.nglfinechem.com

PANCHAMRUT CHEMICALS Contact Details : 9870795121 / 9825242122 Office No.: 7021778189 / 8591740139 Email: sales@panchamrutchemicals.com / info@panchamrutchemicals.com

PRODUCTS

HYDROQUINONE TRI BUTYL PHOSPHATE L ASPARTIC ACID SODIUM FORMATE ORTHO CHLORO BENZOIC ACID SUCRALOSE ASPARTAME GLYCERINE BENZOPHENONE 203, GANGOTRI, HARIDAS NAGAR, SHIMPOLI ROAD BORIVALI (WEST), MUMBAI - 400 092

85

Import

Our Products

l Benzyl Alcohol l Benzyl Chloride l Benzaldehyde l Calcium Chloride-Powder l Caustic Potash Flakes l Caustic Soda Flakes l Chloroform l Hydrogen Peroxide-50% l Methylene Dichloride l Phosphoric Acid 85% Min l Potassium Carbonate Granular/Powder

l Soda Ash l Sodium Bicarbonate

l Ammonium Bicarbonate Powder l Dimethyl Formamide l Sodium Nitrate l Sodium Nitrite l Trimethylamine

l Cyclohexane l Cyclohexanone Cyclohe anone

l ISO Propyl Alcohol

l Acetone l Acetonitrile l Bisphenol-A l Chloroform l Citric Acid l Cyclohexane l Cyclohexanone l Diethylamine l Dimethyl Formamide (DMF) l Dimethyl Sulfoxide (DMSO) l Diethylene Triamine l Epichlorohydin l Ethyl Chloro Formate l Formamide l Formic Acid l Glycering l Gum Rosin l Hydrogen Peroxide 50% l Hydroxylamine Sulphate l L(+) Tartaric Acid

l Melamine M l Methan M Sulfonyl Chloride l Methyl M Aceto Acetate lM Methyl Ethyl Ketone lM Methyl Isobutyl Ketone lM Methylene Dichloride lN N.Propanol lP Per Chloro Ehtylene lP Phthalic Anhydro Maleic Anhydride lP Propylene Glycol Tech lP Purazine Anhydrous lS Sodium Nitrite lS Sodium Bicardonate lS Sodium Metal l Sodium S Nitrate l Sodium Tripoly Phosphate Tertiary Dutanol l Sodium Gluconate l Tetra Hydrofuran l Titanium Dioxide Anatase/Rutile l Triethylene Tetramine

Conttact Details: 1101, Bay View Tower, r,Sector-11, Opp. Domino D z, CBD Belapurr,, Navi Mumbai-410 209 Ph: 022-6464 0085 / 9223434334 / 92 223433883lEmail: rasayan_India@yahoo.In

ATTENTION ACTUAL USERS / TRADERS We request you to send your inquiries by E-mail / Phone Available regularly at Competitive prices from Authorized Distributors / Stock list FOR MORE DETAILS LOG ON TO

www.ketanchemicals.com SODIUM BENZOATE 99% - (BP/IP/USP) | BENZOIC ACID – (BP/IP/USP/Tech) BENZYL BENZOATE – (BP/IP/USP/Tech) Authorized distributors: M/s. MISA Finechem Pvt Ltd / Navyug Pharmachem Pvt Ltd ZINC OXIDE (White seal 99.5% / Metal Grade 99.8% & 95% Feed Grade & Acti.Z grade) Authorized distributors: M/s. Rubamin Ltd. Available Japan / Lanxess also at Very Very Reasonable Price BUTYLATED HYDROXY TOLUENE (2,6-Ditertiary Butyl Para Cresol/BHT) (Original Intact Bags) • Benzyl Alcohol Benzyl Chloride • Benzaldehyde Thionyl Chloride Benzyl Benzoate • BUTYLATED HYDROXY TOLUENE PARA CHLORO TOLUENE (PCT) • ORTHO CHLORO TOLUENE (OCT) Authorized stockiest : M/s. Laxness Group • Benzyl Alcohol Benzyl Chloride Benzyl Acetate Authorized stockiest : M/s. Waylon Pharmaceuticals META PARA CRESOL (Mixed Cresol) – (Imported / Intact) (Sealed Packed Barrels) ORTHO CRESOL - (Imported / Intact) | PARA CRESOL PURE 99% - (China / Atul) | META CRESOL PURE 99% - (Imported / Intact) Transformer Oil – IS 335 Liquid Paraffin (Heavy & Light) (All Grades) Authorized distributors: M/S. Apar Industries Ltd.

CONTACT: KETAN CHEMICAL CORPORATION

24,26, 27, 30, SWASTIK PLAZA, V.L. MEHTA ROAD, NEXT TO KALANIKETAN, J.V.P.D. SCHEME, MUMBAI 400 049 TEL. NO: 6148 4500 ( UPTO 30 LINES) l EMAIL: sales@ketanchemicals.com l WEB: www.ketanchemicals.com

Associate: Kalpana Enterprise & Jimit Chemicals

86

M/S. J.J.TRADERS

405,Parshva Chambers,17/21,Issaji Street, Masjid-(West),Mumbai-400003, Tel No. 66312858, 66312182, 23472627, Tele.Fax- 66312858

E-mail : info@jjtraders.co.in

Sr.No.

Products

Make

Packing

Sr.No.

Products

Make

Packing

1) 2) 3) 4) 5) 6) 7) 8) 9) 10) 11) 12) 13) 14) 15) 16) 17) 18) 19) 20) 21) 22) 23) 24)

Sodium Nitrite Sodium Nitrite Sodium Nitrite Sodium Nitrite Sodium Nitrite Sodium Nitrite Sodium Nitrate Sodium Nitrate Sodium Nitrate Propylene Glycol-Tech Boric Acid Powder-Tech Ammonium Bi- Carbonate Ammonium Chloride Acrylamide Formic Acid-85% Formic Acid-85% Formic Acid-85% Polyvinyl -Alcohol -173 Polyvinyl -Alcohol- Gh 17 R Polyvinyl- Alcohol-Bp 20 Polyvynil Alcohol-Bp24 Polyvinyl Alcohol-Jf 17 R Polyvinyl Alcohol -24 88 Polyvinyl Alcohol- 1799

Rcf China Deepak Indian Oxalate Russia Basf Rcf Deepak Russia China Indo/Organic Rcf Basf China Shandong Rcf Luxi-China Singapore Singapore China China China

50 Kg.(Bag) 25 Kg. (Bag) 50 Kg.(Bag) 50 Kg.(Bag) 25 Kg.(Bag) 25 Kg.(Bag) 50 Kg.(Bag) 50 Kg.(Bag) 25 Kg.(Bag) 215 Kg.(Drum) 50 Kg.(Bag) 25 Kg.(Bag) 25 Kg.(Bag) 25 Kg.(Bag) 35 Kg.(Carboys) 35 Kg.(Carboys) 35kg.(Carboys) 20 Kg.(Bag) 20 Kg.(Bag) 20 Kg.(Bag) 20 Kg.(Bag) 20 Kg.(Bag) 25kg.(Bag) 25kg.(Bag)

25) 26) 27) 28) 29) 30) 31) 32) 33) 34) 35) 36) 37) 38) 39) 40) 41) 42) 43) 44) 45) 46) 47) 48)

Dimethyl Acetamide (Dmac) Dimethyl Acetamide (Dmac) Dimethyl Formamide (Dmf) Dimethyl Formamide (Dmf) Dimethyl Amine (Dma) Dimethyl Amine (Dma) Mono Methyl Amine(Mma)-40 Dicyan Diamide (Dcda) Phospheric Acid Borax Decahydrate Tech.

Citric Acid Caus c Soda Flakes Refined-Glycerine Urea T.G. Urea T.G. Sodium Nitrate Polyvinyl Alcohol Jp-05-Y Dimethyl Acetamide Dimethyl Formamide Caus c Potash Flakes Potassium Carbonate Ace c Acid Sodium Tri Polyphosphate Glycerine

Rcf Balaji Amines Balaji Amines Saudi Rcf Balaji Amines Rcf China Vietnam Argen na Ttca Ccacl Indonesia Iran Gnfc Fluoboric Japan China Luxi-China Universal Korea Gnfc China/Iran Pt Dua Kuda

200 Kg.(Drum) 200 Kg.(Drum) 200 Kg.(Drum) 200 Kg (Drum) 170 Kg.(Drum) 170 Kg (Drum) 170kg.(Drum) 25 Kg.(Bag) 35 Kg.(Carboys) 25 Kg. (Bag) 25 Kg. (Bag) 50 Kg (Bag) 250 Kg (Drum) 50 Kg.(Bag) 45 Kg.(Bag) 50 Kgs Bag 20 Kgs Bag 180 Kgs Drum 190 Kgs Drum 50 Kgs Bag 25 Kgs Bag 30 Kgs Carboys 25 Kgs Bag 250 Kgs Drum

China

87

We provide best solutions in:

APIs | Pellets | Excipients | Flavours | Fragrances Active Pharmaceutical Ingredients (APIs) PRODUCT LIST T u AMOXAPINE

u LEVOSULPRIDE

u RABEPRAZOLE SODIUM

u LOXAPINE SUCCINATE

u TENELIGLIPTIN

u RIFAXIMIN

u AMISULPRIDE

u TORSEMIDE

u DABIGATRAN ETEXILATE

u PRAZIQUANTEL

u SILODOSIN

u PRUCALOPRIDE SUCCINATE

u MONTELUKAST SODIUM

u IRON SURCLOSE

u FINASTERIDE

u CILIDIPINE

u KETOPROFEN u FEBANTEL u OMEPRAZOLE POWDER u BREXPIPRAZOLE u CABERGOLINE u FEBUXOSTAT

Contact : Agam Shah : +91 9920899117

Office Address: 502,Shree Radhe Empire, Chandavarkar Road, Borivali (West), Mumbai:- 400092.

Tel +91 022-35593585 | Email: juanapharma@gmail.com | Web: www.juanapharma.com

88

SKY CHEM 808/809, Ajitnath CHS Ltd., Neelkanth Enclave, LBS Marg, Opp. Shreyas Cinema, Ghatkopar West, Mumbai 400 086.

Tel: 9820330512;9819765791l Email: ajaibros@gmail.com PRODUCT Ammonium Chloropla nate Gold Chloride 12.5 % Gold Chloride 25 % Gold Chloride 50 % Palladium powder Palladium 5% on Charcoal Palladium 5% on Asbestos Palladium 5% on Barium Sulphate Palladium 5% on Alumina Palladium 5% on Calcium Carbonate Palladium 10% on Charcoal Palladium 10% on Asbestos Palladium 10% on Barium Sulphate Palladium 10% on Alumina Palladium 0.5% on Alumina Balls Palladium 10% on Calcium Carbonate Palladium Acetate Palladium Bromide Palladium Chloride Palladium Nitrate Palladium Oxide Palladium Sulphate 5% Pla num on Charcoal 10% Pla num on Charcoal Pla num Black powder Pla num Chloride 40% Pt Pla num Oxide Adams Catalyst (Hydrated) Potassium Chloropla nate Potassium Iodopla nate Potassium Tetrachloropla nate

HSN CODE 28439000 28433000 28433000 28433000 71102100 38151210 38151290 38151290 38151290 38151290 38151210 38151290 38151290 38151290 38151290 38151900 28439019 28439019 28439019 28439090 28259090 28439019 38151210 38151210 71101120 28439019 28259090 28439019 28439019 28439019

PRODUCT Pla nous Chloride Silver Powder (Approx. 200 mesh size) Silver Acetate Silver Bromide Silver Carbonate Silver Chloride Silver Chromate Silver Diethyl Dithio Carbonate Silver Iodide Silver Iodate Silver Nitrate LR / AR Silver Nitrite Silver Oxide Silver Sulphate LR Silver Sulphate AR Silver Sulphide Silver Nitrate S cks Ruthenium Trichloride Ruthenium Red Rhodium Trichloride Rhodium 5% on Alumina Rhodium 5% on Carbon Tetrakis (triphenylphosphine) palladium (O) Bis (triphenylphosphine) palladium (II) Iridium Trichloride Indium Metal Ingots Indium Chloride Indium Nitrate Indium Oxide Indium Sulphate

HSN CODE 28439090 71061000 28432900 28432900 28369990 28273990 28415090 29302000 28432900 28299030 28432100 28341090 28259090 28432900 28432900 28309010 28439019 28439019 38220000 28439019 38151200 71022990 28439019 28439019 28439019 81129200 28273990 28342990 28259090 28332990

VACUUMED C TRAY DRYER R

ROTAR A Y DOUBLE CONE VACUUM DRYER REAC TORS Head Office : EMCO O ENGINEERING PVT. T. LT LTD. 304, 3rd Floo orr,, Western Edge -1, Western Exxpress Highway, y, Borivali (East), Mumbai - 400066, Mah harashtra, India. | Mob. : +91 98 8206 84319 | Email : inffo o@airje etmill.com 89

JEEVAN CHEMICALS AND PHARMACEUTICALS Plot no: - C-431, T.T.C. Industrial area, Turbhe, Navi Mumbai-400705.

Email: - drchopde.jeevan@gmail.com Website: - info@jeevanchempharma.org Phone no: - 9326362295, 9820112971, 9833140986.

BACTERIOLOGICAL RAW MATERIALS

NUTRACEUTICALS

FEED SUPPLEMENT

1. Peptone.

1. Protein Hydrolysate.

1. Liver Tonic.

2. Tryptone.

2. Yeast Extract.

2. Probiotics.

3. Soya Peptone.

3. Betaine Anhydrous.

3. Prebiotics.

4. Yeast Extract.

4. Dimethyl Glycine.

4. Enzymes.

5. Liver Extract.

5. Glycine.

5. Amino Acids.

6. Bile Salt.

6. Cerebro protein Hydrolysate.

6. Dried Yeasts.

7. Brain Heart Infusion etc. 7. Ovotranferrin

NEHA PHARMA PVT. LTD. (Since 1988)

Address: C/ 7, Yatin Mansion, Kalbadevi Road, Kalbadevi, Mumbai - 400002 Tel: +91 9930933530 Mob: +91 9930933662 Email: pratik.gandhi@nehapharma.com

TRIPROLIDINE HCL SELEGILINE HCL METHYLCOBALAMINE MEFENAMIC ACID SODIUM LACTATE USP 60% SOLUTION LACTIC ACID COD LIVER OIL BP FISH LIPID OIL BP 90

Narcotics / Psychotropic Substances

PSEUDOEPHEDRINE HCL EPHEDRINE HCL ALPRAZOLAM DIAZEPAM BUPRENORPHINE HCL TRAMADOL HCL PHENOBARBITAL BASE / SODIUM MEPROBAMATE

v All Amino Acid v Budesonide v Cabergoline v Carbidopa v Caroverine v Carvedilol v Colchicine v Dibucain BP/USP/JP v Edaravone v Empagliflozin v Ezetimibe

v Fofomycin v Fosfomycin Trometamol v Glimpiride IP/USP v Glipizide IP v Iron Protein Succinylate v Indapamide IP/USP v Ketoprofen IP/USP/EP v Levodopa v Linagliptine IP/BP/EP/USP v Midodrine HCL v Orlistat IH

v Oxybutynin HCL BP/EP v Pepsin (1:3000) v Pimecrolimus v Pro-Pre Biotic Blend (As per customer request composition) v Risperidon USP v Rifaximin BP v Rutoside Trihydrate BP v Serratiopeptidase Plain / Granuals v Tacrolimus v Tetrabenazine v Trypsin BP

ALL TYPES OF HERBAL EXTRACTS & NUTRACEUTICAL RAW MATERIAL

402-403 SENETE, AURA BIPLEX, S.V. ROAD, OFF: RAM NAGAR, BORIVALI (W), MUMBAI – 400 092 Tel : 91-022-2802 1117-8 * Email : sales@idcco.com * Web : www.idcco.com R. D. Shah: 9820130897 & D. D. Shah: 9820084312

INTERME EDIIAT TE S

Name

End use e

4-(2-Amino Ethyl) Benzene Sulfonamide Glimepiride Sulphonamide 4-Hydroxy Pyridine-3-Sulfonic Acid 4-(3-Methyl Phenyl)Amino-3-Pyridine Sulfonic Acid Lasamide 4-Amino-2-Chloro-6,7-Dimethoxy Quinazoline 4-Hydroxy-3-Methoxy-5-Nitro-Methyl Benzophenone 2, 5 Dichloro Thiophene 2-Dibutylamino-1-(2, 7-dichloro -9H-Fluoren -4yl0 Ethanol

Glipizide/Glibenclamide Glimepiride Torsemide Torsemide Furosemide Prazosin/Doxazosin/Alfuzosin/Terazosin Pharma Intermediate Pharma Intermediate Lumefantrine Intermediate

APII Name

The era ape eutics Ap pp liication

Name

The erapeutics Application

Alfa Calcidol Baclofen Calcitriol Dapoxetine HCl Dopamine HCl Ethamsylate Fenofibrate Furosemide Glipizide Hydroxyzine HCl

Vitamin D3 Analog Anti Spasmodic Vitamin D3 Analog Cardio Tonic Neurotransmittor Haemostatic Treat High Cholestrol Levels Diuretic Anti Dibetic Antihistamines

Iopromide Nimodipine Probenecid Rivaroxaban Rosuvastatin Calcium Sodium Pico Sulphate Tolperisone Torsemide Trimethobenzamide HCl

Iodinated Radiographic Contrast Agent Calcium Channel Blockers Uricosuric Treat Deep Vein Thrombosis Anti-Hyperlipoproteinemic Laxative Musce Relaxant Diuretic Antiemetic

M /S. S YNTHET TIC MOLE ECUL LES PRIIVAT TE LIMI TE D (An ISO 9001-2015 Certified Company)

Corporate Office: - 308, Highway Commercial Centre, I.B. Patel Road. Off W.E. Highway, Goregaon (E), Mumbai - 400063, India Phone: +91-22-26865407, 40214555 Mobile no.:7021140070 Fax: +91-22-26861298 Email: sales@syntheticmolecules.com URL: www.syntheticmolecules.com

91

Nisha Chemicals

D-501, Neelkanth Business Park, Behind Bus Depot, Vidyavihar (W), Mumbai : 400086.

Tele Nos: (+91)(022) - 61271617 / 18 Fax: (+91)(022) - 35100110 Email: Info@nishachemicals.com Web: http://www.nishachemicals.com

Contact: +919892821414 / +91 9223383831 / +919967186874 Distributors For “ Henan Jindan Lactic Acid Technology Co. LTD.” For Lactic Acid, Sodium Lactate, Magnesium Lactate, Calcium Lactate & Buffered Lactic Acid.

2 Ethyl Hexanoic Acid (Octoic) 2 Ethyl Hexyl Acrylate (2EHA) 4 Di Methyl AminoPyridine (4DMAP) Acetonitrile Acrylamide Acrylic Acid Acrylonitrile Ascorbic Acid Bronopol Buffered Lactic Acid Butyl Acetate Intact Butyl Carbitol Butylated Hydroxy Toluene (BHT) Butylated Hydroxy Anisole (BHA) Bisphenol A Calcium D Panthothenate Calcium Lactate Cyclohexane Cyclohexanone Cyclohexanol Dicyclopentadiene (DCPD) Di Iso Propyl Ether (DIPE) Di Methyl Carbonate Di Methyl Formamide Di Methyl Sulphoxide Di Propylene Glycol (DPG)

Ethyl Acrylate Ethyl Carbitol (IG) Ethylene Glycol Mono Methyl Ether (Methyl Glycol) Formamide Formic Acid 99 % & 85 % Glyoxal 40% Glycine Hexa Methyl DiSilazane (HMDS) Hexamine Hydrazine Hydrate 100% Hydroxylamine Sulfate (HAS) Itaconic Acid L ( + ) Tartaric Acid Lactic Acid 80%, 88% & 90% Lactic Acid Liquid Lactic Acid Powder Lactose Mono / Anhydrous Lauric Acid L Alanine L-Arginine L Lysine L Glutamic Acid L-Valine Magnesium Lactate Methyl Aceto Acetate

Methyl Metha Acrylate (MMA) MethAcrylic Acid (MAA) Methane Sulphonic Acid (MSA) Methane Sulphonyl Chloride (MSC) Methyl Iso Butyl Ketone (MIBK) Methyl Tert Butyl Ether (MTBE) N Butyl MethAcrylate (NBMA) N-Methyl Pyrrolidone (NMP) N Hexane Paraformaldehyde 91% & 96% Para Toulene Sulphonic Acid (PTSA) Pentaarythritol Potassium Bi Carbonate Potassium Bi Sulphate Potassium Carbonate Powder Potassium Sorbate Propylene Glycol Propylene Glycol Technical Skim Milk Powder Sodium BoroHydride Powder Sodium Formate Sodium Lactate Sorbic Acid Tetrahydrofuran (THF) Xanthan Gum

Office : 7 Th Floor , Unit No 716, Highway Commercial Center Premises Co-Op Soc Ltd, I.B. Patel Road Goregaon (E), Mumbai - 400 063 Tel: 91-22-46051578, 9819811703 l Email: info@nakshapharma.com Web: www. Nakshapharma.com

( API ) THERAPEUTICS CATEGORY

PRODUCT NAME

THERAPEUTICS CATEGORY

PRODUCT NAME

ANTI CONVULASNT

PREGABALIN IP PHENYTOIN SODIUM / BASE LORATIDINE BP DIPHENHYDRAMINE HCL AMBROXOL HCL IP BROMHEXINE HCL IP LEVOSALBUTAMOL SULPHATE IP MONTELUKAST SODIUM METFORMIN HCL IP AMOXICILLIN TRIHYDRATE COMPACTED / POWDER IP/ BP CLOXACILLIN SODIUM COMPACTED / POWDER -IP/BP DICLOXACILLIN SODIUM COMPACTED / POWDER -IP/ BP CEFIXIME IP COMPACTED CEFPODOXIME PROXETIL IP / USP CEFUROXIME AXETIL IP / USP URSODEOXYCHOLIC ACID IP ORNIDAZOLE IP DOMPERIDONE IP TRANEXAMIC ACID IP FLUCONAZOLE IP ATORVASTATIN CALCIUM IP

ANTI-INFLAMMATORY

DICLOFENAC SODIUM IP DICLOFENAC POTASSIUM BP NIMESLIDE BP PIROXICAM BP MELOXICAM BP PANTOPRAZOLE SODIUM SESQUIHYDRATE IP METRONIDAZOLE IP/ BP SODIUM PICOSULPHATE BISACODYL PHENYLEPHRINE HCL IP TACROLIMUS USP AZITHROMYCIN IP DEFLAZACORT IH

ANTI HISTAMINE ANTI ASTHAMATIC

ANTI -BIOTIC

ANTI CHOLELITHIC ANTIDIARRHOEALS ANTI EMETICS ANTI-FIBRINOLYTICS ANTI-FUNGALS ANTIHPERLIPIDEMIC

92

ANTI -ULCERATIVE CARDIOPROTECTANT CONSTIPATION / LAXATIVES DECONGESTANT IMMUNOSUPPRESSANTS MACROLIDES STEROIDS

NUTRA ACEU UTICALS NUTRACEUTICALS

ALPHA LIPOIC ACID

E XC CIEPIEN TS EXCIEPIENTS

XANTHAM GUM 200 MESH XANTHAM GUM TRANSPERANT

VIITAMIIN VITAMIN

MECOBALAMIN IP

Address: 77/78 Ashok Chambers, 5th Floor, 56, Devji Ratansey Marg, Masjid - East, Mumbai - 400 009 Tel.: 022-66108086/87/88 | What’s App No. 09223433408 EMail.: nikeoncorp@gmail.com | URL.: www.nikeon.com

SINCE 1985 AMINO ACID l BCAA 2:1:1 l BETA ALANINE l CREATINE MONO 200 MESH l D-ASPARTIC ACID l GLYCINE l INOSITOL l L- GLUTATHIONE REDUCED l L- THERONINE l L-ARGININE BASE l L-ARGININE HCL l L-CARNITINE BASE l L-CARNITINE L-TARTARATE l L-CITRULLINE DL MALATE l L-CITRULLINE PLAIN l L-GLUTAMINE l L-HISTIDINE HCL l L-LYSINE HCL l L-PROLINE l L-TRYPTOPHAN l L-TYROSINE l MELATONIN l N-ACETYL L-CYSTEINE l SODIUM HYALURONATE l TAURINE

SWEETENERS

VITAMINS l ALPHA LIPOIC ACID

l ACESULFAME K

l CO-ENZYME Q 10

l ASPARTAME

l D BIOTIN

l ERYTHRITOL

l FOLIC ACID

l FRUCTOSE

l VITAMIN A DRY POWDER

l NEOTAME

l VITAMIN A PALMITATE 1.7

l SODIUM SACCHARINE

l VITAMIN B1 MONO/ HCL

l SORBITOL POWDER

l VITAMIN B12 (CYANOCOBALAMIN)

l SUCRALOSE

l VITAMIN B2 (RIBOFLAVIN) l VITAMIN B3 (NIACINAMIDE)

l XYLITOL

l VITAMIN B5 (CALCIUM D PANTOTHENATE) l VITAMIN B6 (PYRIDOXINE HCL) IP

FEED PRODUCTS

l VITAMIN C (ASCORBIC ACID) l VITAMIN D3

l BIOTIN 2%

l VITAMIN E ACETATE- BASF

l DL METHIONINE l L-LYSINE HCL

EXTRACTS

l VITAMIN AD3

l GRAPE SEED EXTRACT 95%

l VITAMIN E 50 % POWDER

l SILYMARIN UV 80%

EXCIPIENTS

l BETA CYCLODEXTRIN l CAFFEINE ANHYDROUS l CITRIC ACID MONO /ANHYDROUS l COLLOIDAL SILICON DIOXIDE (AEROSIL) l DIMETHYL FORMAMIDE (DMF) l DIPROPYLENE GLYCOL (DPG) l EDTA DI SODIUM SALT l EDTA TETRA SODIUM SALT l GLYCERIN l ISOPROPYL ALCOHOL l LACTIC ACID 88% l LACTIC ACID POWDER l LACTOSE 200 MESH l MAGNESIUM STEARATE l MANNITOL IP/BP/USP l METHYLENE DICHLORIDE (MDC) l PARACETAMOL IP/ BP/USP l POTASSIUM SORBATE l PROPYLENE GLYCOL - SK PIC GLOBAL KOREA l PVP K-30 l PVP K-90 l SODIUM CITRATE l SODIUM CMC l SORBIC ACID l TITANIUM DIOXIDE (TIO2) l XANTHAN GUM l XANTHAN GUM TRANSPARENT

AUTHORISED DISTRIBUTOR WACKER CHEMIE, GERMANY & CJ BIO, KOREA

f{xà{ gÜtw|Çz VÉÅÑtÇç 2nd floor, Diamond Building, Lohar Chawl, Pathak Wadi, Marine Lines, Mumbai, 400002 Ph.: 022-40048174 l Email: chromasheth@gmail.com / shethchroma@gmail.com.

Kalpesh Sheth : +91-9820715414, Rajesh Sheth : + 91-9821435228, Samyak Sheth : +91-9820715956

AN ISO CERTIFIED COMPANIES DIRECT IMPORTERS & SUPPLIERS , ALL PRODUCTS ALWAYS READY STOCK FOR SPECIAL PRICES ALWAYS CONTACT US PRODUCTS l ADENINE/ ADENINE SULFATE l ADENOSINE l ABSCISIS ACID l 2,2 BIPYRIDE 99% AR l 2 - THIOBARBITURIC ACID AR/ACS l 2,4 Di nitro Phenyl Hydrazine (DNPH) l BISMUTH ALL SALTS l All BUFFER RANGES l ALL NICKEL SALTS l ALL MERCURY SALTS l ALL LITHIUM SALTS l ALL COBALT SALTS l BIOTIN l CARMINE 60% FOR MICROSOCOPY l CHOLESTEROL 97% l GALLIC ACID l 6-BA

l GIBBERELIC ACID (GA 90%) l CHLORAMINE T l 1,5 DIPHENYL CARBAZIDE l D – RAFFINOSE l D - LACTOSE ANHY / MONO l D – CELLOBIOSE AR/ACS l D – MALTOSE ( Japan/China) l ERICHROME BLACK T l 1,10 PHENANTHROLINE MONO l L – ARABINOSE l LIGTH GREEN SF YELLOWISH l LANTHANUM OXIDE / NITRATE / CHLORIDE l HEAMATOXYLIN STAIN CERTIFIED l HOLMIUM OXIDE 99.9 % l MOLYBDEIUM l METAVANADATE (AMMONIUM/SODIUM) l VANADIUM PENTOXIDE / TRIOXIDE

l IODINE DERIVATIVES l ORCINOL MONOHYDRATE l ORCEIN l POTASSIUM TELLURITE l POTASSIUM / SODIUM IODIDE l PYROGALLOL AR/ACS l THIOACETAMIDE 99% l SODIUM AZIDE l SODIUM TETRAPHENYL BORATE AR/ACS l SODIUM LAURYL SULFATE LR/AR/ACS l SULPHANILAMIDE l TANNIC ACID l TETRAZOLIUM SALTS l URIC ACID 99% l ZINC OXIDE / SULPHATE / NITRATE

93

API

PHARMACEUTICAL INTERMEDIATES

Alogliptin Benzoate Trelagliptin succinate Linagliptin Cetilistat Sacubitril/Valsartan Tenofovir Alafenamide Fumarate Osimertinib Ibrutinib Baloxavir marboxil Empagliflozin Tianeptine sodium salt Tofacitinib Veliparib NMN（BETA-NICOTINAMIDE MONONUCLEOTIDE) Sofosbuvir Daclatasvir dihydrochloride Velpatasvir-Co-Povidone (1:1) Ledipasvir:Copovidone Solid Dispersion Molnupiravir Abiraterone Methotrexate Sorafenib

Valsartan /Sacubitril Intermediate Ethyl 2-(Triphenylphosphoranylidene)Propionate{ CAS:5717-37-3} (R,E)-5-([1,1'-biphenyl]-4-yl)-4-((tert-butoxycarbonyl)amino)-2-methylpent-2-enoic acid {CAS: 1012341-48-8} (2R,4S)-5-(Biphenyl-4-yl)-4-[(tert-butoxycarbonyl)amino]-2-methylpentanoic acid { CAS:1012341-50-2} 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoic acid(AHU-377) 1369773-39-6 Alogliptin intermediate 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-bromoxanthine 853029-57-9 3-Methyl-6-Chlorouracil { CAS: 4318-56-3 } 2-[(6-Chloro-3,4-dihydro-3-Methyl-2,4-dioxo-1(2h)- pyriMidinyl)Methyl]benzonitrile {CAS:865758-96-9} (R)-3- Aminopiperidine Dihydrochloride (Cas# 334618-23-4) Linagliptin intermediate 3-Methyl-8-bromoxanthine {CAS:93703-24-3} 2-Aminoacetophenone { CAS:551-93-9} Quinazoline, 2-(chloromethyl)-4-methyl {CAS: 109113-72-6} 8-bromo-7-but-2-yn-1-yl-3-methyl-3,7-dihydro-1H-purine-2,6-dione { CAS: 666816-98-4} (R)-3-Boc-Aminopiperidine Cas: 309956-78-3 Palbocilib intermediates 1 CAS: 571188-59-5 Palbocilib intermediates 2 CAS: 1016636-76-2 Pharma intermediate CAS: 1421372-66-8 Pharma intermediate CAS: 4076-36-2 5-Methyl-1H-tertazole Pharma intermediate CAS: 626-64-2 4-Hydroxypyridine

Unit No – 411, Tower A, Spaze Edge, Sector 47, Sohna road, Gurugram - 122018, Haryana EMAIL.: info@bulatpharmaceutical.com, formulation@bulatpharmaceutical.com MOBILE : +91 8448085662

Synchrom Laboratory Pvt Ltd Silver Spring, A-426, Taloja MIDC, Navi Mumbai, Maharashtra.

Email- synchromqc@gmail.com l Contact No. - 9022165688 / 9987702424 SERVICES Chemical and Pharmaceutical testing Analytical method development and method validation Impurity synthesis, custom synthesis and product development REGULATORY AFFAIRS DMF (API) and Dossier (Formulation) preparation DMF and Dossier submission to various regulatory authorities Assist to prepare draft query responses for DMF/Dossier WE ALSO OFFER FOLLOWING PRODUCTS Calcium thioglycolate l Potassium thioglycolate Ammonium thioglycolate l Ethanolamine thioglycolate PHARMA INTERMEDIATES Isoxepac ( Intermediate of Olopatadine hydrochloride ) CAS No - 55453-87-7 2-(methyl thio) acetamide ( Intermediate of Nepafenac ) CAS No - 529-64-6 Para bromo toluene CAS No - 106-38-7 94

Mumbai Office: 211-212, Goldcrest Business Park, Opp. Shreyas Cinema, LBS Marg, Ghatkopar (West), Mumbai - 400 086.

Tel: + 91-22-4973 0577 / 4973 0677 | Email: kipchemicals@gmail.com / sachin.shah@kip.co.in | Website: www.kip.co.in Contact Person: Sachin Shah - Mob: +91 9892492782

MANUFACTURER AND DISTRIBUTOR OF BELOW PRODUCTS PHARMA INDUSTRY l 2 Pyrrolidone l 1,5 Pentanediol Liquid l 5-5 Dimethyl Hydantoin & Derivatives l 2- Bromo/ 2- Chloro / 2 – Nitro / 2- Acetyl Thiophene l Meta Bromo Anisole / Meta Chloro Anisole l 5 - Acetyl Salicylamide l Di Ethyl Pyro Carbonate

l Acetone Cyanohydrin l Thiophene l Bulyraldehyde l Glyoxylic Acid -50% l Glutaraldehyde-50% l Isobulyraldehyde l Gamma Butyrolactone l 5 - Bromo Indole / 5 - Cyano Indole

TEXTILE INDUSTRY l Anti-Ozone Softener l Ester Quat Fabric Softener

INDUSTRIAL CHEMICALS l 1,6-Hexanediol l BCDMH- Bromo Chloro Dimethyl Hydantoin Powder l Vulkanox BKF- Rubber Antioxidant l Methyl Cyclohexane l Rheovis – HEUR PU Thickener for Paint Industry

COSMETIC INDUSTRY l Isododecane l Allantoin l DMDM Hydantoin l Thioglycolic Acid 80 / 99% & Derivative l Acrylate Copolymer – Liquid / Powder (Thickener) l Benzophenone 3 & 4 l Behentrimonium Chloride 85% pellet form l Silicon Quaternium-22 Conditioning Agent l Pearlcare DS-400- Cold process pearlizing Agent l Carbomers Series – Rheology Modifier l PEG 150 Distearate l APG- Alkyl Polyglucoside

HOME / PERSONAL CARE INDUSTRY l Acid Thickener l PCMX – Para Chloro Meta Xylenol l Ethoxylate Series – Powder/ Liquid

ADITYA MINT Address: F 63,First floor, The Zone Mall, Chandavarkar Road, Borivali West, Mumbai 400092.

Factory: Dewa, Barabanki, U ar Pradesh.

MENTHOL, THYMOL, CAMPHOR Lemongrass oil, Benzyl alcohol Essen al Oils, Herbal Oils, Carrier Oils and Fragrances For product list: Please visit us on www.adityamint.com Email: info@adityamint.com / adityamint07@gmail.com Contact: +91 8788521585 / 9970313727 / 9320208033

95

Manufacturer of

Collodiol Flexible (Passing / Confirming / BP / USP / IP)

GLOBE PRODUCTS Chemical House, LBS Marg, Gokulnagar, Thane (W)-400601

Tel: +91 9223433889 | Email: infoglobeproducts@gmail.com

v Gum Rosin (Indonesia /Indian) v Paraffin Wax (Fully/ Semi Refined) v Waxes – (Slack / Residue) v Chlorinated Paraffin Wax (CPW) v Di Octyl Phthalate (DOP) v Di Butyl Phthalate (DBP) v Liquid Paraffin (Heavy / Light) v Petroleum Jelly v Rubber Process Oil (RPO) v Liquid Glucose v Melamine v Hexamine v Glycerine

v Methanol v Stearic Acid (PVC /Rubber Grade) v Nonyl Phenol (Alphox) v Xylene (Ortho/ Mix) v Maleic Anhydride v Phthalic Anhydride v Pentaerythritol v Formaldehyde v Caustic Soda / Caustic Potash v Soda Ash v Pyridine v MDC v Urea (Technical)

v DCDA v Acrylamide v SLES / SLS v AOS (powder / liquid) v Tri Ethanol Amine (TEA) v Tricloroethelene (TCE) v Ammonium Chloride v Citric Acid (Mono) v Boric Acid / Borax v Oxalic Acid (94% / 99%) v Benzoic Acid v Poly Vinyl Alcohol (PVA) v Phosphorous Oxychloride

v Propylene Glycol (PG) v Phosphoric Acid v DiMethyl Formamide (DMF) v Salicylic Acid v Phosphorus Oxchloride v Di Ethylene Glycol (DEG) v Mono Ethylene Glycol (MEG) v Iso Propyl Alcohol (IPA) v TETA v DETA v Toluene v Acetone v Sodium Petroleum Sulphonate

Contact Person : VISHAL CHAUDHARY - Mobile : 9820443932 Tele Fax: 022-40233999 | Office: 8355953073 | E-mail: vishal@vibgyorchemical.com / marketing@vibgyorchemical.com | Website: www.vibgyorchemical.com

RIDDHI SIDDHI DYE CHEM MULTI DYES & CHEMICALS SALES STOCK OF CHEMICAL & GENRAL SUPPLIES Sales Ofice : F-317, Raghuleela Mega Mall, 1st Floor, Behind Poisar Depot, Kandvali (West), Mumbai - 400067.

Off. Tel. : 49791386, Mob. : 9223259151/9223243338 • Email : info@riddhisiddhidyechem.com, multidyes26@gmail.com Web : www.riddhisiddhidyechem.com • AMMONIUM CHLORIDE (TECHNICAL) • ALLUMINIUM SULPHATE (NON FERRIC) • AMMONIA ALUM LUMPS • AMMONIUM SULPHATE (TECHNICAL) • ALUM POWDER • ACTIVATED CARBON (150 MB/280MB) • CALCIUM CARBONATE (PPT) • CALCIUM CHLORIDE (FUES) AARTI MAKE • CALCIUM CHLORIDE (POWDER) • DI AMMONIUM PHOSPHATE (TECH) • DI SODIUM PHOSPHATE (CRYSTAL) • FERROUS SULPHATE (CRYSTAL)

96

• FERROUS SULPHATE (DRIED) • FERRIC ALUM SLAB / LUMPS • HYDRATE LIME (80% - 90%) • LIQUOR AMMONIA • MAGNESIUM CHLORIDE FLAKES (JCW MAKE) • MAGNESIUM CHLORIDE CRYSTAL • MAGNESIUM SULPHATE • MAGANESE SULPHATE • RESIST SALT (30%) • RESIST SALT (50%) • RESIST SALT (80%) • RESIST SALT (95%)

• SODIUM ACETATE • SODIUM ACETATE (TRIHYDRATE) • SODIUM THIOSULPHATE (ATULMAKE) • SODIUM THIOSULPHATE (P) CRYSTAL • SODIUM SULPHIDE FLAKES (YELLOW) • SODIUM METASILICATE (5H20/9H20) • SODIUM HEXA META PHOSPHATE (TECH) • SODIUM META BI SULPHITE • SULPHAMIC ACID • POTTASIUM META BI SULPHITE • POTASH ALUM

KESHARIYA CORPORATION v Aerosil (Madhusilica)

v Mono Ethanol Amine.(M.E.A)

v Acetic Acid Glacial

v Phosphrous Acid (China)

v Acetone

v Pottasium Chloride

v Ammonium Bi Carbonate (RCF)

v Potassium Sorbate (China)

v Ammonium Chloride (IP) (China)

v Refined Salt(GHCL)

v Carbon Tetra Chloride

v Sodium Benzoate

v Caustic potash Flakes

v Soda Ash (Dense / Light)

v Di Ammonium Phosphate (DAP)

v Sodium Sulphate Anhydrous

v Ethanol Denature.

v Sodium Starch Glycolate

v Ferric Chloride Anhydrous

v Sodium Bi Carbonate

v Glycerine(Indonasia)

v Sorbitol

v Iso Propyl Alcohol. (Taiwan / Deepak)

v Sulphamic Acid

v Liquid Light Paraffin

v Sodium Sulphate Flakes (Yellow)

v Magnesium Nitrate.

v Thioure (Imported)

v Methyl Ethyl Ketone (M.E.K)

v Urea Techincal Grade

v Methanol

v Yellow Dextrin.

v Malto Dexstrine (Ambuja)

v White dexstrine

202, Bldg A/56, Sector-3, Shanti Nagar, Mira Road (East).

Dist-Thane, Pin-401 107. Maharashtra.

Mobile:9820430709 / 9222447459 Email:keshariya_cor@yahoo.co.in, infokc9@gmail.com www.keshariyacorporation.com www.keshariyacorporation.co.in

AARA PHARMA

Email ID : aarapharma9@gmail.com Mobile +919820458152 I Landline : 022 - 28984027 Aceclofenac Adapalene Alpha Lipoic Acid Albendazole Amorolfine Artesunate Artemeether Aspartame Betamethasone Salts Bimatoprost Biotin USP Brimonidine Tartrate Carbamezapine Clotrimazole IP Deflazacort Diclofenac Diethalamine Diclofenac Sodium IP/BP Diclofenac Potassium Dorzolamde Dutasteride

Eberconazole Etizolam Fenticonazole Nitrate Glimipride Hydrocortisone Salts Ibuprofen Latanoprost Luliconazole Misoprostol Montelukast Mupirocin Nepafenac Olopatadine Permethrin Pregabaline Quitiapine Fumerate Rosuvastatin Calcium Travaprost UDCA Voglibose

Plot No. C-1/ 23, M.I.D.C. Ta Tarapur Industrial.

Area, Boisarr, Dist. Palghar-401506.

P Mobile: 9323804995 5/ 7317246324 Email: vitabiotic6 60@gmail.com

VITA AMIN AD3 DRY POWDER: (1000/200) (500/100) (10 00/20) (50/10)

VIT TA AMIN D3 DR RY POWDER: 6000 IU / 60,000 IU

VITA AMIN A PALMITA AT TE DRY POWDER R:

5000 IU /1000 IU / 100000 (100 CWS) / 250000 (25CWS) / 325000 (325 CWS) / 500000 (500 CWS)

VITAMIN TA E ACET TA AT A TE E DRY POWDER: 50 MG /100 MG /250 MG /400 MG /500 MG

VITAMIN A E ACETA AT TE 98 % LIQUID VIT TA AMIN A PALMIT TA AT TE 1.6 MIU / 1.7 MIU LIQUID VITAMIN A E ACETA AT TE 50 DRY POWDE ER (FEED GRADE) FOR USE: USE PHARMA, FOOD, COSMETICS, BEVERAGES, POULTRY LT & CA AT TTLE FEED. 97

S.A.I. PRODUCTS W-54, PHASE II, M.I.D.C.AREA, DOMBIVLI (EAST) – 421 204.

Mob: +91 9821142051 l Email: saiproducts@yahoo.co.in PRODUCTS

APPLICATIONS

CHEMICAL INTERMEDIATES i) Sodium Azide ii) Ethyl/Methyl Palmitate iii) Ethyl/Methyl Oleate AGRICULTURAL PRODUCTS i) MFA (Triacontanol) Powder & Fomulation-2%, 1%, 0.1%, 0.05% ii) Dipping Oil iii) Biosuper iv) SuperFresh v) Vegetable/Fruit Special vi) Herbogaurd BIO PRODUCTS i) Sophorolipid-Biosurfactant

POULTARY FEED ADDITIVE i) EnhanSo Powder ii) EnhanSo Liquid

ARNISH LA ABOR R ATES S PVT T. LTD..

NAME OF PRODUCT

CAS NO

CAPACITY MT/ANNUM

STANDARD/ MINIMUM PACK

ACID FUCSHIN SODIUM SALT

3244-88-0

2

5 Kgs

ACRIDINE ORANGE BASE

494-38-2

3

1 Kgs

ACRIFLAVIN HYDROCHLORIDE

8063-24-9

10

25 Kgs

ALIZARINE COMPLEXONE

3952-78-1

1

1 Kgs

AMMONIUM CERIC NITRATE AR

16774-21-3

50

25 Kgs

AURIN (p-ROSALIC ACID)

603-45-2

5

5 Kgs

AZUR – A

531-53-3

5

25 Kgs

BLUE TETRAZOLIUM (BT)

1871-22-3

5

5 Kgs

CALCON

2583-85-4

2

1 Kgs

CHROMOTROPIC ACID DI-SODIUM SALT D-HYD.

5808-22-0

5

25 Kgs

o-CRESOLPHTHLALEIN

596-27-0

2

10 Kgs

2:6 DICHLOROPHENOL INDOPHENOL SODIUM SALT

620-45-1

10

5 KGS

MALACHITE GREEN OXALATE

2437-29-8

100

25 kgs

METHYLENE BLUE ZINC FREE

7220-79-3

100

25 Kgs

METHYL RED FREE ACID

493-52-7

25-30

25 kgs

MUREXIDE

3051-09-0

25

25 kgs

NINHYDRIN

485-47-2

50

25 kgs

THIOFLAVIN – T

2390-54-7

10

5 Kgs

THYMOLPHTHALEIN

125-20-2

20

25 kgs

Address: 202, 2nd Floor, Modi House, Bajaj Cross Road, Kandivali (West), Mumbai-400 067. India Ph: +91-7208475595 Email: sales@arnishlaborates.com Web: www.arnishlaborates.com

98

For Bulk Drug Intermediates, For Explosives & Agicultural Products As Chemical Intermediate

Plant Growth Promoter Fruit Drying Oil Plant Growth Regulator For Fruits & Vegetables Soil Fumigator Used in Paint Industries, Biological, Agricultural,Bio-Processing, Cosmetic, Soap,Detergent, Mining, Petroleum, Environmental, Food Industries.

Additive for Poultary Feed

)/ 6HULHV )OXLGL]HG %HG *UDQXODWRU &+(0,&$/ 3+$50 (48,30(176

%20%$< (1*,1((5,1* :25.6

- 0 ' (1*,1((5,1* :25.6

*DPEKLU *DPEKLU ,QGXVWULDO ,QGXVWULDO (VWDWH (VWDWH 2ႇ $DUH\ 5RDG *RUHJDRQ (DVW 0XPEDL 7H 7 HO

$DVKLUZ $ DVKLUZDG DG ,1' ,1' (VW (VW 1R 1R R *DOD *DOD 1R 1R 5DP 0DQGLU 5G *RUHJDRQ :HVW 0XPEDL 0DKDUDVKWUD

7H 7 HO

QLWLQ#ERPHQJJ J FRP [ +HOSOLLQH 1XPEHU

9LVLW 8V $W ZZ ZZ Z ERPHQJJ FRP

Email : payalimpex0894@Gmail.Com Tel : 9223439470/9022329470 8830460091

Import | Export | Inden ng | Distribu on | Marke ng CORE PRODUCTS

l HYDROQUINONE (HQ) l PROPIONIC ACID l IODINE PRILLS l BKC 50% AND 80% l TERT BUTANOL (TBA) l TERT BUTYLHYDROQUINONE (TBHQ) l ALL TYPES OF AMMINO ACIDS l ACETIC ACID l BENZOIC ACID l N- BUTYRIC ACID l CITRIC ACID l ISOBUTYRIC ACID l LACTIC ACID l OXALIC ACID l PHOSPHORIC ACID

SOLVENTS

l CYCLOHEXANONE l PROPYLENE GLYCOL (PG) l NORMAL BUTANOL (NBA) l METHYL ISOBUTYL KETONE (MIBK)

FOOD ANTIOXIDANTS l BUTYLATED HYDROXYANISOLE (BHA) l BUTYLATED HYDROXYTOLUENE (BHT)

SPECIALTY CHEMICALS l CALCIUM PROPIONATE (CP) l TOLYLTRIAZOLE (TTA) l XANTHAN GUM

METALLIC SALTS l COBALT OXIDE l COBALT SULPHATE l COPPER SULPHATE l FERROUS SULPHATE l MANGANESE SULPHATE l POTASSIUM IODATE l POTASSIUM IODIDE l SODIUM SELENITE l ZINC OXIDE l ZINC SULPHATE

Regd Address: 101 Madhuram Apartment, Sainagar, Near 60 Feet Road, Vasai Road West, Palghar 401202.

P. G. Shah & Co. Bulk Drugs, Intermediates, Excipients & Formula ons Email: info@pgshah.com Tel: +91-22-28990032; +91-22-28980312 Web: www.pgshah.com APIs : l Azathioprine l Ci coline l Dil azem HCl l Esomeprazole Magnesium Trihydrate l Fexofenadine HCl l Fluconazole l Itraconazole l Levocetrizine Di HCl l Tadalafil l Iron Sucrose l Levosalbutamol Sulphate l Levothyroxine Sodium l Efinaconazole l Mycophenolate Mofe l/Sodium l Tigecycline

l Dapagliflozin l Pantoprazole Sodium l Rabeprazole Sodium l Riboflavin Phosphate Sodium l Enoxaparin l Vardenafil l Sildodosin l Bilas ne l Tirofiban l Terbutaline Sulphate l Tramadol HCl l Valsartan l Salbutamol Sulphate l Sumatriptan Succinate l Heparin Sodium

Vetrinary APIs : l Albendazole l Butaphosphan l Clorsulon l Diminazene Di Aceturate

l Fenbendazole l Triclabendazole l Flunixin Meglumine l Oxfendazole

Excipients : l Cellulose Acetate Phthalate(CAP) l Hypromellose Phathalte(HPMCP) l Calcium Carbonate

l Talcum l Dibasic Calcium Phosphate

99

100

Available in small packing and in Bulk

Chlorosulphonic Acid Oleum Acid 25% and 65% Nitric Acid 72% and 98% Diethyl Sulphate Benzene Sulphonic Acid Thionyl Chloride

SUNRAJ CHEMICAL CO. K. B. Achhra Chambers, 2nd Floor, Behind Hari Kirtan Darbar, Section 17, Ulhasnagar – 421003.

Tel.: 0251 – 2707408, 2731484 Mob.: 9422686622 / 9096576500 Email: sunraajchem@yahoo.co.in

Medisearch Laboratories (Bombay) Pvt. Ltd.

STABILIZED OXYCHLORO COMPLEX (HPLR) Produced in Technical Collaboration with WRC Biolabs (UK).

Meets the stringent European Pharmacopeia Criteria.

COA, MSDS, MOA, and European PET data available Exported to various countries including EU.

Contact : medisearchsoc@gmail.com

Jiya Pharmachem 25,1 St Floor Kapeesh Mall Mulund West 400 080 Tel : 022-25908061 | Cell : 8655408992 Email : Jiyapharmchem@Gmail.Com

Product Offered

Dealing In Speclity Chemicals Dealers Of Surplus Chemicals We Can Buy Spent Sodium Bromide Spent Potassium By Products Bromide Calcium Bromide, Ammonium Bromide Lithimum Bromide Etc Bulk We Can Buy Surplus Chemicals & Recovered Solvents 101

NOBLE CHEMICAL AGENCY O ce: 17-8-187, Chowni Nade, Ali Baig, Hyderabad-500 023, Telangana, India.

We require all types of Spent Bromides Specially , Spent Sodium Bromide Spent Hydrobromic Acid Spent Bromides Above 20% Dis lled / Spent / Crude / Residual Solvent Mixed Tri Butyl Tin Chloride

Spent Raney Nickel Contact: Naziya Sultana: +91 6309361417 Mohammed: +91 9121094090 noblechemicalagency@gmail.com sulphate916@gmail.com brominenoble12@gmail.com

ISO 9001:2015 CERTIFIED LABORATORY State of the Art Advanced Instrumentation Centre for All Analytical Requirements GC-ALS, GC/MS, GC-HSS, ICP-OES, HPLC,GPC, IC, XRD, XRF, DSC, TGA, FTIR, CHNS, Particle size, Porosimetry, SEM, SEM-EDAX and Chemical Analysis

Services: Purity of solvents by GLC and KF Metal tes ng by ICP-OES up to ppb level Anions and Ca ons by Ion Chromatography up to 0.1 ppm Molecular weight determina on by GPC Purity by HPLC FAME Analysis Contact Us @

DR. KETAN MERCHANT Email ID: saslab21@gmail.com , info@saslabindia.com Mobile: 8850413449 / 9821291797 / 9821075247 Tel: 91-22-25000386 / 25000186 / 42150502 Website: www.saslabindia.com Address: 305, 3rd Floor, Jhalawar Building, Patanwala compound, opposite Shreyas Talkies, LBS Marg, Ghatkopar-West-400086

102

v Ethamsylate Bp v Ebastine Bp v Miconazole Nitate v Phenytion Sodium Ip v Lorazepam v Clonazepam v Melitracine v Di Valporate Sodium 70-30 & 45-55 & Bp & Usp v Sodium Valporate Ip & Bp v Valporic Acid Ip & Bp v Mefenamic Acid Ip v Co Enzyme Q1 ( Nutraceticals Grade ) v Hydrocortisone Sodium Succinate v Orlisate Ih v Pitofenone v Chlorthalidone v Disulfiram v Flupenazine Deconate v Flupentixol Hcl v Procyclodiane Hcl v Trihexyphenydine Hcl Ip & Bp & Usp v Nicorandil v Chlordiazepoxide v Clozapine v Ferrous Ascorbate Dc Grade v Tolperisone v Mirtrazapine v Razitriptan v Sumatrptan v Trypsin & Chemotrypsin v Pencreatine v Rutin (Rutoside Trihydrate ) v Valthamate Bromide v Fenpiverium Bromide v Orphenidrine Citrate v Methyl Predinisolone Sodium Succinate & Base v Etizolam Bp v Olmesartan v Miconazole Nitrate Ip v Chlorpromazine Hcl Ip & Bp v Peliperidone v Zolmitriptan v Naratriptan Hcl v Eletriptan Hydrobromide v Anastrazole v Bromolian

Unit No. 203, 2nd Floor, Blue Rose Industrial Area, Near Jaya Petrol Pump, Western Express Highway, Borivali (East), Mumbai-400 066.

GANDHI CHEMICALS 301, Purva Plaza CHS LTD., Shimpoli road, Opp. Adani Electricity, Borivali(W), Mumbai-92 Landline: 91-22-61276444/45 l Phone: 7208855010/11 Website : www.gandhichemicals.com l Email : mktg@gandhichemicals.com Partner : Mr. Alpesh Doshi - 9223433838 | Mr. Alpesh Gandhi - 9223433034

All solvent available in bulk and drum packing All other solvents and chemicals as per the need of customer AUTHORIZED DI STTRI BUTTOR OF

l Acetone l Acrylic Acid l Aerosil 200 l Butyl Acetate l Di Methyl Formamide (DMF) l Ethyl acetate l Glycerine l Iso propyl Alcohol (IPA)

l Methanol l Methylene Chloride (MDC) l N-Butanol l N-Propanol l Propylene Glocol (PG) l Sorbitol l Toluene l Xylene

Unipharma

AVAILABLE PRODUCTS

PARACETAMOL IP / BP/ EP / USP

(Dealers In Ac ve Pharmaceu cal Raw Material) 28, Lohar Chawl, Ground Floor, Mahim (West), Mumbai-400016 Contact: 022-24451832 /24457618/9820051832 E-Mail: Unipharma81@Gmail.Com

Products l Albendazole

l Griseofulvin

l Aceclofenac

l Isoxsuprine Hcl

l Alpha Lipoic Acid

l Ketoconazole

l Ascorbic Acid

l Levo Salbutomal Sulphate

l Azithromycin

l Lumifentrine

l Cefalexin Monohydrate

l Metronidazole

l Cefixime Trihydrate

l Norfloxacin

Compacted l Ciprofloxacin Hcl l Diclofenac Potassium l Doxycycline Hydrochloride l Enrofloxacin l Fusidic Acid

l Ofloxacin l Paracetamol l Pvpk 30 l Salbutamol Sulphate l Sodium Fusidate l Teneliglip n

Hydrobromide Hydrate l Terbutaline Sulphate

We Can Provide Any Item Other Than Above As Per Your Valuable Requirement

FOLIC ACID IP / BP / EP / USP DOMPERIDONE MALEATE IP / BP ENELAPRIL MALEATE IP / BP GLIPIZIDE IP / BP FUROSIMIDE IP / BP.

SRI PHARMACARE 205, Srish Plaza, Saki - Vihar Road, Powai, Mumbai 400072 Ph: +22 - 40151518 / 19 l Fax: +22 - 40151520 Email: pharma@sripharmacare.com Website: www.sripharmacare.com

For Direct Import of the following products

Regularly available at competative rates:

Diethyl Carbonate Dimethyl Carbonate Ethylene Carbonate Ethyl Methyl Carbonate Propylene Glycol Propylene Carbonate

Amino Acids Benzoic Acid Beta Cyclo Dextrin Citric Acid (Anhydrous/Monohydrate) Filter Aids (Eq to Hyflo Super Cell) Fumed Silica/Colloidal Silicon Dioxide Iso Pthalic Acid Isovaleraldehyde Lithium Hydroxide Monohydrate N Butyric Acid / Iso Butyric Acid Propylene Carbonate Propylene Glycol USP Sodium Benzoate Powder Sodium BoroHydride (Powder/Granular) Sodium Citrate Sucralose Tetrahydrofuran Thioglycolic Acid 80% Xanthan Gum (80 Mesh & 200 Mesh)

Please contact :

Flora Dyechem Flora Pharmachem Flora Home & Personal Care (International Marketing & Sourcing Agent for all kind of Raw Materials / Ingredients) E-MAIL: pc@floradye.com / dyes@floradye.com / floradyechem@gmail.com Website : http://www.floradye.com

TEL: 0091 - 28541307 / 28547508 MOBILE E : +91 9152234933

Contact:

JAY CHEM MARKETING (Estd : 1988)

ADD: 101, Labh Sarita, opp. Manek Nagar, M.G.Rd, Kandivali (W), Mumbai - 67. INDIA. TEL. NO.: 0091-22- 28072677 / 78 / 80 / 28020141 MOBILE NO.: 0091-9223433781, 9821153754 E-MAIL: info@jaychemmarketing.com; sales@jaychemmarketing.com

103

Rajshi Chemical & Products Manufacturers of : Life Saving Drugs

NIACINAMIDE IP / BP NIACIN IP /BP ISONIAZID IP / BP Intersted in one consultant for API New item in our plant.

B-81 , Roop Nagar, Industrial Area, LONI-201102, Distt. GHAZIABAD (U.P) Mob: 9810435979, 9312417547 E-mail : rajshichemical@yahoo.com

Manufacturing Best Quality Bulk Drugs & Fine Chemicals Since 30 Years

PRODUCTS MANUFACTURED BY US SODIUM CHLORIDE I.P. / B.P. / U.S.P. / FOOD (ALL GRADE) POTASSIUM CHLORIDE I.P. / B.P./ U.S.P. / PURE (ALL GRADE) AMMONIUM CHLORIDE I.P. / B.P. / U.S.P. / PURE/TECHNICAL DRIED FERROUS SULPHATE I.P. / B.P. / USP (FOR FEED ALSO AVAILABLE) FERROUS SULPHATE HEPTAHYDRATE I.P. / B.P. / U.S.P / COMMERCIAL QUALITY ALSO DI-SODIUM HYDROGEN CITRATE I.P. / B.P. (FOR USE IN DIURETICS) SODIUM CITRATE I.P.

NEWLY LAUNCHED PRODUCTS CITRIC ACID MONOHYDRATE I.P.

CITRIC ACID ANHYDROUS I.P.

MAGNESSIUM SULPHATE I.P. / B.P.

SODIUM BI CARBONATE I.P. / B.P.

For Your Requirement Kindly Contact

PRAVINA PHARMA CHEM PRODUCTS Factory: 1709, GIDC, Indl. Estate, Sarigam, Via Bhilad, Dist: Valsad, Gujrat – 396 155.

Corr. Add.: 803 Mohid Tower, Daman Road, Near Jayshree Cinema, Chala : Vapi – 396191 (Gujrat) Cell: +90993 03555 / 93770 06330 Telefax: 0260 2462360 Email: info@ppcp.co.in

PRODUCT LIST

RAJAN DYE D CHEM Dealers & Suppliers : Chemicals & Solventss HYDROGEN HYDROGEN PEROXIDE PEROXIDE 50% 50% A ACETIC CETIC A ACID CID 99% 99% CHEMICALS CHEMICALS & SOLVENTS SOLV LVENTS A ACRYLAMIDE CRYLAMIDE l MDC MDC CAUSTIC CAUSTIC SODA SODA FLAKES FLAKES FORMIC FORMIC A ACID CID 85% 85% COUSTIC COUSTIC POTASH POTA TASH FLAKES FLAKES PHOSPHORIC PHOSPHORIC A ACID CID 85% 85% GLYCERINE GLY LYCERINE 99.5 99 . 5 Office: Unit No. 303, Gala Complex Premises Co., Op. Housing Society Ltd., DDU Marg, Mulund (W), Mumbai-400 080, Maharashtra, Inida.

Phone: (0) 7208114530 l Email: ranjadyechem@gmail.com

MR. RAKESH SANGHVI | MOB: +91-92234 32613 3 104

l Thioglycolic Acid 80%,99% l 3-Mercaptopropionic Acid 99% l Potassium Thioglycolate l Monoethanolamine Thioglycolate l Diammonium Dithiodiglycolate l Pentaerythritol 3-Mercaptopropionate l POLYTHIOLS l Monothioglycerol 90,98,NF l Thiodipropionic Acid l 2-Sulfoethyl Methacrylate l An oxidant for Polymers l Ditridecyl Thiodipropionate l Distearyl Thiodipropionate l Dilauryl Thiodipropionate

For best prices, please contact:

S WAN EN NTE E RPR RIS SE Mob.: 07498166675 / 08291142569 Email: swanenterprise@gmail.com

2, Geet Krishna, Navghar Road, Mulund - East, Mumbai - 81 Phone: 8425031410 / 9769681471 Email: ganesh@chemicalmatrix.co.in Website: http://chemicalmatrix.co.in

PRODUCTS : APIS AND IMPURITIES Anti Viral Lipid Lowering Agent Erectile Dysfunction Psychostimulant Anti Coagulants Anti Asthmatic Anti Inflammatory CNS Drugs Analgesic Oncology Anti Ulcer Anti Epileptic Dyslipidaemic Arthritic Anti Histamine Anti Fungal

Laxatives / Pregnancy Antiobsessional Drug Anti-Gout Antidepressant Anti-Biotic Antiulceratives Veterinary Product Anti Chloinergic Antimalarials Anti Retroviral Anti Osteoporosis Antidiabetic Anti Emitic Anti Parkinson Nootropic

105

CAN OFFER FOR IMPORT FROM RELIABLE SOURCES FOLLOWING HIGH PURITY MATERIALS: ALUMINA ACTIVATED ALUMINA ALUMINUM HYDROXIDE BOEHMITE PSEUDO-BOEHMITE SPECIALITY ALUMINA FOR FINE POLISHING ALUMINA PRODUCTS: GRANULES, PELLET, CRACKLE CRYSTAL, POLYCRYSTALLINE ACTIVATED ALUMINA BALL AMMONIUM ALUM For your import, please contact: Mobile: +91-9820408556/ 9819880118 E-mail: contact@kailashmarke ng.co.in Web: h ps://www.kailashmarke ng.co.in 106

%\ 3URGXFW DV =,1& +<'52;,'( =Q 2+ 0DQJDQHVH 0Q ,URQ )H 3RWDVVLXP .

1LWURJHQ 1 3KRVSKRUXV 3 3OHDVH FRQWDFW U 0DLO WR ODE #JPDLO FRP 107

IMPORTERS & DEALERS IN PHARMACEUTICAL RAW MATERIALS Ready Stock AZITHROMYCIN IP HYDROCHLOROTHIAZIDE IP – IPCA CYANOCOBALAMIN IP (VITAMIN B12)

Dev Pharmaceuticals Shop No. 8, Gr. Floor, Shree Naman Plaza, Behind Namaha Hospital, S. V. Road, Kandivali- West, Mumbai – 400067.

Tel: 022 40140356 l E-mail: devpharma@ymail.com

Boric Acid IP Heavy Magnesium Oxide Light Magnesium Oxide Frusemide IP / BP Gylcine IP Mannitol Powder IP [Pyrogen Free] Para Chloro Meta Cresol Sodium Bi Carbonate IP / BP 18, Commerce House, Gheekanta Road, Ahmedabad-380 001, Gujarat, INDIA. phone : +91-79-22120569, fax : +91-79-22170034 e-mail : arcopharma@gmail.com | Mobile : +91-98240 59105

R1/103, 1st Floor, Munishuvarat Complex, Phase 2, Munidhara Warehousing, Rahanal Village, Bhiwandi, Thane - 421302. Maharashtra.

Mob: 98209 29367 | Email: vijendra@ompharmachem.com

AVAILABLE IN READY DELIVERY METHYLCOBALAMINE IP IVERMECTIN IP CO-ENZYME Q10 (NUTRACEUTICAL) PREGABALIN IP ALBENDAZOLE IP/USP MICRONISED Website: www.ompharmachem.com 108

B.Pankaj & Co. FOLIC ACID IP / BP METHYL FOLATE CALCIUM L CARNITINE L TARTARATE LEVOCARNITINE USP L CARNITINE FUMARAT A-202, Shanti Bldg. No.2, Opp. Atul Tower, Mathuradas Extn. Road, Kandivli (W), Mumbai – 400067, INDIA Off: 022 28052244 / 28052255 Email: bpankajco@gmail.com Mob: +91 9082811397

ARIHANT ENTERPRISES Product List EDC / MIBK DEG / MEG / MTO / HEXANE / MEK ETHYL ACETATE (SATYAM / SOMAIYA / LAXMI / GNFC) TOLUENE / METHANOL / CYCLOHEXANONE BUTYL ACETATE / BUTANOL THINNER HEXAMINE / DMF / DI ACETONE ALCOHOL / FORMLDEHYDE TETA / DETA / MIBK / TCE / PCE / CTC / ALL GLYCOLS PROPYLENE GLYCOL / ACETONE / GLYCERINE / CYCLOHEXANE IPA

608 Atlan c Tower, 6th Floor, Bldg No 2, R.B Mehta Road, Ghatkopar East, Mumbai 400 077 Email Id :Arihant.Jayu11@Gmail.Com Landline No: 913 603 3431/3432, 92234 33432

SUBSCRIPTION FORM

Subscriber's Name : Mr. / Mrs...................................................................... Company's Name :.........................................................................................

Company's Address:............................................................................................................................................................................................................

Rs.600 (12 Issues 1 Year) Rs.1500 (36 Issues 3 years) Tel. No. :

City...........................State ............................. Pin ......................Country...........................

E m a il .............................................................

You can deposit in your Town also BANK OF BARODA MAZADA PUBLICATIONS, A/C. 04150200000909, MUMBAI

azada

PUBLICATIONS Publishers Of Magazines, Directories & CD’S

Signature of Subscriber

Manufacturer

Broker

Trader

Indentor

Importer

Machinery

Enclosed Herewith Is Cheque / DD No. ................................................ Of Rs...........................

Dated ........................... Drawn On ................................................ Branch...............................

Towards Above Marked Subscription In Favor of MAZADA PUBLICATIONS Payable In Mumbai. (Please Pay Rs.30/- Extra In Case Of Outstation Cheques)

Date.

Please Send The Complete Form With Cheque / DD To Subscription Department

Gala No. 1 A, Sharma Compund, Old Nagardas Road, Andheri (E), Mumbai -400 069 Mob: Website : https://joom.ag/ITNa

109

110

111

(Fortnightly)

REGULAR ADVERTISEMENT TARIFF Rate Per Insertion

SIZE

M/C

B/W

Dimensions

Full Page

10,500/-

5,700/-

183mm x 250mm

Half Page

6,000/-

3,000/-

183mm x 120mm

1/3 Page

----

2,250/-

183mm x 78mm

1/4 Page

3,900/-

1,800/-

90mm x 120mm

1/6 Page

----

1,125/-

91mm x 78mm

Premium Position Front Cover 30,000/Front Inside Cover 22,500/-

(M/C only)

Back Cover 30,000/Back Inside Cover 22,500/-

(Monthly)

SIZE

M/C

B/W

Dimensions

Full Page

15,000/-

7,500/-

183mm x 250mm

Half Page

----

4,500/-

183mm x 120mm

1/3 Page

----

3,000/-

183mm x 78mm

1/4 Page

----

2,250/-

90mm x 120mm

----

1,500/-

90mm x 55mm

Visiting Card Size ( Bold Listing )

Premium Position Front Cover 30,000/Front Inside Cover 22,500/-

(M/C only)

Back Cover 30,000/Back Inside Cover 22,500/112

PUBLISHERS NOTE ALL INDIA API & BULK DRUG DIRECTORY 2023 - 2024

M

azda publications is proud to present their Third edition for the Pharmaceutical Industry. The All India API & Bulk Drug Directory (AIABDD) 2023 2024.

This directory is full of information which will be of ultimate use to manufacturers, traders, brokers in the Active Pharma Ingredient and Bulk Drug Industry. The Indian pharmaceutical industry is at a very unique cross-road owing to the expected growth in the overall economy because of the new central government which is seen to the pro - growth and extremely business friendly.

The AIABDD is our humble attempt at aiding business to business interaction and help growth in the Pharma Industry. Owing to the huge amount of data this directly is made in three section.

Section 1 - Prchase Manager - Pharmaceutical Industry Section 2 - API and Bulk Drug Traders / Importers / Exporters Section 3 - API and Bulk Drug Manufacturers Section 4 - API and Bulk Drug Industry Brokers Needless to mention we are sure that the AIABDD will prove to be a business tool parexcellence for all your information needs in the Active Pharma Ingredient and Bulk Drug Industry.

We have tried our level best in providing you with the very best and updated information.

Users are welcome to sent in their feedback, comments and suggestions so that we can incorporate then in the next edition of AIABDD. Lastly, let me take this opportunity to thank our advertisers who have supported us and also team which has worked very hard for this AIABDD. May you and your business prosper Prakash Anjalekar Publisher 113

ADVERTISERS INDEX Company name

Pg No

AARA PHARMA 97 AD PHARMACHEM PVT LTD 42 ADI METCHEM PRIAVTE LIMITED 6 ADITI ESSENTIALS 10 ADITYA MINT 95 AGR ENTERPRISES 19 AKSHAR CHEMICALS INDIA PVT LTD 78 AMIT HYDROCOLLOIDS 3 AMNEM 46 AMRUT ENTERPRISES 73 AMRYS IPR SERVICES 99 APRA INNOVATIVE PVT LTD 37 ARCO PHARMA 108 ARIHANT ENTERISES 108 ARIL PAHRMACEUTICALS 25 ARK CHEMICALS PRIVATE LIMITED 80 ARNISH LABORATES PVT LTD 98 ASIA LABEX 2023 44 ASIEL CHEMPHARMA 45 ASTER BIOPHARMA LLP 14 AYON PHARMA CHEM 107 AZEOCRYST ORGANICS PVT LTD 53 B.J. SCIENTIFIC CO 76 B.PANKAJ & CO 108 B.SHAH & SONS 67 BALAJI CORPORATION 33 BALAJI STEROIDS AND HORMONES PVT LTD 38 BIOTECH SOLUTIONS & PHARMACEUTICALS LTD 30 BOMBAY ENGINEERING WORKS 98 BULAT PHARMACEUTICAL PVT LTD 94 BUMBPER OFFER RATE CARD 111 CHEMICAL PROCESS CONSULTANTS 95 CHEMIMAN 100 CHEMKART 66 CHEMSTAR GLOBAL PRODUCTS LLP 69 CHROMA CHEMICAL CORPORATION 93 CHEMINO PHARMA LTD 81 CHEMICAL MATRIX 105 COSMIC CHEMICALS 60 CR PHARMA 83 CRYSTAL CHEM 71 DEEPA PHARMA 99 DEV INTERNATIONAL 88 DEV PHARMACEUTICALS 108 DPB PHARMACEUITICALS Back Cover Inside DIPTI CHEMICALS AND PHARMACEUTICALS 46 EARTH CHEMICAL & SCIENTIFIC PVT LTD 81 114

CITY MUMBAI AURANGABAD GUJARAT MUMBAI MUMBAI MUMBAI THANE MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI AHMEDABAD MUMBAI MUMBAI MUMBAI MUMBAI GHANDINAGAR MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI VADODARA MP MUMBAI MUMBAI HARAYANA MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI GUJARAT MUMBAI MUMBAI MIRA ROAD MUMBAI

Company name

Pg No

EMCO DYESTUFF PVT LTD 77 EMCO ENGINEERING PVT LTD 89 ESKAY IODINE PRIVATE LIMITED 27 FILTROMIX EQUIPMENTS LLP 70 FLORA DYECHEM 103 FORBES PHARMACEUTICALS 9 G.M. CHEMIE PVT .LTD 74 GANDHI CHEMICALS 102 GANGOTRI INORGANIC (P) LTD 32 GLOBAL MARCHANTS 50 GLOBE PRODUCTS 96 HAP ENTERPRISE 57 HELIX MULTICHEM 82 HITEN PHARMA CHEM 71 HRITIK CHEMICALS PVT LTD 52 H.K ENTERPRISE 79 INDIA LAB EXPO & PHARMA PRO & PACK EXPO 47 INDIAN PLATINUM PVT .LTD 51 INTEGRRATED PROJECT MANAGEMENT SERVICES 105 INTERNATIONAL DRUG & CHEMICAL CO 91 IRIS INGREDIENTS 11 INFOZEN INDIA ENTERPRISES 49 JAKSON PHARMA 70 JAY CHEM MARKETING 103 JAYANT AGRO -ORGANICS LTD 82 JAYSUM BIOTECH 75 JEEVAN CHEMICALS AND PHARMACEUTICALS 90 JIYA PHARMACHEM 101 JKW CHEMICALS PVT LTD 80 JPC AIR HANDLERS ENGINEERING 21 JUANA PHARMA 88 J R DRUGCHEM PVT LTD 50 JYOTI GLOBAL PLAST PVT LTD 47 KAILASH MARKETING ASSOCIATES 106 KAMLESH ENTERPRISES 78 KANCHAN RASAYAN 7 KEMS RAW PHARMA 83 KESHARIYA CORPORATION 97 KESHAV HICHEM PRIVATE LIMITED 36 KETAN CHEMICAL CORPORATION 86 KHUSHBU DYE CHEM PVT LTD 54 K. PATEL INTERNATIONAL Back Cover KIP CHEMICALS PVT LTD 95 KIRAN TRADERS 40 KRISHNA SOLVECHEM LTD 23 KRONOX LAB SCIENCES LTD 64 LABORATORY SOLUTIONS INDIA 77

CITY MUMBAI AHMEDABAD MUMBAI MUMBAI MUMBAI MUMBAI NAVI MUMBAI MUMBAI AHMEDABAD NAVI MUMBAI THANE MUMBAI MUMBAI THANE MUMBAI MUMBAI HYDRABAD MUMBAI THANE MUMBAI MUMBAI GUJARAT MUMBAI MUMBAI MUMBAI THANE NAVI MUMBAI MUMBAI MUMBAI GUJARAT MUMBAI GUJARAT NAVI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MIRA ROAD MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI GUJARAT MUMBAI

ADVERTISERS INDEX Company name

Pg No

CITY

LUCONIC CHEMICALS 102 M/S. J.J. TRADERS 87 M/S. ALBA ORGANICS 100 MALAY ENTERPRISES 68 MARUTI INDUSTRIES 39 MARUTI PETROCHEM 15 MEDISEARCH LABORATORIES 101 MEHTECH ENGINEERING PVT LTD 105 MERU CHEM PVT LTD 76 MIVON CHEMICALS 13 MODY CHEMI PHARMA LTD 20 NAKSHA PHARMA NUTRACEUTICAL PVT LTD 92 NALANDA RESEARCH LABORATORIES 98 NANDLAL BANKATLAL PVT LTD 43 NEHA ENTERPRISES 101 NEHA PHARMA PVT LTD 90 NGL FINE -CHEM LIMITED 85 NIKEON CORPORATION 93 NIRA LIFESCIENCE PVT LTD 50 NISHA CHEMICALS 92 NISHCHEM INTERNATIONAL PVT LTD 24 NITCO WATERTECH AND INDUSTRIAL CONCEPTS 105 NOBLE CHEMICAL AGENCY 102 NORTH INDIA PHARMA 59 NOVA CHEMIE 43 OCEANIC LABORATORIES PVT. LTD 41 OM PHARMACHEM PVT LTD 108 OMKAR LOGISTIC 106 OXFORD LAB CHEM 65 P.G.SHAH & CO 99 PACIFIC ORGANICS PVT LIMITED 18 PANCHAMRUT CHEMICALS 85 PANCHSHEEL ORGANICS LTD 58 PARAS CHEM 100 PARESH CHEMICAL CORPORZTION 84 PARSHWA PHARMA CHEM 41 PAYAL IMPEX 99 PHARMA LIVE EXPO 38 PHARMA CUPBOARD 107 PHARMALABCHEM EXPO 42 POWDER PACK CHEM 87 PRUDENCE PHARMA CHEM Front Cover PRAVINA PHARMA CHEM PRODUCTS 104 PRAVINCHANDRA & CO 4 PROGRESS LIFE SCIENCES PVT LTD 49 PYRAMID TECHNOPLAST PVT LTD 29 QUALIKEMS LIFESCIENCE PVT LTD 62 RAJAN DYE CHEM 104 RAJESH A. SHAH 106

MUMBAI MUMBAI PALGHAR VADODARA GUJARAT MUMBAI MUMBAI PALGHAR MUMBAI THANE MUMBAI MUMBAI NAVI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI GUJARAT MUMBAI MUMBAI THANE TELANGANA DELHI MUMBAI BOISAR THANE THANE PALGHAR MUMBAI THANE MUMBAI MUMBAI MUMBAI MUMBAI THANE PALGHAR MUMBAI VADODARA INDORE/PUNE MUMBAI GUJARAT GUJARAT MUMBAI MUMBAI MUMBAI PALGHAR MUMBAI MUMBAI

Company name

Pg No

RAJSHI CHEMICAL & PRODUCTS 104 RASAYAN INDIA 86 RATE CARD 112 RATI PUSHP INTERMEDIATES PVT LTD 45 REGAL REMEDIES LIMITED 16 RELIC CHEMICALS 84 RESEARCH LAB FINE CHEM INDUSTRIES 31 RIDDHI SIDDHI DYE CHEM 96 ROSETTA LIFE CARE PRIVATE LTD 39 ROUTE 99 INTERNATIONAL 100 RUSKIN CHEMIPHARMA 28 RYCE YASH INDIA 107 S.A.I. PRODUCTS 98 SADHANA ENTERPRISES 44 SALICYLATES AND CHEMICALS 34 SANJAY ENTERPRISES 106 SDA PRODUCT 12 SHAGUN PHARMACEUTICALS 73 SHAH TC Front Cover Inside SHEETAL CHEM 61 SHRADDHA ANALYTICAL SERVICES 102 SHREEDHAR ENTERPRISE 97 SHRIYA PHARMA & SURGICAL 48 SIDDHAMBIKA IMPEX 63 SIDDHARTH INTERNATIONAL 55 SIDDHIVINAYAK PHARMA 79 SIGMA INC 72 SML LIMITED 107 STELLAR EXIM 5 SKY CHEM 89 SOHYOG LIFESCIENCE 74 SRI PHARMACARE 103 STANDARDCON PVT LTD 75 SUBSCRIPTION FROM 109 SUNRAJ CHEMICAL CO 101 SUNRISE HEALTHCARE INDIA 22 SUPPLIMENT RATE CARD 110 SURYA LIFE SCIENCES LTD 40 SYNCHROM LABORATORY PVT LTD 94 SWAN ENTERPRISES 104 SYNTHETIC MOLECULES PRIVATE LTD 91 SYROCHEM LABORATORIES PVT LTD 8 UNIPHARMA 103 UNITRADE AGENCIES 56 VARAHI INTERNATIONAL 48 VIBGYOR CHEMICAL INDUSTRIES 96 VINIPUL INORGANICS PVT LTD 26 VITA -MIN PROBIOTIC 97 VITRO PHARMA MACHINERY 35 V. VORA & SONS 108 YAKSH PHARMA 17

CITY GHAZIABAD NAVI MUMBAI U.P MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI THANE THANE MUMBAI MUMBAI MUMBAI INDORE DELHI MUMBAI MUMBAI THANE MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI MUMBAI NAVI MUMBAI ULHASNAGAR GOA GUJARAT NAVI MUMBAI MUMBAI MUMBAI NAVI MUMBAI MUMBAI MUMBAI AHMEDABAD MUMBAI MUMBAI PALGHAR MUMBAI MUMBAI MUMBAI 115

SPECIAL FEATURE

UNDERSTANDING FORMULATIONS: THE KEY TO EFFICIENT DRUG DEVELOPMENT Karan Chechi he creation of novel drugs is a challenging, prolonged process that necessitates substantial research and experimentation. The formulation of the drug, which entails choosing the right components and producing a dosage form that is both efficient and secure for patients, is one of the most important steps in the development of novel drugs.

Understanding formulations is essential for effective drug development because it can help spot possible problems early on and speed up the process.

The process of developing a drug that may be administered to patients via a particular route of delivery involves combining an active pharmaceutical ingredient (API) with appropriate excipients (inactive chemicals). The formula must satisfy the necessary standards for quality, effectiveness, stability, and patient acceptability.

Preformulation and formulation optimization are the two processes that make up the drug formulation. The initial phase in formula development is preformulation research. In order to choose the inactive components, or excipients, that should be used with a drug, researchers must identify its chemical, physical, and mechanical properties. Preformulation research are also useful in determining the best dosage form and mode of administration for a certain drug product, such as oral, intravenous, topical, etc.

The second stage of formulation development is formulation optimization. In this stage, researchers test numerous excipient types and amounts, production processes, storage conditions, etc. to fine-tune the formulation. Based on the understanding of bioavailability and processing needs of the drug product, it is intended to optimise the formulation's properties. To make sure that the drug product retains its quality and effectiveness over time under varied environmental circumstances, formulation optimization often entails undertaking stability tests.

Development of formulations is crucial for several reasons. It can influence a drug's bioavailability, or how quickly and how much of an API gets into the bloodstream and starts working its pharmacological magic. The solubility, dissolving rate,

T

116

permeability, metabolism, and elimination of the API are some of the factors that affect bioavailability. By utilizing several processes like particle size reduction, solubilization, encapsulation, coating, etc., for-

mulation development can improve or modify these aspects.

The ability of the API to maintain its identity, strength, quality, and purity during its shelf life is known as stability, and it can be affected by formulation development.

Temperature, humidity, light, oxygen, pH, and other variables all affect stability.

Various methods, including buffering, antioxidants, preservatives, packaging, etc., can be used in the formulation creation process to increase or maintain stability.

The simplicity and efficiency with which a drug product can be produced on a large scale, or its manufacturability, can be impacted by formulation development.

Several factors, including flowability, compressibility, homogeneity, cohesiveness, etc., influence manufacturability. By utilising different procedures like granulation, mixing, drying, compaction, etc., formulation development can improve or manage these factors.

The attractiveness and competitiveness of a drug product in terms of patient preference, convenience, compliance, and differentiation can be influenced by formulation development. By utilizing multiple techniques including flavoring, sweetening, masking, coloring, shape, and size, among others, formulation development can enhance or adjust these factors.

By reducing the time, cost, and risk involved in bringing a novel drug product to market, formulation development can facilitate efficient drug development.

Formulation development can lessen the

number of unsuccessful or suboptimal formulations that must be screened and tested in later stages of drug development by conducting rigorous preformulation studies and choosing the ideal dosage form and route of administration for the API. Formulation development can improve the likelihood of accomplishing clinical effectiveness and safety targets as well as regulatory standards for quality and performance by optimizing the formulation's features based on bioavailability and processing needs. Formulation development can increase shelf life, decrease wastage, and prevent recalls due to contamination or degradation by maintaining or enhancing stability under a range of environmental conditions.Formulation development may assist scale-up and mass production processes by improving or managing manufacturability characteristics like flowability and uniformity and ensuring consistent quality and output.Formulation development may increase patient acceptance and adherence by improving or altering marketability elements like taste and appearance and provide it a competitive edge over already available or comparable drugs.

Scientists and engineers are always looking into novel approaches and concepts to improve drug formulation in the ever-evolving field of pharmaceutical research and development. By using these novel strategies, problems with drug delivery, stability, and patient compliance can be solved. Researchers are laying the foundations for more effective drug and better therapeutic outcomes by utilizing the potential of emerging technology.

The utilization of nanotechnology is one area where drug formulation has advanced significantly in the past few years. Drug delivery could be revolutionized by nanoparticles, which typically has unique characteristics and sizes between 1 and 100 nanometers. Scientists can improve the solubility, stability, and bioavailability of medications by encapsulating them within nanoparticles. The drug may be shielded against deterioration by nanoparticles, which also enhance drug absorption and enable targeted distribution to organs, tissues, or cells in the body. Additionally, regulated drug release, prolonged drug release, and triggered release in response

to physiological events are all made possible by surface modifications of nanoparticles. These developments in nanotechnology have the potential to completely alter diseases, including cancer, are treat by improving therapeutic effectiveness and lowering systemic side effects of drugs.

Harnessing 3D printing technology is another feasible method of drug formulation. With the aid of 3D printing, sometimes referred to as additive manufacturing, complex drug dosage forms with a variety of features can be precisely created. Using this method, patient-specific formulations can be made, providing personalized treatment. Scientists can regulate the drug release profile, change dosage strengths, and combine multiple drugs into a single dosage form by incorporating drug and excipient components into a 3D printing system. Drug formulations that can be tailored to the demands of specific patients can greatly enhance patient compliance and treatment success. Additionally, 3D printing has the potential for on-demand manufacturing, which would cut down on both production costs and time while enabling quick reaction to new healthcare concerns.

Lipid-based drug delivery systems have attracted a lot of attention lately in the area of drug development. Lipid-based formulations use lipids or lipid-like substances as medication delivery carriers. Poorly watersoluble medications' solubility and absorption can be enhanced by these formulations, increasing the drugs' bioavailability.

Liposomes, solid lipid nanoparticles (SLNs), nanostructured lipid carriers (NLCs), and self-emulsifying drug delivery systems (SEDDS) are instances of lipidbased systems. Benefits like enhanced medication stability, controlled release, and targeted distribution are provided by these systems. Lipid-based formulations have proven effective at delivering a range of therapeutics, such as anticancer medications, antiviral agents, and difficult-to-solubilize substances.

The development of microencapsulation technology has also had a big impact on drug formulation. Active pharmaceutical ingredients (APIs) are enclosed in a protective shell that is typically formed of polymers through the process of microencapsulation. By using this method, drugs' stability can be boosted they can be kept from degrading, and their release profiles may be managed. Sustained release formulations, in which the drug is given gradually over a long period of time to ensure a consistent therapeutic impact, are made possible via microencapsulation. This method is especially helpful for medications that have a limited therapeutic window or call for

long-term administration. Additionally, sensitive APIs can be shielded by microencapsulation from the harsh gastrointestinal environment, enabling tailored delivery to body sites.

Advances in biomaterials and biodegradable polymers have also created new opportunities for drug formulation, in addition to these methods. Biomaterials have special qualities that may replicate the body's natural environment, enhancing biocompatibility and minimizing adverse consequences. A regulated release of the medicine can be achieved by designing biodegradable polymers to break down over time. These components can be utilized to make scaffolds, injectable depots, or implants. Enhancing drug solubility is a significant benefit of formulation research.

The solubility problems that many drugs experience can reduce their potency.

Researchers can increase the solubility and bioavailability of drugs by choosing suitable solvents, cosolvents, and surfactants carefully. As a result, the drug can be administered to the target site at a larger concentration, enhancing therapeutic efficacy. The stability of drug formulations is a further significant consideration. Over the span of a defined shelf life, formulations must maintain their efficacy and integrity. It is possible for researchers to create formulations that maintain the drug's potency by understanding the variables that can affect stability, such as pH, temperature, and light exposure. This assures that the drug maintains its therapeutic characteristics throughout its entire lifecycle, resulting in consistent and dependable therapeutic outcomes.

Additionally, an essential field of study in drug formulations is the creation of tailored medication delivery methods.

Traditional oral formulations frequently cause drug waste and non-specific body distribution. Researchers can improve the targeting of medications to tissues or cells by utilizing innovative delivery approaches, such as liposomes, nanoparticles, or microencapsulation. By decreasing the drug's interaction with healthy tissues, this not only increases its therapeutic index but also reduces its risk of side effects.

Targeted drug delivery systems are

extremely beneficial in the treatment of cancer as they can boost the accumulation of drugs in tumour tissues, resulting in more potent therapy.

Understanding drug formulations helps to increase patient compliance in addition to increasing drug efficacy and safety.

Patient compliance is the degree to which patients follow their doctors' recommended treatment regimens. Large tablet sizes, undesirable flavours, and complicated dosing regimens can all have an effect on patient compliance. Researchers can increase patient acceptance and improve adherence to treatment strategies by developing patient-friendly formulations, such as chewable tablets, oral films, or flavoured liquids. In the end, this results in enhanced patient satisfaction and better treatment outcomes.

The intricacy of the drug development process and the factors that must be taken into consideration can make drug development difficult. Choosing the right excipients for the medicine is one of the biggest issues. Excipients are inactive components used in the formulation of drugs to help keep them stable and improve their effectiveness. Since excipients might affect the drug's safety and effectiveness, they should be cautiously picked. Making sure the medicine is stable is another difficulty in formulation development. Understanding formulations from a business point of view is essential for maintaining competitiveness in the pharmaceutical industry. It enables companies to stand out from the competition by providing distinctive formulations that meet unmet medical needs.

The market may benefit from formulations that offer increased therapeutic effectiveness, fewer side effects, or greater patient convenience. Understanding formulations also enables businesses to patent new distribution methods or formulations to safeguard their intellectual property, giving them a competitive edge and market exclusivity. The demand for personalised drugs, escalating research and development efforts, and technological improvements are driving a major expansion in the global market for understanding formulations.

Among the advances reshaping the market are enhanced excipients, 3D printing, and nanotechnology. Additionally, the rise in chronic diseases, the shift towards personalised therapy, and the ageing population all contribute to the market's expansion. By maintaining uniform quality across markets, regulatory harmonisation and quality standards are also essential in fostering market expansion.

The author is research director, TechSchi Research

117

SPECIAL FEATURE

FUTURE OF INDIAN API MARKET Dr. Vikas Pandey ctive Pharmaceutical Ingredients (API) serves as the fundamental building block within the strategic framework of the pharmaceutical value chain. An API refers to any substance or combination of substances utilized in the final pharmaceutical product, with the purpose of delivering a pharmacological action and directly influencing the diagnosis, treatment, alleviation, therapy, or prevention of diseases. Of significant importance, APIs are responsible for producing the therapeutic effects of medicines and are consequently the key drivers of innovation and often the crucial intellectual property within the industry.

The market for API is divided into various segments based on different factors.

These include the business mode, which includes captive API (produced in-house by pharmaceutical companies) and merchant API (purchased from external suppliers).

Another segmentation factor is the synthesis type, which includes synthetic APIs (chemically produced) and biotech APIs (produced using biotechnological processes). The type of drug is also considered, with segments for generic APIs (nonbranded) and branded APIs (specific to a particular brand). Additionally, the market is segmented by application, encompassing various medical fields such as cardiology, pulmonology, oncology, ophthalmology, neurology, orthopedics, and more. Finally, the market is further divided geographically into regions including North America, Europe, Asia-Pacific, Middle East and Africa, and South America.

A

Market Outline Over the past ten years, the API market on a global scale has witnessed substantial expansion, primarily driven by the rise in chronic diseases. This growth can be attributed to advancements in API manufacturing techniques and the increasing prevalence of conditions like cardiovascular diseases and cancer. Furthermore, favorable government policies promoting API production and shifts in geopolitical circumstances have contributed to the market's upward trajectory. However, the API market is currently undergoing significant transformations due to disruptions in the supply chain caused by the COVID-19 pandemic. As a result of geopolitical factors and the desire to reduce reliance on China for API products, countries like India

118

are now being favored for API exports.

Table: Number of facilities manufacturing active US-approved APIs, by region The market experienced a positive influence in 2020 due to the outbreak of COVID-19, with countries and prominent industry players producing substantial

quantities of ingredients to meet the demand for COVID-19 treatment. The pandemic prompted pharmaceutical manufacturers to reorient their strategies towards catering to a larger patient population.

In 2020, the global API market was valued at $180 billion, and it is projected to exhibit a mid-single-digit compound annual growth rate (CAGR) of around five to six percent during the period of 2021 to 2026.

By 2026, the market is expected to reach US $250 billion and surpass US $300 billion by 2030, with an estimated increase of approximately $50 billion every five years.

According to IMS 2020 data, the generic segment holds a significant market share of 94 percent in terms of volume, while the innovator segment holds a six percent share. This indicates the substantial opportunity for penetration into the generic market. Given the immense size of the market, there is a strong possibility of significant ancillarization, similar to what occurred in the automobile industry in the 1950s. We anticipate the emergence of a considerable standalone capacity for API intermediates, which can be seen as a new rising star in the industry.

New opportunities for India in global API market The pharmaceutical industry possesses a unique characteristic wherein the consumer does not make the ultimate deci-

sion, and the decision-maker is not the one who pays. Additionally, unlike other sectors, pharmaceutical products do not become obsolete over time. Medications like Aspirin, paracetamol, and metformin remain the gold standards in front-line therapy. Therefore, the key drivers of growth in this industry are scale, quality, compliance,

and process excellence. However, despite these factors, India must prioritize the creation of robust and resilient supply chains and accelerate infrastructure development to ensure it actively participates in the upcoming phase of growth, rather than being a passive observer.By volume, the pharmaceutical industry in India ranks as the third-largest global producer of drugs.

With more than 250 facilities approved by the US Food and Drug Administration (USFDA) and the UK Medicines and Healthcare products Regulatory Agency (UKMHRA), India plays a crucial role in supplying affordable generic pharmaceuticals to millions of people across the world.

The growth of the API market is being driven by several key factors. These include the growing focus on drug research and development for manufacturing, the rising significance of generic drugs, and the increasing adoption of biopharmaceuticals. However, the market's progress is expected to face obstacles due to unfavorable drug price control policies implemented in various countries and the presence of high manufacturing costs.According to the International Diabetes Federation (IDF) statistics of 2022, the number of individuals with diabetes in India was approximately 74 million in 2021. This figure is projected to rise to around 92.9 million by the year 2030. The significant diabetic population in the country has heightened the emphasis

placed by pharmaceutical companies on the development of advanced and safe drugs. This increased focus necessitates a substantial quantity of active pharmaceutical ingredients (API), thereby driving the growth of the market.

The Indian pharmaceutical industry has expressed significant concerns regarding its reliance on China for APIs (Active Pharmaceutical Ingredients). The proportion of API imports from China has dramatically increased from 0.5 percent in 1987 to approximately 78 percent in 2020.

Around 55 percent of India's API requirements are imported, with the vast majority sourced from China. China holds a competitive advantage over India due to factors such as scale, subsidies, access to cheaper capital with lower interest rates (around four to five percent compared to 12-15 percent in India), lower logistics costs (0.9 percent compared to four percent in India), and more affordable power sources. As a response to this situation, several Indian companies have shifted their API, KSM (Key Starting Materials), and intermediates requirements to domestic manufacturers who have rapidly expanded their production capacity to meet the increased demand.

The Government of India has also taken steps to support selfreliance (Aatmanirbharta) through initiatives like the Production Linked Incentive (PLI) scheme, aiming to encourage the industry to enhance capacity building within the country.

In addition, the Indian government is implementing initiatives to promote the presence of API products in the market, which will contribute to the growth of the industry. For instance, according to the India Brand Equity Foundation (IBEF), in January 2021, the Central government announced the establishment of three bulk drug parks with an investment of INR 14,300 crores (US$1,957 million). These parks aim to manufacture

particularly noteworthy. While the global generic API markets are predicted to grow at approximately 6%, the Indian market is expected to demonstrate an impressive CAGR of 13.7% within the first four years alone. Furthermore, significant investments of approximately US$ 4-5 billion have been made in the API sector in India over the past few years.

chemical compounds and APIs for medicines, thereby reducing the country's dependence on imports from China.

Furthermore, in June 2021, the Finance Minister of India announced an additional outlay of INR 197,000 crores (US$26,578.3 million) that will be utilized over a period of five years for the pharmaceutical PLI scheme. This scheme will focus on 13 key sectors, including active pharmaceutical ingredients, drug intermediaries, and key starting materials, to further support the growth of the industry. In India, API Market leaders include AurobindoPharma, Lupin Ltd, Viatris Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd. In terms of drug manufacturing volume, India ranks as the second-largest producer globally, following China and Italy. In value terms, India stands at the 12th position on a global scale. Projections indicate that the Indian pharmaceutical sector will reach a market size of US$75 billion by 2024 and is expected to grow further to US$130-138 billion by 2030. India has played a significant role in improving global healthcare outcomes, fulfilling approximately 60 percent of the global demand for Anti-retroviral (ARV) drugs. Over the past five years, Indian manufacturing sites have accounted for about 38 percent of the total Abbreviated New Drug Applications (ANDAs) filed.

Furthermore, India boasts the highest number of US FDAapproved manufacturing plants outside of the US and is known for consistently meeting the rigorous standards set by the US FDA and the European Directorate for the Quality of Medicines (EDQM).

The Future Prospects By the year 2030, the global API market is projected to reach approximately US$ 328 billion in size. In 2020, the market was valued at US$ 169 billion, and it is expected to grow at a compound annual growth rate (CAGR) of 6.1% from 2021 to 2030. Among the regions, Asia-Pacific exhibits the highest CAGR during the period of 2021 to 2030, positioning it as the region with the most substantial growth rate in the API market.Under the PLI scheme, India initiated domestic manufacturing of 35 APIs in 2022, reducing the country's dependency on import activities from China by 90%.According to credible industry sources, the Indian pharmaceutical market anticipated US$39 billion in 2022. However, the projections for the following six years are

Figure:API Market Size from 2021 to 2030 Currently, majority of API manufacturers is concentrated in Asia Pacific, primarily India, China, and Taiwan. Teva Active Pharmaceutical Ingredients (TAPI), Aurobindo, and Sun Pharma are the leading API manufacturers in the region.

Conclusions: The Indian pharma industry is a sunrise industry in the Indian economy.APIs serve as vital components in drug manufacturing, but the global market for APIs faces various challenges.

To ensure operational resilience during unforeseen circumstances, the API industry must undertake restructuring efforts in its production processes. China and India, offering cost advantages, play significant roles in driving API production. Additionally, the Asia Pacific region is expected to witness a gradual increase in the market for both generic and innovative APIs.While the API industry presents a promising opportunity that has already been tapped into, there is an even greater opportunity for India to become a comprehensive supplier of medicines.

Currently, raw materials for APIs are imported, indicating a scope for significant backward integration. By establishing sufficient backward integration, India can seize the space of Key Starting Materials (KSMs) or intermediates and further enhance its position in the pharmaceutical supply chain.

The author is associate professor, Amity Institute of Pharmacy, Amity University

119

SPECIAL FEATURE

FUTURE PROSPECTS OF BULK DRUGS IN INDIA Dr. S. Mohana Lakshmi Bulk Drug Substance ulk drug substances, referred to as Active Pharmaceutical Ingredients (API) according to the USP-NF definition, are utilized in the production of drug products, typically in conjunction with excipients. These bulk drug substances can be obtained through chemical synthesis, plant or animal sources, or through biological or recombinant technology.

Alongside the API, the drug substance may contain additional substances or impurities related to the product and its manufacturing process.

The World Health Organization defines API as any substance or combination of substances employed in a finished pharmaceutical product (FPP) to provide pharmacological activity or directly impact the diagnosis, cure, mitigation, treatment, or prevention of diseases.

Furthermore, they may have an immediate effect on restoring, correcting, or modifying physiological functions in human beings.

Drug product (also called the dosage form or finished product per USP-NF definition) contains one or more drug substances, usually with excipients, in the final packaging intended for marketing.

B

Bulk drugs (Active Pharmaceutical Ingredients) The Indian Pharmaceutical Industry The Indian pharmaceutical industry has experienced remarkable growth in recent decades and contributes approximately 1.72 percent to the nation's GDP. It is projected to achieve a market value of $65 billion by 2024 and $130 billion by 2030. This growth is primarily fueled by the rising demand for affordable and high-quality medicines, both domestically and internationally. Currently, India ranks as the 3rd largest producer in terms of volume and the 14th largest in terms of value on a global scale. Indian pharmaceutical exports have witnessed an impressive growth rate of 103 percent since 2013-14, increasing from INR 90,415 Crores to INR 1,83,422Crores in 2021-22. India meets approximately 20% of the global demand for generic drugs, earning it the reputation of being the "Pharmacy of the World."

Bulk drug industry – Indian Scenario Despite the significant growth, India faces a significant reliance on China for the supply of active pharmaceutical ingredients (APIs). The country's competitive position

120

in the pharmaceutical sector is weakened by its heavy dependence on China, particularly for vitamins and antibiotics, where approximately 70% of the bulk drugs or APIs are sourced. China holds a dominant position in the production of APIs using fermentation processes. In the fiscal year 2021, India imported APIs and drug intermediates worth Rs 28,529 crore, with imports from China accounting for 68% (Rs 19,402 crore) of the total value. The quantity of these imports in the same fiscal year amounted to 3,90,475.7 metric tonnes.

Indian government’s initiative in the making of domestic bulk drugs In an effort to enhance self-sufficiency in the pharmaceutical sector, the Indian government has implemented a scheme worth Rs. 3,000 crores to promote the establishment of bulk drug parks. The objective of this scheme is to address the existing situation. Under this initiative, the government is facilitating the establishment of three bulk drug parks within the country. The financial support provided by the central government for each park is capped at a maximum limit of Rs. 1000 crore. A total of 13 states, including Uttar Pradesh, Tamil Nadu, Telangana, Karnataka, Maharashtra, Gujarat, Madhya Pradesh, Rajasthan, Punjab, Haryana, Himachal Pradesh, Andhra Pradesh, and Odisha, have submitted proposals to the Department of Pharmaceuticals for the three parks. The Department, guided by an Advisory Committee led by the CEO of NITI Aayog, evaluated the proposals using both quantitative and qualitative methodologies. After careful evaluation, the proposals from Andhra Pradesh, Gujarat, and Himachal Pradesh have received final approval for the development of the bulk drug parks.

The Department of Pharmaceuticals – Government of India: Bulk Drug Parks The Department of Pharmaceuticals has granted provisional approval to the proposals put forth by three states, namely Himachal Pradesh, Gujarat, and Andhra Pradesh, as part of the "Promotion of Bulk Drug Parks" scheme. This scheme is a significant initiative aimed at supporting the manufacturing of bulk drugs in the country.

Notified in 2020, the scheme has a financial allocation of Rs. 3,000 crores and provides financial assistance to the three states for the establishment of Bulk Drug

Parks. Its objective is to reduce the manufacturing costs of bulk drugs by creating top-notch shared infrastructure facilities supported by the Central Government, ultimately enhancing the competitiveness of the domestic bulk drug industry.

The government is dedicated to minimizing the country's reliance on imports and bolstering indigenous manufacturing.

The Bulk Drug Parks developed under this scheme will offer comprehensive common infrastructure facilities in one location, fostering a robust ecosystem for bulk drug manufacturing within the country. This approach will significantly reduce manufacturing costs. The scheme is expected to promote domestic production of bulk drugs, reducing import dependence and enabling India to establish a prominent position in the global market by facilitating access to standardized testing and infrastructure facilities. Additionally, the scheme aims to assist the industry in meeting environmental standards at a reduced cost through innovative methods of shared waste management systems, while optimizing resources and achieving economies of scale.

The proposed Bulk Drug Parks in Gujarat and Andhra Pradesh will receive financial assistance equivalent to 70% of the project cost for common infrastructure facilities. However, for Himachal Pradesh, being a hilly state, the financial assistance will be 90% of the project cost. The maximum assistance provided under this scheme for a single Bulk Drug Park is limited to Rs. 1000 crores.

According to the proposals submitted by these states, the Bulk Drug Parks will be established on specific land areas. These include 1402.44 acres of land in Tehsil Haroli, District Una, Himachal Pradesh; 2015.02 acres of land in Tehsil Jambusar, District Bharuch, Gujarat; and 2000.45 acres of land in K.P. Puram&Kodhada of ThondagiMandal, East Godavari District, Andhra Pradesh. Additionally, the Government of Assam has proposed a Pharmaceutical Park in Chaygaon, Kamrup Rural, covering an area of 100 acres with an estimated project cost of INR 153.64 crores. In the Budget 2023, Union Finance Minister NirmalaSitharaman allocated Rs 1000 crore for the development of bulk drug parks.

This scheme exemplifies the spirit of cooperative federalism, where the Central Government and State Governments collaborate to establish Bulk Drug Parks, aim-

of which have substantial API businesses, have greatly benefited from the scheme. It is projected that Indian API-producing firms will experience a Compound Annual Growth Rate (CAGR) of 9-11 percent over the next five years.

Under the Production Linked Incentive (PLI) scheme, India has initiated the production of 22 active pharmaceutical ingredients (API) or bulk drugs. These include 1,1 cyclohexane diacetic acid (CDA), para amino phenol (which serves as a raw material for paracetamol), sulfadiazine, atorvastatin, carbamazepine, oxcarbazepine, levofloxacin, and more. These APIs have generated sales during the current financial year..

ing to enhance the performance of the sector..

Other interventions of the Department of Pharmaceuticals, Government of India in making bulk drugs: Production Linked Incentive (PLI) The Indian government has granted approval for INR 6,940 crore for the Production Linked Incentive (PLI) Scheme, which aims to promote domestic manufacturing of Key Starting Materials (KSMs), Drug Intermediaries (DIs), and APIs. A total of 51 projects have been approved under this scheme, with 14 projects already commissioned and actively engaged in drug manufacturing. The PLI for Pharmaceuticals initiative offers financial incentives to 55 selected applicants, including 20 Micro, Small & Medium Enterprises (MSMEs), focusing on the manufacturing of identified products categorized into three distinct groups, which are as follows: •Category 1: Biopharmaceuticals; Complex generic drugs; Patented drugs or drugs nearing patent expiry; Cell based or gene therapy drugs; Orphan drugs; Special empty capsules, Complex excipients, •Category 2: Bulk drugs (except those 41 eligible products notified under “PLI Scheme for Bulk drugs) and •Category 3: Drugs not covered under Category 1 and Category 2 such as

Repurposed drugs; Auto immune drugs, anti-cancer drugs, anti-diabetic drugs, antiinfective drugs, cardiovascular drugs, psychotropic drugs and anti-retroviral drugs, including In vitro diagnostic devices (applicable to 5 applicants out of 55 applicants).

The following four pharmaceutical companies have received the first tranche of

incentives of up to ₹165.74 crore under the Product Linked Incentive (PLI) scheme of the Department for Pharmaceuticals.

•Dr. Reddy’s Laboratories Limited, •Biocon Limited, •Strides Pharma Science Limited and •Premier Medical Corporation Private Limited.

Prominent pharmaceutical companies such as Sun Pharma, AurobindoPharma, Dr. Reddy's, Lupin, Mylan Laboratories, Cadila Healthcare, Cipla, and Glenmark, all

Future prospects of Indian API industry India, as the third largest producer of API, holds an 8 percent share in the global API industry. The country manufactures over 500 different APIs, contributing 57 percent of the APIs on the WHO prequalified list.

The Indian API market is projected to grow at a CAGR of 13.7 percent in the first four years, surpassing the growth rate of the generic API industry by about 8 percent.

This has attracted the attention of investors and venture capitalists, making the Indian API space highly lucrative.

India possesses several advantages that contribute to its API potential, including a robust domestic market, a well-developed chemical industry, a skilled workforce, stringent quality and manufacturing standards, and cost advantages in setting up and operating modern plants. To leverage its API potential, India is actively creating a comprehensive and supportive ecosystem. The country's emergence as an alternative source of bulk drugs has been remarkable, and with ongoing efforts, India is poised to become a global leader in the pharmaceutical industry. In the budget speech, Finance Minister Sitharaman also announced the government's plan to introduce a new program aimed at promoting research and innovation in the pharmaceutical sector.

This initiative will be implemented through centers of excellence established across the country.

The author is director and principal, Amity Institute of Pharmacy, Amity University

121

SPECIAL FEATURE

INDIAN API TO REACH US $130 BN BY 2030 Komal Saini, Vandita Kakkar ver the past few decades, the pharmaceutical industry in India has experienced significant growth, contributing approximately 1.72% to the nation's GDP. The industry is expected to reach $65 billion by 2024 and $130 billion by 2030, driven by the rising demand for affordable and highquality medicines both domestically and globally. Currently, India ranks as the 3rd largest producer by volume and 14th largest by value in the world. The country's pharmaceutical exports have seen remarkable growth, increasing by 103% since 2013-14, from INR 90,415 crores to INR 1,83,422 crores in 2021-22. India meets approximately 20% of the global demand for generic drugs, earning the title of the "Pharmacy of the World."

Active Pharmaceutical Ingredient (API) is a critical segment of the pharmaceutical industry, accounting for around 35% of the market.

APIs are the biologically active components of drugs that produce the intended medical effect. As defined by the World Health Organization, APIs are substances or combinations of substances used in finished pharmaceutical products (FPPs) intended to provide pharmacological activity or have a direct effect in the diagnosis, cure, mitigation, treatment, or prevention of diseases, or to restore, correct, or modify physiological functions in human beings. India holds the position of the 3rd largest API producer globally, with an 8% share of the global API industry. The country manufactures over 500 different APIs and contributes 57% of APIs to the World Health Organization's prequalified list. The Indian API market is projected to grow at a Compound Annual Growth Rate (CAGR) of 13.7% in the next four years, which is approximately 8% higher than the generic API industry growth rate. The Indian API sector has become an attractive investment opportunity for various investors and venture capitalists.

The industry benefits from India's robust domestic market, advanced chemical industry, skilled workforce, stringent quality and manufacturing standards, and lower costs (around 40% less than in the West) for establishing and operating modern plants, giving it a competitive edge.

O

The major players India holds a crucial position in the global active pharmaceutical ingredients (API) market, particularly in the US generic pharmaceutical industry, where it accounts for about half of the certified dossiers filed worldwide for APIs. The Asian region, specifically India

122

and China, is home to significant API manufacturers, with over 1,600 operating in these two countries. Leading API manufacturers in India include GlaxoSmithKline, Teva Active Pharmaceutical Ingredients (TAPI), Dr. Reddy's Laboratories, Aurobindo Pharma, Lupin, Ipca, Cipla, Divi's Laboratories, Sandoz, Ranbaxy, Matrix, Sun Pharma, BASF, and Pfizer.

Ipca has emerged as one of the top exporters of APIs in India, with nearly 25% of its turnover coming from this segment.

Around 75% of their API products are exported to regulated markets such as the USA, Canada, Europe, and Australia. Ipca has been a prominent player in the Indian API market for over 20 years, particularly in the anti-malarial and anti-hypertensive therapeutic segments. Other major domestic players such as Dr. Reddy's Laboratories, Aurobindo Pharma, Ipca Laboratories, Alembic Pharmaceuticals, Glenmark Pharmaceuticals, Jubilant Life Sciences, and Shasun Pharmaceuticals have also established a strong presence in these markets and are well-positioned to seize future opportunities.

Highlights of API market There is a misconception that India's patent regime provided it with a structural advantage. While this may be true for the domestic market, where APIs could be produced and sold even under patent, it did not necessarily contribute to India becoming a major exporter to regulated markets. Additionally, several other countries also had a process patent regime until they joined TRIPs in 1998.

As of 2020, the global API market was valued at $180 billion, and it is projected to grow at a mid-single-digit CAGR (around five to six percent) from 2021 to 2026, reaching $250 billion by 2026 and $300 billion by 2030, adding approximately $50 billion every five years. According to IMS 2020, generics hold a 94% share of the API market by volume, while innovators hold a six percent share. This indicates a tremendous opportunity for penetration into the generic market. Given the size of the market, ancillary industries, similar to what happened in the automobile industry in the 1950s, are expected to develop, leading to a significant standalone capacity for API intermediates.

APIs reside at the base of the value pyramid, making them highly susceptible to the impact of genericization. Price erosion is also most pronounced in this segment. Therefore, for mature APIs, the focus will shift from R&D capabilities to excellence in engineering.

Improving kinetics, process engineering, solvent recovery, optimal batch sizes, scale, and minimizing changeovers will be critical for cost efficiency. Companies will concentrate on fewer APIs but manufacture them in larger quantities to achieve scale, procurement, and cost efficiencies.

The industry's reliance on China for APIs has been a major concern for the Indian pharmaceutical sector. The percentage of API imports from China has risen from 0.5% in 1987 to around 78% in 2020. India imports approximately 55% of its API requirements, with almost all imports coming from China.

China enjoys advantages such as scale, subsidies, access to cheaper capital (with a cost of four to five percent compared to 12-15% in India), lower logistics costs (0.9% versus four percent in India), and cheaper power.

Indian API manufacturers are actively enhancing their credibility in regulated markets by obtaining approvals for their products, therapeutic applications, and manufacturing facilities. These companies, including those selling finished dosage forms, continue to outperform competitors from China, Italy, and other countries in terms of Drug Master Files (DMFs), which are seen as a measure of quality. India's combination of higher quality and cost containment makes it increasingly attractive for API outsourcing. In fact, India has been recognized as one of the leading global players, with a significant number of DMF filings and dossier registrations for active pharmaceutical ingredients, along with numerous manufacturing facilities approved by regulatory authorities in developed countries.

Conclusion The API market is being propelled by the cost advantages of China and India, which have established themselves as key manufacturing hubs. With strong government support, advancements in intellectual property (IP) systems, and improved manufacturing standards, both countries are driving the growth of the generic and innovator API markets in the Asia-Pacific region. As a result, the API market in this region is anticipated to experience consistent expansion. In the near future, India has the potential to surpass China and become a leading player in the global API market.

Saini is from Chandigarh College of Pharmacy, Chandigarh Group of Colleges and Kakkar is from University Institute of Pharmaceutical Sciences, Panjab University

SPECIAL FEATURE

OPPORTUNITIES AND CHALLENGES FOR INDIAN PHARMA DRUGS Dr. Vikas Pandey ealth is important for a value life and having good health is a right of all humans. India's healthcare sector is experiencing rapid growth, encompassing various components such as hospitals, pharmaceuticals, medical equipment and devices, health insurance, and telemedicine.

Pharmaceuticals play a crucial role in providing medicinal solutions for treating illnesses.

The pharmaceutical industry not only contributes to employment generation but also plays a significant role in maintaining economic stability. India is globally recognized as the largest supplier of generic drugs, renowned for its affordability in vaccines and generic medications. Currently, the Indian pharmaceutical industry holds the third position in terms of pharmaceutical production volume. Over the years, it has evolved into a thriving sector, exhibiting a Compound Annual Growth Rate (CAGR) of 9.43% over the past nine years. The Indian pharma industry comprises various segments, including generic drugs, over-the-counter medications, bulk drugs, vaccines, contract research and manufacturing, biosimilars, and biologics.

India boasts the highest number of pharmaceutical manufacturing facilities that adhere to the regulations set by the US Food and Drug Administration (USFDA).

Additionally, it is home to 500 active pharmaceutical ingredient (API) producers, representing approximately 8% of the global API market. To unlock the full growth potential of the Indian pharmaceutical industry, it is imperative to prioritize the development of a skilled workforce, enhance research capabilities, and foster stronger collaborations between industry and academia.

H

Prospective of the Indian Pharmaceutical Industry India holds the position of the largest global supplier of generic drugs, meeting more than 50% of the global demand. It is a significant contributor to the vaccine market, fulfilling over 50% of the global requirement.

Moreover, the Indian pharmaceutical sector caters to 40% of the generic drug demand in the United States and supplies 25% of all medicines in the United Kingdom. The domestic pharmaceutical industry is comprised of a vast network of 3,000 drug companies and approximately 10,500 manufacturing units. India's pharmaceutical sector enjoys a prominent position in the global arena, supported by a large pool of skilled scientists and engineers who have the potential to propel

the industry to greater heights. Notably, Indian pharmaceutical firms currently supply more than 80% of the antiretroviral drugs utilized worldwide in the fight against AIDS (Acquired Immune Deficiency Syndrome). With its costeffective and high-quality medicines, India is rightfully recognized as the "pharmacy of the world." According to a study, the Indian generic drugs market reached USD 24.53 billion in 2022, and it is projected to exhibit a steady compound annual growth rate (CAGR) of 6.97% during the forecast period.

The Indian pharmaceutical market has gained a reputation for its global supply of high-quality medicines. According to IBEF data in 2022, India leads the world with the highest number of US FDA-approved units, reaching 741 as of August 2021. Indian pharmaceutical companies excel in manufacturing a diverse range of products, including generic drugs, over-the-counter medicines, active pharmaceutical ingredients (APIs), vaccines, contract research and manufacturing, as well as biosimilars and biologics. Notably, the United States serves as the primary export market for Indian pharmaceutical products. To encourage investments in the pharmaceutical sector, the government has streamlined the approval process for new facilities. With the increased export of generic drugs and robust research and development activities, the market is poised for further growth.

Globally recognized for its generic medicines and affordable vaccines, the Indian pharmaceutical industry has undergone a remarkable transformation and now holds the third position in terms of pharmaceutical production volume. In addition, it ranks as the 14th largest pharmaceutical industry in terms of value. The pharmaceutical sector in India currently contributes approximately 1.72% to

the country's GDP, reflecting its significant economic impact. According to the Indian Economic Survey 2021, the domestic market is expected to grow 3x in the next decade.

India’s domestic pharmaceutical market stood at US$ 42 billion in 2021 and is likely to reach US$ 65 billion by 2024 and further expand to reach US$ 120-130 billion by 2030.

India holds the position of being the largest global supplier of generic medications, contributing to 20% of the global supply by volume and satisfying approximately 60% of the global demand for vaccinations. The Indian pharmaceutical sector has garnered a significant market worth of US$ 42 billion on a global scale. Notably, in August 2021, the Indian pharmaceutical market witnessed a remarkable annual growth rate of 17.7%, surpassing the previous rate of 13.7% recorded in July 2020. India Ratings & Research reports that the revenue of the Indian pharmaceutical market experienced a year-onyear increase of over 12% in FY22.

Furthermore, the domestic pharmaceutical industry in India is projected to reach a substantial value of USD 130 billion by 2030.

Despite the challenges posed by the Covid-19 pandemic, the pharmaceutical market in India has sustained its growth momentum, as stated in the Economic Survey 2022-23 released on January 31, 2023.

Generics have emerged as a cost-effective alternative to branded drugs, commanding a substantial share of the retail market, ranging from 70% to 80%. With India's population steadily growing, particularly the aging population, there has been a significant surge in the demand for generic medicines due to their affordability and comparable efficacy to branded medications. According to a recent study, the global market for generic drugs was

123

valued at USD 390.57 billion in 2020, and it is anticipated to reach approximately USD 574.63 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 5.59% between 2021 and 2030.

The Pradhan Mantri Bhartiya Janaushadhi Pariyojana (PMBJP) aims to make quality medicines accessible to the general public in India at affordable prices. As part of this initiative, PMBJP stores have been established to offer generic drugs that are available at lower costs, while ensuring they maintain the same level of quality and effectiveness as expensive branded medications.

Challenges The pharmaceutical industry in India faces several policy and regulatory challenges. The intellectual property rights (IPR) regime in India is not considered favorable for the Pharma industry. The drugs price control order puts pressure on prices, and the Goods and Services Tax (GST) levy based on maximum retail price (MRP) imposes additional burdens on companies with higher taxes.

Furthermore, challenges such as inadequate data collection on drugs and insufficient training for drug inspectors have resulted in widespread malpractice among drug sellers, hindering the smooth entry of drugs into the market.

India heavily relies on China for approximately 77% of its active pharmaceutical ingredients (APIs), which are imported. This heavy dependence on China for APIs poses a risk to the drug supply chain. The quality of drugs has also been affected, leading to availability and quality issues. Regulatory bodies have imposed bans on certain drugs due to poor quality. Moreover, pharmaceutical companies often engage in unethical practices by offering freebies and gifts to doctors to promote their drugs. This raises concerns about the integrity of the healthcare system and patient safety.

Another challenge is the lack of adequate training for medical representatives, as well as the presence of quacks (fake doctors), which increases the risk to patients' lives.

Additionally, there is a shortage of research and development due to funding constraints, resulting in limited academia-industry collaboration. This hampers innovation and the development of new drugs and therapies.

New opportunities for India in global API market The Indian pharmaceutical industry is highly regarded worldwide and has emerged as one of India's most successful sectors. Its contributions to healthcare outcomes and the economy have been significant. With world-class

124

capabilities and favorable market conditions, India has established itself as one of the most lucrative pharmaceutical markets globally.

In every industry, there are established processes to benefit society. For instance, third-party manufacturing pharma companies require students who can become future researchers and developers. It is crucial for the pharmaceutical industry to provide the necessary training to students aligned with their specific needs. Unfortunately, only a few industries are actively considering this approach. Pharmaceutical companies should collaborate with Indian academic institutions to identify qualified candidates who possess the knowledge and skills required by the industry.

A new era of biopharmaceutical innovation is on the horizon. As our understanding of genetics improves, so does our ability to target drugs more effectively. This enhanced knowledge, coupled with robust and costeffective genetic profiling, will enhance patient outcomes and expedite the speed and reduce the cost of clinical trials. These advancements signify a significant shift in the pharmaceutical landscape and hold great promise for the future.

The Future Prospects In order to achieve their objectives, Indian pharmaceutical companies need to adopt bold strategic measures and venture into unexplored territories. It is essential to establish policies that instill confidence in drug pricing and foster a stable regulatory environment. A key focus should be on bolstering API manufacturing capabilities to reduce dependence on imported APIs. This can be accomplished through various means, including the establishment of dedicated zones exclusively for API production. Positive strides have already been taken by several state governments in India to promote industry growth.

Provinces such as Andhra Pradesh and Uttar Pradesh have announced plans to develop "pharma parks" that will provide a competitive advantage to the sector.

To facilitate the growth of the pharmaceu-

tical industry in India, regulatory authorities need to streamline the approval process, particularly for investments in emerging research and development (R&D) fields that often require higher investments compared to generic drugs.

Collaborating with global regulatory bodies can also encourage pharmaceutical growth in the country.

Generic medicines are not only cost-effective but also as safe and effective as branded medications. Their widespread use in India has been further promoted through initiatives like the PMBJP, which aims to raise awareness among the public.

Furthermore, the pharmaceutical industry has demonstrated remarkable progress and adaptability in response to a changing environment, positioning it for greater success in the export of generic drugs from India.

Conclusions: India has emerged as a significant and increasingly influential player in the global pharmaceutical sector. However, there is still untapped potential for further growth.

Strengthening communication channels between stakeholders and Indian regulators is crucial to establish a robust platform for the Indian Pharmaceutical Industry. Traditional major pharmaceutical companies are no longer offering the same level of service as before. Recognizing the importance of responsible and human-centric development and AI utilization, India has become a founding member of the "Global Partnership on Artificial Intelligence" (GPAI). This demonstrates the government's positive approach to supporting such initiatives. As a developing country, India must continue focusing on fostering similar innovative mindsets in the future.

The government has also fostered an environment conducive to the establishment of healthcare startup firms. This enables patients and companies to coexist harmoniously without placing excessive burdens on one another. With its existing advantage of scale and global reach in the pharmaceutical space, India now needs to ascend the value chain by scaling up its research and development (R&D) efforts and fostering innovation.

This will propel the industry forward, transitioning from a "Make in India" approach to a more comprehensive "Discover and Make in India" approach.

The author is associate professor, Amity Institute of Pharmacy, Amity University

SPECIAL FEATURE

OVERVIEW OF INDIAN PHARMA MACHINERY Rajesh Nath he Indian pharmaceutical machinery industry plays a crucial role in the manufacturing and packaging processes of pharmaceutical products, encompassing a wide range of machinery and equipment used in areas such as formulation, filling, packaging, labelling, and quality control of pharmaceuticals.

The industry has experienced significant growth over the years, driven by the country's robust pharmaceutical sector. The industry is characterized by the presence of both domestic and multinational players, offering a diverse range of machinery solutions to meet the industry's needs. Indian manufacturers cater not only to the domestic market but also export pharmaceutical machinery to various countries worldwide. The industry has established manufacturing facilities across various regions of India, equipped with modern technology and a skilled workforce to meet the growing demand for pharmaceutical machinery.

In recent years, the industry has gained recognition for its ability to provide cost-effective machinery solutions without compromisingon quality. Indian pharmaceutical machinery manufacturers have made significant strides in complying with international quality standards, such as Good Manufacturing Practices (GMP) and various certifications, to ensure that the machinery meets global regulatory requirements. Furthermore, the industry has actively expanded its export market, capitalizing on the growing demand for pharmaceutical machinery worldwide. Indian machinery has gained a reputation for its competitiveness in terms of pricing, adherence to quality standards, and the ability to cater to diverse customer requirements.

As the pharmaceutical industry continues to evolve, the Indian pharmaceutical machinery sector is keeping pace with the changing needs of pharmaceutical manufacturers. The industry is investing in research and development, embracing automation and digitization, and exploring advanced technologies such as robotics, artificial intelligence, and data analytics to enhance productivity, efficiency, and

T

quality control.

With a positive growth trajectory, increasing domestic demand, a focus on quality compliance, and a proactive approach to innovation, the Indian pharmaceutical machinery industry is poised for further expansion and is well-positioned to contribute to the growth and success of the pharmaceutical sector in India and abroad.

ceutical machinery industry has witnessed significant growth in its export market. In recent years, India has become a prominent exporter of pharmaceutical machinery to various countries worldwide. The industry's export revenue reached approximately USD 650 million in 2020, highlighting the industry's competitiveness in the global market.

Statistics and Industry Highlights: The industry's adherence to quality standards, government support, and focus on research and development contribute to its competitiveness in the global market.

• Growth Rate: The Indian pharmaceutical machinery market has experienced a robust growth rate of approximately 8% CAGR over the past few years. This growth is fuelled by the increasing demand for pharmaceutical products and the need for advanced machinery to support production.

• Employment Generation: The pharmaceutical machinery industry plays a vital role in job creation. It provides employment opportunities to a large workforce engaged in manufacturing, research and development, quality control, and maintenance of pharmaceutical machinery. The industry's growth contributes to the overall employment landscape in India.

• Market Size: The market size of the Indian pharmaceutical machinery industry was valued at approximately USD 2.0 billion in 2021. The industry has shown consistent growth, driven by the expanding pharmaceutical sector and the government's focus on promoting healthcare and pharmaceutical manufacturing.

• Domestic Consumption: India's pharmaceutical market is one of the largest globally in terms of volume, with a high demand for pharmaceutical machinery to support production. The domestic consumption of pharmaceutical machinery is driven by the need to cater to the growing population's healthcare needs and the rising demand for quality pharmaceutical products.

• Manufacturing Facilities: India has established a strong manufacturing infrastructure for pharmaceutical machinery. Several manufacturing facilities are located in key regions such as Maharashtra, Gujarat, and Tamil Nadu. These facilities are equipped with advanced technology and employ a skilled workforce to meet the industry's demands.

• Export Market: The Indian pharma-

• Government Initiatives: The Indian government has undertaken several initiatives to support the pharmaceutical machinery industry. Programs such as "Make in India" and "Pharma Vision 2020" aim to promote domestic manufacturing, research and development, and technological advancements in the pharmaceutical sector. These initiatives have facilitated the growth of the pharmaceutical machinery industry.

• International Recognition: Indian pharmaceutical machinery manufacturers have gained international recognition for their quality products and competitive pricing. The industry has witnessed increased demand for its machinery in global markets due to its adherence to international quality standards and compliance with regulatory requirements.

• Collaboration and Partnerships: Indian pharmaceutical machinery manufacturers actively collaborate with domestic and international pharmaceutical companies to develop customized machinery solutions. Such collaborations enhance technology transfer, promote knowledge exchange, and foster innovation in the industry.

• Research and Development: The industry invests significantly in research and development activities to stay at the forefront of technological advancements. Manufacturers focus

125

on developing innovative machinery and equipment that meet the evolving needs of the pharmaceutical industry, such as high-speed automated systems, advanced packaging solutions, and precision control systems.

Latest Figures and Trends: • Automation and Digitization: The industry is witnessing a shift towards automation and digitization in line with global trends. Manufacturers are increasingly incorporating advanced technologies such as robotics, artificial intelligence, machine learning, and data analytics into pharmaceutical machinery to improve efficiency, productivity, and quality control.

• Quality Compliance: With a focus on meeting stringent regulatory requirements, Indian pharmaceutical machinery manufacturers are adopting international quality standards such as Good Manufacturing Practices (GMP) and ISO certifications. Compliance with these standards ensures the safety, efficacy, and reliability of pharmaceutical products.

• Pharmaceutical Packaging: As the demand for pharmaceutical products grows, there is an increased focus on advanced packaging solutions. Indian machinery manufacturers are developing innovative packaging machinery that offers features such as tamper-evident packaging, blister packaging, track-and-trace systems, and serialization to meet the industry's evolving needs.

• Contract Manufacturing: The trend of outsourcing pharmaceutical manufacturing to contract manufacturers is gaining momentum. This presents an opportunity for the pharmaceutical machinery industry as contract manufacturers require machinery and equipment to meet the production demands of their clients.

Future Outlook: The future of the Indian pharmaceutical machinery industry looks promising, driven by several factors: • Rising Domestic Demand: The domestic demand for pharmaceutical machinery in India is driven by the country's growing pharmaceutical sector. The Indian pharmaceutical market is estimated to reach a value of USD 65 billion by 2024, further fuelling the demand for machinery and equipment.

• Increasing Exports: The Indian pharmaceutical machinery industry has

126

been actively expanding its export market. In 2020, exports of pharmaceutical machinery from India amounted to approximately USD 650 million. This export revenue is projected to grow at a CAGR of over 12% from 2021 to 2026.

• Growing Market Size: The Indian pharmaceutical machinery market is expected to witness substantial growth in the coming years. By 2025, the market size is projected to reach USD 3 billion, reflecting a compound annual growth rate (CAGR) of around 10%.

• Favourable Government Policies: The Indian government has been implementing various policies and initiatives to promote the pharmaceutical sector, including the pharmaceutical machinery industry. The "Pharma Vision 2020" initiative and schemes like "Make in India" encourage domestic manufacturing and innovation in the pharmaceutical machinery sector.

• Technological Advancements: The industry is witnessing rapid technological advancements, with a focus on automation, digitization, and advanced manufacturing techniques. The adoption of technologies like robotics, artificial intelligence (AI), and Internet of Things (IoT) in pharmaceutical machinery is expected to enhance productivity, efficiency, and quality control.

• Investment in Research and Development: Indian pharmaceutical machinery manufacturers are investing significantly in research and development (R&D) activities to develop innovative machinery solutions. These investments are aimed at improvingprocess efficiency, product quality, and meeting the evolving needs of the pharmaceutical industry. In recent years, R&D investments in the pharmaceutical sector have reached around 8-9% of sales.

• Contract Manufacturing Opportunities: The trend of outsourcing pharmaceutical manufacturing to contract manufacturers is gaining momentum. This presents opportunities for the pharmaceutical machinery industry, as contract manufacturers require advanced machinery and equipment to meet the production demands of their clients.

• International Collaborations: Indian pharmaceutical machinery manufacturers are actively engaging in collaborations and partnerships with international players to expand their global presence. These collaborations facilitate technology transfer, knowledge exchange, and market access, leading

to enhanced growth prospects for the industry.

• Focus on Quality Compliance: Indian pharmaceutical machinery manufacturers are increasingly focusing on adhering to international quality standards such as Good Manufacturing Practices (GMP) and obtaining certifications like ISO 9001 and ISO 13485. This emphasis on quality compliance ensures the safety, efficacy, and reliability of pharmaceutical products and enhances the industry's reputation.

• Export Market Diversification: Indian pharmaceutical machinery manufacturers are actively exploring new export markets and diversifying their customer base. Apart from traditional markets like the United States and Europe, manufacturers are targeting emerging markets in Asia, Latin America, and Africa, where there is a growing demand for pharmaceutical products.

Over the past years, the industry has significantly built-up production capacities. This is in response to the continuing good economic situation and the good structural conditions in the pharmaceutical industry.Many factors have a stimulating effect on the demand for production and packaging machinery for pharmaceuticals: There is the increasing superannuation of the population in the industrialized countries, the trend towards small and very small batch sizes, e.g. for personalised medication, the development of production capacities for the rapid supply of vaccines in the event of a pandemic, the increase in lifestyle diseases in the emerging countries, an increasing population with improved drug supply in emerging and developing countries as well as the increasing cost pressure on drug manufacturers by health care providers.

In conclusion, the Indian pharmaceutical machinery industry has witnessed significant growth, driven by domestic demand and exports. The industry is evolving by adopting advanced technologies, focusing on quality compliance, and catering to the changing needs of pharmaceutical manufacturers. With a positive outlook and favourable market conditions, the industry is poised for further expansion in the coming years.

The author is managing director, VDMA India Services Private Limited

SPECIAL FEATURE

FUTURE PROSPECTS OF INDIAN PHARMA FORMULATIONS Dr. Sanjay Agrawal he Covid-19 pandemic has had devastating effects on economies worldwide and has caused a global health crisis. The manufacturing sectors, including the pharmaceutical industry, have faced significant challenges during this period, highlighting the urgent need for India to achieve self-sufficiency. However, despite the initial push towards selfreliance with the "Atmanirbhar Bharat" narrative, the ongoing pandemic has disrupted self-sufficiency.

One of the major revelations of the outbreak was India's reliance on imports for basic medical supplies.

Export limitations and supply inconsistencies sharply increased domestic pricing for essential medications and disrupted international trade. This exposed the areas for improvement in India's pharmaceutical industry, particularly the low availability of Key Starting Material (KSM), which is essential for formulation development.

The pharmaceutical industry is a significant revenue generator, with an annual revenue of US$1.2 trillion. To thrive in the future, the industry must embrace new technologies, patientcentric design, and innovations while prioritizing prevention and digital health. The stakes are high, and the industry needs to adapt quickly to the fast pace of technological disruption.

One of the challenges faced by the Indian pharmaceutical industry is overdependence on China. While Indian businesses have positioned themselves as leaders in the global pharmaceutical industry, the heavy reliance on Chinese imports for fundamental raw materials, particularly Active Pharmaceutical Ingredients (APIs), has been a cause for concern.

About 70% of the pharmaceutical industry's API needs are met through Chinese imports, which offer lower costs than Indian-made APIs. The heavily subsidized pricing of Chinese APIs led to the shutdown of domestic API production plants in India. The higher cost of technology and infrastructure required for API production in India further contributed to the decline in domestic API manufacturing.

The pharmaceutical and healthcare industries are undergoing significant

T

changes, influenced by the current health priorities and the need to adapt to the "new normal." The focus is shifting towards prevention rather than treatment, and patients are becoming more empowered and involved in their healthcare. The industry is embracing digital health technologies, automation, and analytics tools to make healthcare more patient-centric and efficient.

Stable supply chains have become crucial, as the pandemic exposed the vulnerabilities of heavily dependent supply chains. Businesses are considering relocating their production and supply hubs closer to their target consumers to mitigate risks. Efforts are being made to ensure a stable supply of essential medicines and reduce reliance on vulnerable areas.

To thrive in the future, pharmaceutical businesses must prioritize patientcentric approaches, embrace digital health strategies, and explore innovative technologies. Patients should be included as equal partners in healthcare decision-making, and the industry should focus on creating more than just medications by integrating digital health technologies. Digital pills, virtual reality applications, pharmacogenomics-based precision medicine, and AI-driven drug development are some trends shaping the pharma industry's future.

Some Relevant Sectors for Future Prospects of Indian Pharma Formulations Growing Domestic Market: The Indian pharmaceutical market has been witnessing steady growth due to an aging population, rising disposable incomes, and increased access to healthcare.

The demand for affordable and highquality medicines is expected to drive the growth of Indian pharma formulations in the domestic market. The government's focus on improving healthcare infrastructure and increasing healthcare spending further enhances the opportunities for domestic pharma companies.

Increasing Global Demand: Indian pharma formulations have gained significant traction in the international market, primarily driven by cost-effectiveness and adherence to stringent quality standards. With a strong emphasis on research and development, Indian

companies increasingly focus on developing complex formulations, biosimilars, and specialty drugs. This shift towards innovative and niche formulations is expected to propel the growth of the Indian pharma industry in global markets.

Favourable Regulatory Environment: The regulatory environment in India has undergone significant improvements in recent years, making it more conducive for pharmaceutical companies. Initiatives such as implementing the Goods and Services Tax (GST) and introducing the Drug Price Control Order (DPCO) have brought transparency and standardization in pricing and taxation. Additionally, the government's emphasis on promoting ease of doing business and protecting intellectual property rights has created a favourable ecosystem for the growth of Indian pharma formulations.

Technological Advancements: The Indian pharmaceutical industry has embraced technological advancements to enhance productivity, quality, and efficiency.

Rapid technological advancements will shape the future of the pharmaceutical industry. Precision medicine, which includes personalized and predictive medicine, will significantly impact access to medicines.

Artificial intelligence (AI) will revolutionize healthcare by improving medical research, creating treatment plans, accelerating medical imaging, and even aiding in developing new drugs.

AI-driven drug development processes can significantly reduce the time and cost of bringing new medicines to market.

Automation, artificial intelligence (AI), and data analytics are increasingly integrated into various aspects of the pharma value chain, including formulation development. These advancements enable companies to streamline processes, improve product quality, and reduce time-to-market for new formulations. Incorporating technologydriven solutions will be crucial in shaping the future of Indian pharma formulations.

Focus on Research and Development: Indian pharma companies invest heavily in research and development to develop novel formulations and drug delivery systems. The

127

emphasis on innovation and intellectual property has led to collaborations with global pharmaceutical giants, research institutions, and academia.

This focus on R&D has resulted in development of new formulations and enabled companies to file for patents and strengthen their product pipelines.

Expansion into Emerging Markets: Indian pharma companies are expanding their presence in emerging markets, such as Africa, Southeast Asia, and Latin America. These markets offer significant growth potential due to rising healthcare expenditure, an increasing middle-class population, and a growing demand for affordable medicines. By leveraging their expertise in formulation development and cost-effective manufacturing, Indian pharma companies can tap into these markets and establish a strong foothold.

Sustainable Manufacturing

Practices: Sustainability has become a global key focus for the pharmaceutical industry, and Indian companies are no exception. With a greater emphasis on environmental consciousness and responsible manufacturing practices, Indian pharma companies are adopting sustainable measures throughout the formulation development process. This includes reducing waste generation, optimizing energy consumption, and implementing eco-friendly packaging solutions. Such sustainable practices contribute to environmental preservation and enhance the reputation and competitiveness of Indian pharma formulations in the global market.

In conclusion, The pharmaceutical industry is undergoing significant transformations driven by the need for selfsufficiency, technological advancements, and changing healthcare priorities. To succeed in the future, the industry needs to adapt to the "new

normal," ensure stable supply chains, prioritize prevention and patient-centric approaches, and embrace innovative technologies. The prospects of Indian pharma formulations look promising, driven by a growing domestic market, increasing global demand, a favourable regulatory environment, technological advancements, and a focus on research and development.

With the right strategies and investments, Indian pharma companies can continue to play a significant role in providing affordable and high-quality formulations to meet the evolving healthcare needs of the world. Only by rethinking traditional business models and putting the patient first can pharmaceutical businesses thrive in an era focused on prevention, early detection, and personalized therapies.

The author is pharmaceutical consultant

Experts recommend adopting good documentation practices W ith growing concerns around quality issues of medicines exported from India and to be audit ready for unannounced audits, experts recommend it is high time to adopt Good Documentation Practices (GDP) to avoid warning letters, product recalls or import alerts with increasing USFDA inspections. Experts say that the US Food and Drug Administration (FDA) have raised concerns over the quality of drugs manufactured by some pharmaceutical firms and that has led to a slump in the number of Indian pharmaceutical companies receiving approvals from the FDA, resulting in loss of business for them. GDP is a set of rules that are required for the safety and quality of pharmaceutical products. In the pharmaceutical sector, documentation is required in the areas of manufacturing, distribution, laboratory, clinical and documentation.

Highlighting the role of GDP, Dr Sanjt Singh Lamba, Managing Partner, Trillyum Consulting and Advisory and chief executive officer of Biocuris Pharmaceuticals Private Limited said, “A GDP record must have only one Official Record. GDP records must have a defined Record Owner (either function or person). Record Owners must be defined in the record management inventory.

This inventory must be approved by the corresponding Quality group and be stored in the Electronic Document Management System (eDMS).”

"Senior management, under the European Union (EU) Good Manufacturing Practices (GMP) Chapter 1 is responsible for the overall quality system and that includes data integrity", added Dr Lamba.

There are also rampant cases of data falsification and fraud in the pharma industry which include copying a passing result file from one batch into a new batch without doing the actual analysis. This

128

may include doing an analysis and then calculating what the weight of the sample should be to pass and then fabricating the balance data.

Performing 'chromatographic analysis' without any physical chromatographs, merely reintegrating and printing the same sets of data using a chromatography data system is yet another form of falsification.

Experts have also pinpointed lack of awareness and effectiveness of trainings leading to data integrity issues in pharma companies.

Data integrity refers to maintaining and assuring the accuracy and consistency of data over the entire data life-cycle to ensure data is recorded exactly as intended and upon later retrieval, ensure the data is the same as it was when it was originally recorded.

Dr Lamba further explained, “Employees need to be trained to understand GMPs. Inadequate training causes employees to consider activities as a chore rather than understanding their relevance in light of GMP.” Besides quality assurance, lack of investment in research and development and disruptions due to Covid-19 pandemic is also a cause of concern.

Experts also voiced the concern that diversion of management and employees’ attention from their daily activities, to focus on Corrective Action and Preventive Actions (CAPAs) as a part of the lengthy remediation process tends to cost time, money and often loss of talent. Therefore there is an urgent need towards creating awareness and sending a clear message of “Zero tolerance to data integrity breach (DIB)”.

- Our Bureau, Mumbai

SPECIAL FEATURE

THE IMPORT AND EXPORT OF INDIAN APIS : A GLOBAL PERSPECTIVE Dr. Sanjay Agrawal he pharmaceutical industry is a vital component of global healthcare, with Active Pharmaceutical Ingredients (APIs) being the crucial building blocks for producing various medicines. India, known as the "pharmacy of the world," has emerged as a significant player in the API market, both as an importer and exporter. In this blog, we will explore the significance of the import and export of Indian APIs, highlighting India's role in the global pharmaceutical landscape.

T

Indian API Industry Overview India plays a significant and vital role in the global pharmaceutical and vaccine industry. It holds the distinction of being the largest provider of generic medicines worldwide. With a share of 20% in global supply volume, India contributes approximately 60% of the global vaccines. Regarding volume, India ranks third globally and holds the fourteenth position in terms of value. The Indian pharmaceutical industry encompasses various segments, including OTC medicines, generics, APIs, vaccines, biosimilars, and custom research manufacturing (CRM).

Notably, India is the global leader in supplying vaccines such as DPT, BCG, and Measles. Moreover, it boasts the highest number of US FDA-approved plants outside the United States. The Indian Pharmaceutical Industry's unique selling point (USP) lies in its ability to offer medications at affordable prices without compromising on quality. This has earned India the well-deserved reputation of being the "Pharmacy of the World."

One of the remarkable achievements of the Indian Pharma Industry is its role in providing access to affordable HIV drugs. Additionally, India is one of the largest suppliers of low-cost vaccines globally, contributing significantly to global healthcare initiatives.

Regarding exports, India primarily focuses on drug formulations and biologicals, constituting about 75% of the country's total pharmaceutical exports.

This highlights the nation's strong presence in the international market as a reli-

able exporter of pharmaceutical products.

Overall, India has a robust and rapidly growing API industry, supported by factors such as a large skilled workforce, cost advantages, established manufacturing infrastructure, and adherence to international quality standards. The country is known for producing diverse APIs, catering to domestic and international markets.

The Indian API industry has grown substantially over the years, fuelled by factors like patent expirations, increasing generic drug production, and rising demand for affordable healthcare solutions worldwide. India's pharmaceutical industry holds a critical global position, driven by its extensive production of generic medicines, a wide range of vaccine offerings, adherence to quality standards, and affordability. Its contributions to global healthcare accessibility and affordability make it a pivotal player in the pharmaceutical and vaccine landscape.

Import of APIs in India While India is a significant exporter of APIs, it also relies on imports to meet domestic pharmaceutical requirements.

Several factors contribute to the import of APIs, including the need for specialized molecules, technological limitations, and cost considerations. India imports APIs from various countries, including China, the United States, Germany, Italy, etc. The import of APIs is crucial in ensuring a steady supply of essential drugs within the country.

Importance of API Imports: 1. Meeting Domestic Demand: India is the largest provider of generic medicines globally, and a significant portion of its pharmaceutical production depends on imported APIs. Importing APIs helps meet the increasing demand for affordable and quality drugs in the country.

2. Ensuring Drug Quality and Safety: APIs imported from reputed international suppliers contribute to maintaining the quality and efficacy of pharmaceutical formulations. It allows Indian pharmaceutical companies to produce drugs that meet stringent quality standards and comply with regulatory requirements.

3. Wide Range of Therapeutic Options: API imports enable Indian pharmaceutical manufacturers to access a diverse range of APIs, expanding the therapeutic options available to healthcare providers and patients. This facilitates the production of a wide range of medications to address various medical conditions.

Opportunities for API Imports: 1. Collaborations and Technology Transfers: Collaborating with international suppliers and entering into technology transfer agreements can enhance India's capabilities in API manufacturing. This collaboration can help build local capacities, improve process efficiencies, and reduce import dependency.

2. Research and Development: Increased investment in research and development (R&D) activities can lead to the development of innovative and complex APIs within India. Focusing on indigenous R&D capabilities can help the country reduce its reliance on imported APIs and foster self-sufficiency.

3. Export Potential: India's expertise in pharmaceutical manufacturing and its cost competitiveness can create opportunities to export APIs to other countries.

By leveraging its manufacturing capabilities and adhering to global quality standards, India can become a significant player in the API export market.

Export of Indian APIs India's prowess in the API sector extends to its role as a significant exporter. India holds a 5.92% share of the global market for pharmaceuticals and drugs. The central portion of India's exports comprises formulations and biologics, accounting for 73.31% of the total share, followed by drug intermediates and bulk drugs. In the fiscal year 202122, the value of India's pharmaceutical product exports reached US$ 24.62 billion, maintaining a steady performance compared to the previous year.

India's pharmaceutical products find their way to various regions around the world, including North America, Africa, the European Union (EU), the Association of Southeast Asian Nations (ASEAN), Latin America and the Caribbean (LAC), the Middle East, Asia,

129

the Commonwealth of Independent States (CIS), and other European regions. The majority of India's exports, nearly two-thirds, are directed towards NAFTA (North American Free Trade Agreement), Europe, and Africa. In the fiscal year 2021-22, the top five export destinations for the Indian Pharma Industry were the United States, the United Kingdom, South Africa, Russia, and Nigeria.

To summarize, India's presence in the global pharmaceutical market is substantial, with a 5.92% market share. The country's exports predominantly consist of formulations and biologics, and in the fiscal year 2021-22, the pharmaceutical product exports were valued at US$ 24.62 billion. India's export destinations encompass various regions, with NAFTA, Europe, and Africa being the key recipients of Indian pharmaceutical products.

Regulatory Landscape and Quality Assurance Ensuring the quality, safety, and efficacy of APIs is paramount in the pharmaceutical industry. Regulatory bodies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have stringent guidelines for importing and exporting APIs. Indian API manufacturers adhere to these regulatory standards to maintain compliance and enhance their credibility in the global market. Quality assurance practices, including Good Manufacturing Practices (GMP), are implemented to meet international quality requirements, thus ensuring the reliability of Indian APIs. Governing Authority 1: Pharmaceutical Export Promotion Council of India (Pharmexcil) Pharmexcil, established by the Government of India, is a promotional body for the Indian pharmaceutical industry. The council's responsibilities include: ● Guiding the government. ● Organizing seminars and meetings to address export-related matters. ● Arranging domestic and international business meetings. ● Coordinating trade delegations.

Pharmexcil also supports its members in securing Market Access Incentive (MAI) claims from the Indian government.

2: Department of Pharmaceuticals Formed in 2008, the Department of

130

Pharmaceuticals focuses on developing the pharmaceutical sector within India.

The department's primary functions involve ensuring the availability of drugs at affordable prices, overseeing the operations of Central Pharma Undertakings, supporting projects and revitalizing schemes, ensuring effective management, developing human resources and infrastructure, formulating schemes and projects, and preparing an annual plan, budget, and monitoring expenditure.

Continued investment in research and innovation is vital for the growth of the Indian API industry. By developing novel APIs and improving manufacturing processes, Indian companies can differentiate themselves and offer value-added products to the global market.

What are the Challenges and Opportunities for the Import and Export of Indian AP?

● Collaborations and Partnerships: Collaborations with international pharmaceutical companies and research institutions can help Indian API manufacturers enhance their capabilities and access new technologies. Partnerships can facilitate knowledge exchange, joint research projects, and market expansion opportunities.

● Increasing Competition: The global API market is highly competitive, with several countries vying for market share.

India faces competition from countries like China, which has a strong presence in the API industry. Indian companies must continuously innovate and improve their manufacturing processes to stay competitive.

● Digital Technologies: Embracing digital technologies such as data analytics, artificial intelligence, and blockchain can streamline supply chain processes, improve efficiency, and enhance traceability. Adopting digital solutions can help Indian API manufacturers meet global standards and enhance their competitiveness.

● Dependence on Imports: India is a significant exporter of APIs but still relies on imports for certain specialized APIs. This dependency poses a challenge as it makes the country vulnerable to supply chain disruptions and price fluctuations in the global market. ● Regulatory Compliance: Meeting stringent regulatory requirements set by various international bodies, such as the US FDA and the EMA, can be a challenge.

Compliance with Good Manufacturing Practices (GMP) and other quality standards is essential for Indian API manufacturers to gain acceptance in the global market. ● Research and Development: Investing in research and development is crucial for the long-term growth of the API industry. Indian companies must focus on developing new molecules and processes to stay ahead of the competition and meet evolving market demands.

Conclusion The import and export of Indian APIs present challenges and opportunities. To overcome challenges, Indian companies must focus on innovation, research and development, regulatory compliance, and building solid partnerships. By leveraging opportunities such as exploring new markets and embracing digital technologies, India can strengthen its position as a critical player in the global API industry. Continued investment and strategic planning will be crucial for the sustainable growth and success of the Indian API sector in the years to come.

The import and export of Indian APIs have played a pivotal role in shaping the country's pharmaceutical industry and contribution to global healthcare. India's position as a significant exporter reflects its ability to provide cost-effective and high-quality APIs to meet the global demand for affordable medicines.

Simultaneously, India's reliance on API imports highlights the need for strategic planning and investments to enhance domestic manufacturing capabilities. As the Indian API industry continues to evolve, it is imperative to prioritize research, innovation, regulatory compliance, and collaborations to strengthen India's position as a global API powerhouse.

Opportunities: ●Exploring New Markets: Indian API manufacturers have the opportunity to expand their reach and explore new markets. Emerging economies in Asia, Latin America, and Africa offer potential growth opportunities for Indian APIs. By understanding the unique requirements of these markets, Indian companies can establish a strong presence and capture market share. ● Research and Innovation:

The author is pharmaceutical consultant

SPECIAL FEATURE

IMPORT AND EXPORT SCENARIO OF INDIAN BULK DRUGS Komal Saini, Vandita Kakkar ndia's pharmaceutical industry is renowned as one of the most advanced among developing nations. In terms of volume, it ranks third globally, and in terms of value, it stands as the thirteenth largest.

India plays a significant role in the global supply of generic medicines, accounting for approximately 20% of the world's demand in terms of volume. Moreover, India serves as the primary source for around 60% of the global demand for vaccines and HIV/AIDS medicines. The country has gained worldwide recognition for providing internationally acceptable quality products at affordable prices. Indian pharmaceutical products are exported to over 200 countries, including developed nations with stringent regulatory standards. Notably, the United States serves as the largest market for India's pharmaceutical formulations.

India's prominence extends to the export of bulk drugs (active pharmaceutical ingredients - APIs) as well. With 664 manufacturing plants approved by the US Food and Drug Administration (USFDA), India holds the highest number of such facilities outside the United States. Indian companies have filed 4,500 drug master files (DMFs) for active pharmaceutical ingredients as of September 30, 2019, and have obtained 5,029 abbreviated new drug application (ANDA) market authorizations for formulations as of June 30, 2020. However, despite these accomplishments, India remains heavily reliant on China for the supply of bulk drugs and drug intermediates. Approximately two-thirds of India's total pharmaceutical imports originate from China. It is important to note that India's import dependence on China primarily lies in bulk drugs and not in formulations.

India's reliance on China for a significant portion of its active pharmaceutical ingredients (APIs) manufactured through fermentation, including penicillin, cephalosporins, and macrolides, is notable.

In 2016, the Minister of State in the Ministry of Commerce and Industry acknowledged the considerable dependence on imports for 12 essential drugs, such as paracetamol, metformin, ranitidine, amoxicillin, ciprofloxacin, cefixime, acetyl salicylic acid, ascorbic acid, ofloxacin, ibuprofen, metronidazole, and ampicillin. The influx of Chinese imports has gradually eroded India's manufacturing capacity for many

I

bulk drugs. As a result, Indian pharmaceutical manufacturers, including Alembic, Sarabhai, Indian Drugs & Pharmaceuticals Ltd. (IDPL), Hindustan Antibiotics, JK Torrent, Ranbaxy, and Standard3, have been compelled to shut down their facilities due to the competition posed by low-cost Chinese intermediaries like Penicillin-G/V. The COVID-19 pandemic further exposed India's vulnerability to disruptions in global supply chains and its heavy dependence on China for pharmaceutical requirements. Lockdown measures caused scarcity in basic raw materials necessary for drug production. In response to these challenges and to mitigate future risks associated with unforeseen events, India introduced a production-linked incentive (PLI) scheme. This initiative aims to strengthen the domestic pharmaceutical industry, which is valued at $50 billion, and reduce its reliance on China. By doing so, India seeks to safeguard its pharmaceutical sector from future black swan events like the COVID-19 pandemic.

Despite the introduction of the production-linked incentive (PLI) scheme, India's efforts to reduce its reliance on China for active pharmaceutical ingredients (APIs) and other pharmaceutical products have not yielded the desired outcomes, at least not yet. Nearly three years have passed since the launch of the scheme, but India's dependence on China has only intensified.

According to data from the Ministry of Chemicals and Fertilisers, imports of bulk drugs or APIs and drug intermediates from China increased by 20% in FY22, reaching Rs 23,273 crore. This accounted for 66% of India's total imports of medical products worth Rs 35,249 crore during that fiscal year. Furthermore, data from the commerce ministry reveals that imports of 30 crucial medical devices rose by 25-152% during April-December 2022 compared to the previous year.

Current industry challenges To unlock its full potential, the bulk drug industry must establish a well-defined roadmap consisting of actionable steps and milestones. This endeavour requires the support of key stakeholders who must execute the agreed-upon action plan in a coordinated and timely manner. Just like any other industry, the bulk drugs market thrives when it has a conducive ecosystem for growth and sustainability. This necessi-

tates collaborative efforts between the government and the private sector to formulate a long-term plan that delineates their respective responsibilities and aligns with a shared vision of revitalizing the industry.

Without a clear plan incorporating defined roles, responsibilities, and timelines, the bulk drugs sector will continue to face challenges.

The "Make in India" initiative presents a promising platform for the growth of the bulk drug industry. However, to fully leverage the support provided by this initiative, it is crucial to address various business environment-related challenges. These challenges encompass areas such as land acquisition, ease of doing business, taxation, and operational infrastructure.

Acknowledging and resolving these challenges require the active participation and collaboration of all relevant stakeholders.

Recent development of bulk drug In the Budget 2023, Union Finance Minister Nirmala Sitharaman has allocated Rs 1,250 crore for the development of bulk drug parks and the promotion of medical device parks in India. The allocation comprises Rs 1,000 crore for bulk drug parks and Rs 200 crore for the promotion of medical device parks, according to an official from the Department of Pharmaceutical.

This allocation marks a significant increase of over 1150% compared to the previous year. In the previous year, the government had only allocated Rs 100 crore for the development of bulk drug and medical device parks. The Department of Pharmaceuticals is entrusted with the implementation of the "Promotion of Medical Devices Parks" scheme, aimed at creating world-class infrastructure to establish the Indian medical device industry as a global leader.

The "Promotion of Bulk Drug Parks" scheme, with a financial outlay of Rs 3,000 crore from FY 2020-2021 to FY 2024-25, provides financial assistance to three states for establishing bulk drug parks. The Minister of State of Chemicals and Fertilizers, BhagwanthKhuba, had previously stated that the "Promotion of Medical Devices Parks" scheme has a total financial outlay of Rs 400 crore, with a maximum assistance limit of Rs 100 crore for a medical device park. Additionally, Sitharaman announced in her Budget speech the introduction of a new program to promote

131

research and innovation in the pharmaceutical sector through centers of excellence in the country.

The government's focus on allocating funds for the development of bulk drug parks, medical device parks, and research and innovation in the pharmaceutical sector demonstrates its commitment to strengthening the domestic pharmaceutical industry and establishing India as a leader in this field.

Future directions Short-term establishment Location assessment and land acquisition: Conduct a thorough evaluation to select an ideal location for bulk drug manufacturing that ensures easy access to raw materials and proximity to transportation hubs such as airports and ports. Acquire sufficient land for setting up new plants.

Streamlined approval process: Implement a single-window clearance system, enabling swift and efficient issuance of necessary clearances by placing officials from relevant departments within the park.

Financial support and incentives: Provide funding support, facilitate access to affordable finance, and offer tax incen-

tives and subsidies to attract private investment.

Medium-term establishment Infrastructure development: Construct essential infrastructure within the park, including common effluent treatment plants (ETPs), testing facilities, captive power plants, storage facilities, and well-connected roads.

Research and development (R&D): Establish dedicated R&D centers within the park to support drug manufacturing activities and foster the development of new technologies for pollution control and sustainable production.

Policy reforms: Introduce policy reforms such as promoting the use of domestically manufactured active pharmaceutical ingredients (APIs) in formulations and relaxing price controls to encourage growth and investment in the bulk drug industry.

Dedicated investment fund: Establish a professionally managed equity fund specifically dedicated to promoting API manufacturing and developing cluster and individual unit infrastructure.

Long-term establishment Achieve self-sufficiency: Create a comprehensive ecosystem where India's phar-

maceutical industry achieves self-sufficiency in bulk drug manufacturing, reducing reliance on imports.

Industry-academia collaboration: Foster collaboration between the industry and academia by establishing colleges or educational institutions within the park that offer specialized courses and training programs in drug production and related fields.

Skill development and training: Establish training infrastructure and institutes focused on providing industry-specific training and skill development programs tailored to the needs of the bulk drug manufacturing sector.

Innovation focus: Incentivize bulk drug manufacturers to prioritize process innovations and adopt key technologies such as fermentation and bio-catalysis. Recognize and reward companies that embrace innovative approaches to enhance efficiency and sustainability in their operations.

Saini is from Chandigarh College of Pharmacy, Chandigarh Group of Colleges, Kakkar is from University Institute of Pharmaceutical Sciences, Panjab University.

INDIA’S PHARMA EXPORTS REGISTERS GROWTH OF 3.25% IN 2023 ndia’s pharma exporters have a success story of registering a growth of 3.25% with successful trade agreements with UAE and Australia in 2023. Trade negotiations are also underway with the UK, Canada, Israel and the European Union (EU).

India’s Pharma exports contributed 5.6% of Merchandise exports during 2022-23. Drug formulations & Biologicals is the third largest Principal commodity being exported by India.

India’s pharma Exports of Pharmaceuticals during April 2022 till March 2023 has been to the tune of USD25.4 billion.

Global market had recorded a turnover of USD 1,407 billion during the calendar year of 2022 and had grown by just 1%.

The Indo-Australia Enhanced Cooperation and Trade Agreement (ECTA) will fast-track market authorization for Indian medicines exported to Australia.

The ECTA with Australia was inked on April 2, 2022 and is India's first complete trade agreement to be signed with any devel-

I

132

oped country in a decade. The ECTA has been operationalised with effect from December 29, 2022.

Building the manufacturing facility for APIs in the Australia and Oceania region is a challenging one for not only formulations but also generic and patented drugs. Therefore the medicine requirement is majorly dealt by imports from the western countries, India and China.

Australia’s pharma market was of US$ 14.6 billion size in 2021 and is largely a patent driven market with a share of 70%.

Generics have a miniscule share of 12% and are valued at US$ 1.7 billion. India has exported medicines worth US$ 387 million in FY-2021-22 with a growth rate of 11.6%.

The India-UAE Comprehensive Economic Partnership Agreement (CEPA) is today all set to facilitate automatic registration and marketing authorisation in 90 days for pharma products meeting specified criteria based on a separate Annex on Pharmaceuticals.

The India-UAE CEPA provides for an institutional mechanism to encourage and improve trade between the two countries.

The historic agreement which was signed between the two nations on February 18, 2022, officially came into force on May 1, 2022.

The UAE is also the eighth largest investor in India with an estimated investment of USD 18 billion. Overall, India will benefit from preferential market access provided by the UAE on over 97% of its tariff lines which account for 99% of Indian exports to the UAE in value terms particularly from labour-intensive sectors such as pharmaceuticals and medical devices.

India’s Exports of Pharmaceuticals during April 2022 till March 2023 has been to the tune of USD 25.4 billion with a growth of almost 3.25%.

Global generic market as per Fitch solutions has touched USD 422.81 billion in 2022 and has grown by just 1%. Out of this India’s domestic generic market

was of the value USD 24.2 Billion.

Currently India is ranked as the 11th largest market and is expected to be ranked as 9th largest by 2025. India is the largest exclusive generic exporter in the world.

Access to affordable HIV treatment from India is one of the greatest success stories in medicine. Because of the low price and high quality, Indian medicines are preferred worldwide, thereby rightly making the country called the “pharmacy of the world”. India is one of the biggest suppliers of low-cost vaccines in the world.

During the calendar year of 2022, USFDA has granted 1181 Market authorizations of ANDAs. Out of these Indian companies garnered 493 working out to 41.74% (Source: Orange Book USFDA site). There were 107 market authorizations granted by USFDA of first time generics in 2022, out of which India origin companies bagged 41 of them.

- Our Bureau, Mumbai

SPECIAL FEATURE

IS INDIA READY FOR BIG LEAP IN API MARKET Ravi Shet ver the few decades, Indian pharmaceutical industry has shown an upward trajectoryby contributing around 1.72% of the GDP of the nation.Active Pharmaceutical Ingredients (APIs) is a crucial segment of the pharma industry, contributing to around 35% of the market. Without shadow of doubt our expertise was mostly in formulations, but we never cultivated a robust mechanism to produce APIs over here to cater our as well as global need.The main reason being lowprofit margins and non-lucrative industry, Indian pharmaceutical companies had gradually stopped manufacturing APIs and started importing APIs, which was a cheaper and feasible option with increased profit margins on drugs.Post COVID-19, dynamics involving API industry in our country has changed as well as the geo-political tensions between China and Western countries have propelled major global pharmaceutical companies to source more from countries other than China and we as country are getting geared up to take a big leap in API market.

The global Active Pharmaceutical Ingredients (API) market size is expected to gain market growth with a CAGR of 8.2% in the forecast period of 2022 to 2027 and is expected to reach $216.4billion by 2027, from $145.9 billion in 2022.Technological advancements in API and growing importance of generics have been the key factors driving the growth of this market.

Indian pharmaceutical industry is the 3rdlargest in the globe by volume and 14thlargest in terms of value. India contributes 3.5% of total drugs and medicines exported globally. Medicine spending in India is projected to grow 9 to 12 % over the next five years, leading India to become one of the top 10 countries in terms of medicine spending.Pharmaceutical business in our country has undergone an incredible transformation, moving from being a volume producer to a valued supplier.

Time has come now to become AtmaNirbhar with recent incentives by our government to boost indigenous manufacturing of APIs and key starting materials that can put a full stop to supply chain disruption risk for Indian pharmaceutical companies. Incentives are significant in the case of the bulk drugs industry, because it is capital-intensive and needs huge area of land. Indian government has also allocated

O

about Rs 3,000 crore under the Capex assistance scheme to fund up to 90% of the investment need to build common infrastructure facilities in three bulk drug parks.Government of India unveiled 'Pharma Vision 2020' to make India a global leader in end-to-end drug manufacture.

Approval time for new facilities has been reduced to boost investment.India contributes the second largest share of pharmaceutical and biotech workforce in the world which plays a vital role in bringing up the new era for APIs in India. To sum up, with all these packages and initiatives coming up, API industry over here should be able to revive and further capitalize on the full potential to have world class API manufacturing capabilities.

Road Ahead Industry players should create a clear roadmap with a detailed and defined action plan, goal driven priorities and milestones along with a sustainable and encouraging environment to nurture, sustain and achieve the goal of self-sufficiency. A strong collaboration is required between industry players, universities, and Government to foster the API industry, so that we produce here and cater it to the local as well as global demand effectively.

The economy of strategic scale is very important and we need to speak, make, and act swiftly. We can have a bilateral trade with different countries to encourage foreign partners to invest in India to make our country, an API hub with a global trade alliance. Pool of financial support from

banking sector to support the API industry will be boon to them. Interactions between Government and industry players must increase and they need to be taken into confidence by Government while taking key policy decisions. Curriculum needs to be changed to gear up the future workforce to align and equip themselves to cater to the changing dynamics of this industry. It is a great opportunity for our country right now and industry is committed to work collectively for the growth of the country as well as the industry.

Conclusion To sum up, it will not be an easy ride for Indian pharmaceutical industries; however, they need to be in top gear and make themselves AtmaNirbhar with the packages and policies rolled out by the government and to leverage the talent pool available in our country to produce quality APIs over here as well as becoming global leader in exporting these APIs toother countries. A strong and transparent collaboration between Government and industry players will be required to boost production capabilities, spend in new advanced technologies,and leverage digital capabilities to become more competent. This will help us to produce large volume of APIs in a costeffective manner on a continual and consistent basis to cater our country as well as globally and be in a commanding and leadership position.

The author is clinical data management professional

133

SPECIAL FEATURE

BANGALORE HOSTS 11TH EDITION OF ASIA LABEX Our bureau, Mumbai he 11th edition of Asia LABEX, the laboratory show took place at Karnataka Trade Promotion Organisation (KTPO), Whitefield, Banagalore, Karnataka, India from 8-10 June 2023 The event was organised by Fenza Exhibitions Pvt Ltd. The event also had Labotica seminar.

T

Labotica seminar 2023 The concurrent seminar Labotica inspiring speakers and industry experts. The theme for the seminar was “Science Meet Industry.” The seminar witnessed new and future developments in the sector.

Guest of honour for the seminar was Dr Ramesh Jagadessan, vice president, analytical development (PDU) Recipharm Pharmaservices Pvt Ltd. Jaspal, Fenza Exhibitions Pvt Ltd said, "We welcome everyone at the event and hope everyone learns new things in two day seminar, so i request everyone to take full advantage of the seminars."

Dr Ramesh Jagadessan, vice president, analytical development (PDU) Recipharm Pharmaservices Pvt Ltd said, "I am privileged to be here at the event and seminar and i feel there should more of such seminars, where people can learn more about new technology. I hope organisers keep more seminars next year."

Dr Jegan Jayabalan, sr director analytical development (PDU), Recipharm Pharmaservices Pvt Ltd, gave presentation on novel approaches in analytical research and development. He spoke about the importance of novel approaches during analytical development and turning ideas into solutions. He also said that one needs to have knowledge on entire product development and also mentioned about current regulatory requirements, method validation, challenges and limitations and dissolution method development.

Dr Srinivas Seekallu, head preclinical research, Anthem Biosciences Pvt Ltd. He gave presenation on preclinical reseaerch.

He spoke about objectives of principal research and types of preclinical studies and ADME-INVITRO. He also spoke about pharmacokinectics and toxicology and importance of preclinical reearch in drug discovery. He also mentioned about optimisation of drug candidates, regulatory compliance, ethical consideration, reduction of risks and costs.

Dr Amarnath Chatterjee, senior lead

134

investigator & head analytical development, biologics, Syngene International Limited. He spoke on topic, OTPP and CQA driven regulation of biosimilars. The understanding of QTP and CQA are imperative for biosimilar drug regulations, biologically derived pharmaceuticals. He also mentioned about novels/biosimilars, regulatory requirement and functional characterisation work flow for biopharmaceuticals.

Dr Srinivas Seekallu, gave presentation on good laboratory pratice in preclinical research. He also spoke about key elements of GLP in preclinical research, preclinical study-OECD principles of GLP and key aspects of GLP in preclinical research.

He also mentioned about, organisation and personel, facilities and equipment, study plan and protocol, standard operating procedures (SOPs), qquality assurance, study conduct and documentation, reporting and archiving, data integrity principles ALCOA+, benefits of GLP in preclinical research.

Second day of the seminar saw presentation from Purimetla Linganna, GM quality, Jugaat Pharma. He spoke about life cycle management of analytical procedures, a modern concept of QbD principles to analytical procedures. He also mentioned about analytical guidelines from ICH, USP and FDA, concept of quality by design, AQbD tools and stages of lifecycle management and advantages. ObD tools for synthetic and analytical development, ATP identification (selection); method requireents selection (CQA) critical quality attributes, CQA with risk assessment, analytical control strategy, MODR (Method Operable Design Region), analytical procedure lifecycle, multi-variate experiment and method optimisation.

Next presentation was on biosimilar insulin'sregulatory updates and case study

by K Bramhendra, head QQC, MJ Biopharma Pvt Ltd. He spoke on insulins and function, insulins and analogues modifications, biosimilars and interchangeables, biosimilars. He also spoke about specific guidelines on biosimilar insulins-EMA, nonclinical and clinical requirement for biosimilar insulin and insulin analogues. Indian regulations on biosimilar insulins. He also mentioned about EMA, issues for refusal of solumary biosimilar, always refer updated regulatory guidelines for biosimilar insulins developments, clinical immunogenicity is required for biosimilar as per CDSCO guidelines. Insulin and analogues are having same mecahnism as action with different durations.

Abhishek Awasthi, international marketing manager, Microlit, gave presentation on unical-single step calibration technology in micropipettes. He mentioned that key attributes of a micropipette are accuracy, safety, convenience, What is caliberation?

It is a procedureof configuring an instruments, so that is starts giving results within an acceptable range , as defined in the applicable standard, tradition calibration and challenges. Mentioning about advantages he said it is guided single step caliberation, no multiple adjustments, recalibrate and anyone can calibrates and it saves money. Basavaraj Gadag, director, eDiscovery Automation Pvt Ltd gave presentation on innovation in laboratory automation for the modern drug discovery.

He spoke about recent development in laboratory automation, advanced automation tools, advantages, automated analysis, high throughout screening, especially for the drug discovery. He also mentioned about automated robotic solutions, pipeting solutions, powder handling with redi-tips, powder dispensing via redi-tips, filteration or solid phase extraction (SPE).

SPECIAL FEATURE

FUTURE PROSPECTS OF INDIAN ACTIVE PHARMA INGREDIENTS MARKET' Raheel Shah Introduction: he Indian pharmaceutical industry has witnessed remarkable growth in recent years, establishing itself as a global leader in the production and export of generic drugs. One crucial factor that has contributed to this success is the presence of a robust Active Pharmaceutical Ingredients (API) manufacturing sector.

APIs are the core components responsible for the therapeutic effects of drugs, making them an integral part of the pharmaceutical supply chain. In this article, we will delve into the future prospects of the Indian API market, analyzing the opportunities and challenges that lie ahead from a pharmaceutical perspective.

Rising Global Demand for Generic Drugs: The rising global demand for generic drugs is a significant trend in the pharmaceutical industry. Generic drugs are gaining popularity due to their affordability and accessibility. As healthcare costs continue to rise, patients and healthcare systems are seeking cost-effective alternatives to brand-name medications. Generic drugs offer the same therapeutic benefits as their brand-name counterparts but at a fraction of the cost. This affordability factor is particularly important in developing countries where access to essential medications is a challenge.

Furthermore, the expiration of patents on several blockbuster drugs has opened the market for generic drug manufacturers, fostering competition and driving down prices. Governments and healthcare organizations are also promoting the use of generic drugs through policies and incentives, further boosting their demand.

The increasing prevalence of chronic diseases and the aging population has also contributed to the demand for generic drugs. As more individuals require longterm medication regimens, generic drugs provide an economical solution. Overall, the rising global demand for generic drugs is expected to continue as they offer a viable option to reduce healthcare costs and improve access to essential medications worldwide.

Favorable Government Initiatives: The Indian government has taken significant steps to support the pharmaceuti-

T

cal industry, particularly the API manufacturing sector. The government is aggressively encouraging the expansion and development of local API production through programmes like "Pharma Vision 2020" and the "Make in India" campaign.

These initiatives have a twofold objective: reducing the reliance on imported APIs and positioning India as a global manufacturing hub for APIs. The government's efforts are complemented by policy reforms and incentives that have been implemented to create a conducive business environment for API manufacturers. These measures encourage investments in research and development (R&D) for the development of new and innovative APIs. By incentivizing R&D activities, the government aims to foster a culture of innovation within the industry, leading to the creation of high-quality APIs that meet global standards.

Growing Emphasis on Research and Development: The Indian API (Active Pharmaceutical Ingredient) manufacturers are recognizing the importance of research and development (R&D) activities to stay ahead in the highly competitive global pharmaceutical market. By investing in R&D, these manufacturers aim to develop complex and specialized APIs, thereby expanding their product offerings and catering to niche therapeutic areas. Moreover, R&D efforts

also focus on improving process efficiencies, enhancing quality standards, and meeting the stringent regulatory requirements set by international authorities.

The growing emphasis on R&D holds significant implications for the future of the Indian API market. By actively engaging in research and development, manufacturers can stay at the forefront of innovation, ensuring they remain competitive and meet the evolving demands of the global pharmaceutical industry. This strategic approach enables Indian API manufacturers to gain a competitive edge, foster technological advancements, and ultimately drive growth in the market.

Quality Compliance and Regulatory Challenges: The Indian active pharmaceutical ingredient (API) market is a promising sector, offering significant opportunities for growth and expansion. However, it is not without its challenges, particularly concerning quality compliance and regulatory standards.

International agencies have established strict regulations and requirements for API manufacturers, emphasizing the need for adherence to Good Manufacturing Practices (GMP) and stringent quality control measures at every stage of the manufacturing process.

To successfully compete in the global market, Indian API manufacturers must invest in modern infrastructure, adopt

135

advanced technologies, and cultivate a highly skilled workforce. These investments are essential to consistently meet the stringent quality standards set by international regulatory bodies. By ensuring compliance with these regulations, Indian API manufacturers can maintain trust and reliability among global partners and customers.

The significance of adhering to international regulations cannot be overstated. It not only demonstrates a commitment to producing high-quality APIs but also assures global buyers that the products meet safety and efficacy standards. Failure to meet these standards can result in reputational damage, loss of business opportunities, and potential legal consequences.

Shift Towards Specialized APIs and Biopharmaceuticals: The pharmaceutical industry is currently undergoing a significant transformation, with a notable focus on specialized APIs (Active Pharmaceutical Ingredients) and biopharmaceuticals. This shift is primarily propelled by advancements in personalized medicine, targeted therapies, and the field of biotechnology. Recognizing this trend, Indian API manufacturers have started to adapt their operations to meet the rising demand for specialized APIs and biologics.

To stay competitive in this evolving landscape, Indian API manufacturers are strategically expanding their capabilities.

They are actively collaborating with research institutes, academia, and biotech companies, which not only fosters innovation but also provides them with the opportunity to enter niche market segments.

These partnerships enable Indian manufacturers to diversify their product offerings and bolster their position in the market.

136

By embracing this shift towards specialized APIs and biopharmaceuticals, Indian manufacturers are aligning themselves with the evolving needs of the pharmaceutical industry. This strategic move allows them to tap into the growing demand for personalized and targeted therapies, ensuring their relevance and sustainability in the market.

Increasing Focus on Sustainability and Green Chemistry: The pharmaceutical industry is witnessing a growing emphasis on sustainability and green chemistry due to the increasing global focus on environmental conservation. In line with this trend, Indian active pharmaceutical ingredient (API) manufacturers are actively adopting sustainable practices to reduce their environmental footprint. One significant aspect of this shift is the implementation of green chemistry principles, which seek to minimize the adverse impact of manufacturing processes on the environment.

Indian API manufacturers are integrating sustainable practices into their operations by utilizing renewable energy sources, reducing waste generation, and adopting eco-friendly manufacturing techniques. By embracing sustainability, these manufacturers not only contribute to global environmental goals but also enhance their reputation and competitiveness in the international market. The adoption of sustainable practices reflects a commitment to responsible manufacturing and resonates well with environmentally conscious consumers.

Through their efforts to incorporate green chemistry and sustainable practices, Indian API manufacturers are actively contributing to the larger goal of creating a

greener and more sustainable pharmaceutical industry. By prioritizing environmental responsibility, these manufacturers play a vital role in advancing sustainable development and promoting a healthier future for both people and the planet.

In conclusion, the Indian API market holds promising prospects for the future, driven by various factors that contribute to its growth and success. The rising global demand for generic drugs, driven by affordability and accessibility, presents a significant opportunity for Indian API manufacturers to cater to a vast market and provide cost-effective alternatives to brand-name medications. Moreover, favorable government initiatives such as "Pharma Vision 2020" and the "Make in India" campaign, coupled with policy reforms and incentives, support the growth and development of the domestic API manufacturing sector.

Recognizing the importance of research and development (R&D), Indian API manufacturers are investing in innovation to stay ahead in the competitive global pharmaceutical market. By expanding their product offerings, focusing on specialized APIs and biopharmaceuticals, and improving process efficiencies, they aim to meet the evolving demands of the industry and maintain a competitive edge.

However, the Indian API market faces challenges related to quality compliance and regulatory standards. Adhering to international regulations and ensuring strict quality control measures throughout the manufacturing process are essential for Indian manufacturers to maintain trust and reliability among global partners and customers. Non-compliance can have significant consequences, including reputational damage and loss of business opportunities.

To remain relevant and sustainable, Indian API manufacturers are also embracing sustainability and green chemistry principles. By integrating sustainable practices into their operations, such as utilizing renewable energy sources and adopting eco-friendly manufacturing techniques, they contribute to environmental conservation goals and enhance their reputation in the international market.

Overall, the future of the Indian API market looks promising, with opportunities for growth and expansion. By capitalizing on the rising global demand for generic drugs, investing in R&D, ensuring quality compliance, and embracing sustainability, Indian API manufacturers can solidify their position as global leaders in the pharmaceutical industry and contribute to a healthier and more sustainable future for all.

(The author is managing director, BDR Pharmaceuticals)

SPECIAL FEATURE

HYDERABAD HOSTS 9TH EDITION OF PHARMALYTICA EXPO Our bureau, Mumbai he 9th edition of the PharmaLytica expo, kickstarted on 1st June at HITEX, Hyderabad. In welcome address, Yogesh Mudras, managing director, Informa Markets India said, We welcome everyone ata the event and we are happy to be back in Hyderabad.

Pharma industry in India is growing at very fast pace and third largest globally.

At the event, you can see all the latest innovation and we are happy to see the strength at the event". He further stated that Hyderabad has become pharma hub of India. The event was organised by Informa Markets in India and the last day of the event was 3rd June 2023.

“We are thrilled to announce the highly anticipated 9th edition of the PharmaLytica Expo, which will bring together the complete pharmaceutical ecosystem and industry stakeholders.

Then show is supported by key government body, Invest Telangana, among others, and it is a pleasure to return to Hyderabad and focus on the expanding pharmaceutical hub of Southern India in addition to the Western market. This also signifying our commitment to the growth of the Indian pharmaceutical industry. As a key player in the global pharmaceuticals industry and the largest supplier of generic medications worldwide, India has witnessed a significant increase in health sector funding. The Indian government has raised the funding from Rs 86,200.65 Crores to Rs 89,155 crores for the current fiscal year 2023-24. As we progress towards becoming a leading pharmaceutical market, PharmaLytica aims to serve as a comprehensive platform amidst an increasingly digitized ecosystem, maintaining a global supply chain in a constrained environment, and new analysis methods for optimizing laboratory processes, thereby creating smart pharma technological hubs,” he added.

RK Agrawal, National President, BDMA said, "Its my pleasure to be here and i request everyone to take full advantage of the event. India is truly pharma hub of the world and i thank and congratulate organisers to bring such event in Hyderabad". He said that instrumental technology is increasing in pharma industry.

T

Shankar Gupta said, "Thank you for inviting me for the event, India is known for its pharma industry. Covid has brought attention of world towards India, as we supplied vaccines and medicines to the world. I must complement organisers for their effort to bring such event".

Harish Jain, "Its being honor to share stage with such big people. India is 14th largest in terms of value in pharma and we will be US$130 bn business by 2030.

Government machineries and players have observed innovations as important factor. R&D is also key to development.

Innovative way to best products is also important. We should take help of technology for development of the industry, so that we can give good products to potential".

Avinash Talwar, "I would like to tahnk organisers at the event. Pharma industry is Us$ 50bn market now and will reach US$ 65 bn dollar by 2024 and to grow at 11% pa. CAGR lab equipment market is also growing. There are many small labs in Hyderabad. Events like these help labs to showcase their products. Packaging business is increasing. Sustainable packaging is increasing but lot has to be done in this segment".

Jayesh Ranjan IAS Principal Secretary to Govt, Industries & Commerce Dept Government of Telangana, "I congratulate organisers to bring this event in Hyderabad. Response in the event looks good. Pharma industry us keeping their optism. Industry in India should showcase best technologies.

India exports pharma process to more than 150 countries". Rahul Deshpande, Sr. Group Director, Informa Markets India gave vote of thanks.

The event saw keynote panel discussion – Why the pharmaceutical industry is turning to outsourced manufacturing?

Vishwas Sovani, Director, Pharma Wisdom was the moderator for the session and other panelists included, Sudeep Srivastava, Senior Vice President, Biological E. Limited; Satya Babu, Sr. VP and Head - Operations, Quality, Regulatory and Scientific Affairs, Biological E. Limited; Vimal Kothari, Associate Director External Manufacturing, Dr. Reddy's Laboratories; Rajkumar Rajgopal, Head, Fermentation Technology Development Centre

(FTDC), Dr. Reddy's Laboratories; Anish Agarwal, Global Head of Analytics, Dr. Reddy's Laboratories. They discussed, collaborating with partners that meet your business needs; Points to be considered by pharma and bio-techs when choosing the right CMO; assessing if your current partnerships are effective in achieving the desired output and standards; understanding the needs, culture and relationship required to partner successfully with CMOs; creating improvement opportunities with CMOs; creating a win-win approach; flexibility in operations and contractual agreements that don’t constrain development.

Yogish HN, AVP – Business Development, Enerparc Energy gave presentation on solar PV adoption for pharmaceutical industry for their operational cost savings and sustainability goals. He also spoke about, rooftop and ground mount solar PV solution suitability; OPEX, CAPEX and open access mode of solar PV adoption; case study of solar adoption for a pharmaceutical client.

Next was panel discussion on latest developments and trends in the pharma API industry, Vishwas Sovani, director, Pharma Wisdom was the moderator for the discussion and other panelists includes, Nasir Ali, associate vice president - API R&D, Aurobindo Pharma; Krishna Bhavanasi, VP head formulation R&D, Natco Pharma; Narender Rao Somisetti, vice president, Head-R&D, Metrochem API; Tausif Ahmed, head-biopharmaceutics, Preclin & Clinical Bioanal, global clinical management (VP), Dr. Reddy's Laboratories; Srinivasa Rao Sambangi, Sr. General Manager, Aurobindo Pharma. They discussed points such as, how to reduce API manufacturing costs and get the best value for your money without cutting back on the importance of safety and containment procedures; importance of proper communication - Information sharing between the API manufacturer and the drug product manufacturer; increasing trend toward more potent therapies and the consequences of the changing face of pharma; comply - Must have QR code in each packing of API and medicine; regulatory hurdles and opportunities.

Shakthi Nagappan, director (life sci-

137

ences & pharma) & CEO, Telangana Life Sciences gave presentation on Telangana Life Sciences - Overview of the Life Sciences sector in the state of Telangana. He also spoke about With a focused approach in incentivizing investments, the Life Sciences sector in Telangana has received over Rs 25,0000 crores investments creating over 1.3 Lakh jobs and 4 Lakh indirect jobs. Some of the initiatives like dedicated industrial parks ,personalised incentive schemes for corporates, skilling and training programs and BioAsia - Asia's biggest life sciences forum have helped Telangana Life Sciences position Telangana as the "Hub of Life Sciences in Asia".

BM Rao, CEO - QDOT Associates gave presentation on scientific approaches to analytical procedure development He also spoke about, guidance to the analytical procedure development and validation of developed methods, method performance through system suitability testing - future expectations from USP<621>. Practical challenges and suggested solutions, key validation parameters that characterise analytical procedures, use of analytical testing to support pharmaceutical quality systems, discussion of analytical lifecycle management.

There was another keynote panel discussion on pioneering laboratory knowledge- future of lab and moderator was Pawan Patinge, founder, Academy of Analytical Instrumentation and other panelist included, Srinivas Achanta, VP, Dr. Reddy's Laboratories; Gnanadev Gudipati, vice president ARD & QC Natco Pharma; Balaram Patro, CEO, GRK Research Laboratories; Rajesh Thempadiyil, Head – Quality Digital Transformation & Compliance, Dr. Reddy's Laboratories. They discussed points like, quality management in the laboratory; sustainability in the laboratory / Lab automation / Lab and tech integration; future-proofing labs through smart technology and innovation; future of lab is digitalisation, automation and connectivity: challenges and tools to engage staff; IoT in the lab of medicinal chemistry and the simultaneous impact of AI; identify out-ofthe-box systems and solutions; review outdated processes, workflows, and tools and safety and its journey towards improvement.

Second day saw panel discussion on, latest trends and developments in your supply chain – moving up the value chain. Other panelist included, P V Raju, senior vice president supply chain, Biological E. Limited; Kamaraj Abraham, associate vice president, head quality assurance, Aurobindo Pharma; Appaji Venkat

138

Padmanabhuni, advisor, BDMA (FormerPolicy Advisor, Pharmexcil); Manjeeth Singh Rawat, head of pharma supply chain - CIS & Romania, Dr. Reddy's Laboratories; Himal P. Desai, vice president, supply chain management, Virchow Biotech; LAKSHMI NARAYANA, Associate Director, SCM, Aragen. They discussed points like, innovative strategies implemented from small-midsize pharma to overcome supply chain issues without incurring significant costs; pragmatic solutions for overcoming supply chain hurdles; transportation and logistics issues - where are we heading with this problem? Common pitfalls in SCM - What are the lookout for facts? How to insulate your risks against supply disruption; steps needed to insure supply chain integrity from the raw material stage through the end user; role of CFAs in in supply chain operation for effective drug supply / distribution to trade.

Next panel discussion was on reshaping pharma industry in the way of digital transformation. Moderator for the discussion was Rithesh P, director, leading technology acceleration (digital solutions), Novartis and other panelists included Dilip Kastala, VP & global head - digital, IT & process excellence, Dr. Reddy's Laboratories; Ram Kumar, director MSTG, Cipla; Kavita Lamror, expert, Real World Investigator & RWD Product Owner, Sanofi; Narendra Kumar, senior general manger (Quality) | site quality head, Viatris. They discussed topics such as, looking beyond pharma 4.0: future initiatives and advanced manufacturing approaches; What’s New? innovation in pharma industry; ensure the success of Technology transfer; addressing main challenges in implementing digitisation in pharma; making big data useful: practical approaches; How is AI resolving the tech problems faced by the industry? How will the near future be? Do digital trends really help in manufacturing? How? Increasing agility through digitalisation; technological evolution in drug manufacturing and drug delivery.

Narendra KumarUMAR, senior general manger (Quality) | site quality head, Viatris gave presentation on quality culture excellence. He also discussed points such as to transform from "Compliance led" to "excellence led"; guidance and tools for cultural assessment and few QMS elements as quality culture enablers.

Kavita Lamror, expert, real world investigator & RWD Product Owner, Sanofi gave presentation on RWD & RWE - creating value from next-generation real-world evidence. She also spoke about, how pharma will handle complexity of data in RWD? discussing how the RWE helps to get custommade treatments and drug therapies for

patients; What helps us to have a better understanding about data quality and data privacy? RWE gives efficient and costeffective clinical trials? How? What are complications will rise by inserting new data source? And it leads to breakup in data? Obtaining patient-centric using RWE; what kind of changes needed to be place in RWE? Compelling with regulatory; market access for innovative medicines in emerging markets.

Next panel dicsussion was – future in manufacturing – roadmap to 2024 – moving forward. Moderator for the discussion was Sandhya Pittala, founder and COO, Crenza Pharmaceuticals and other panelists included Rajendar Burki, associate vice president, (R&D), Biological E. Limited; K. Suresh Babu, vice presidentquality assurance, Natco Pharma; Rahul Mittal, head strategy - emerging markets, Dr. Reddy's Laboratories; Vivek Jha, head - strategy and operations, global drug development -India, Novartis. They discussed points such as, lessons learnt from covid times – making the best from the worst times. Relationshipswt partners – How should this look by 2024; overcoming challenges – Increasing costs and competition; RWD and RWE drive in pharma; electronic quality management systemHow trackwise, Edms, LMS, LIMs to be maintained for successful audit outcome?

Overcoming regulatory constraints.

The last panel discussion for the day was PPLST – Pharma Packaging Labelling Serialisation Track & Trace – Where are we heading? Which way is the right direction to improve? Moderator for the discussion was Sandhya Pittala, founder and COO, Crenza Pharmaceuticals and other panelists included, Gunjan Singh, VP and head mature markets API (US, EU, Mexico, Canada, CIS), Dr. Reddy's Laboratories; Vinay Singh, associate director – Supply Chain Management, Dr. Reddy's Laboratories; Chandi Prasad Ravipati, head - packaging development, Aurobindo Pharma; Lokesh Patel, founder director, URL Aseptic Automation; Sunil Chandupatla, AGM, Labelling, COE, Freyr Solutions. They discussed points such as, preparing for the future of pharma packaging; fightback against counterfeit online medicine suppliers – How does the packaging help? How packaging requirements for pharmaceuticals are changing in post pandemic? Maintaining quality, traceability and accessibility in labeling; recent trends in serialization track and trace; new and major problems in implementing trace and trace in supply chain; ensuring end to end supply chain in pharma – How the serialization helps maintaining dignity of products.

SPECIAL FEATURE

INDIAN CHEMICAL INDUSTRY TO REACH US$ 304 BN BY 2025 Brief us about your product portfolio.What makes you different from other players?

We are into manufacturing of Phase Transfer catalyst, Bromine derivatives, Pharma intermediates, Speciality Chemicals & Lithium Compounds.

ow do you see the Indian speciality chemicals market going ahead?

Speciality chemical manufacturing Industry will be a key player in providing India a boost in export industry worldwide.

The Indian chemicals industry is projected to reach $304 bn by 2025 Indian ranks 14th in export and 8th in import of chemicals (Excluding Pharmaceuticals products) globally

H

What are the challenges and growth factors for the market?

There has been a continuous volatility in prices for raw materials affecting regular production planning and targeting sales figures. It has also caused Liquidity crunch

issues causing slow down in overall market.

Scalability Issue due to less skilled manpower on operational mid-level hierarchy of the production team.

According to you, what is the reason, fluorination (specialty chemical) is doing well, especially in the pharma industry?

Speciality chemicals have various internal and external driving factors which will favour the growth in worldwide market.

Post Covid, Indian as well as world wide market has seen India as a major manufacturing hub and also advancing towards major economic power.

New age technology, advance machinery and a good technical support are available. Improving Logistic support like High-speed Road corridor’s, Sea ports

RAHUL RAJPUROHIT (DIRECTOR) PACIFIC ORGANICS PVT. LTD. Spoke about their expansion plans

with better facilities and air cargo networks.

Bromine compounds and Lithium Compounds in Pharma Industry We specialised in bromination industry as its one of core strength and important segment in our varied product list.

Bromine compounds are used by pharma industry in multiple applications and have a worldwide demand.

In Lithium compounds we are exclusive manufacturers currently in India for Lithium Hydroxide Monohydrate material and with our other Lithium Compounds we are highly competitive in Pharma industry with our prices and quality.

What are your expectations from the government for the market?

Promote more technical institute to generate skilled manpower to operate advance machinery and equipment’s.

What makes you different from other players?

Team of skilled technical and production staff to ensure most optimized system through the whole process We have our presence in the niche chemistry spaces with relatively low competition Pushing innovation agenda – introducing high value products and pioneering technologies, thereby changing the industry landscape.

Please tell us about your expansion plans.How much will you be investing in expansions?

Our Upcoming Additional Facility and Infrastructure at Saykha - Bharuch Dist – Gujarat: Phase 1 Exclusive 2500 MT Manufacturing capacity for Bromine Derivatives with ultra-modern production facilities and Bromine storage ISO tanks.

Will be followed by Phase 2 and 3 where we shall also be targeting contract manufacturing for speciality product.

Investment 20 Crore INR in the financial year 23 -24 followed by Next financial year investment of another 20 Crore INR. Any plans to launch new products.

R& D has always been a key driving factor of Pacific Organics Pvt Limited, as we are increasing our production capacity there will always be development in our product portfolio year on.

139

SPECIAL FEATURE

INDIAN API EXPECTED TO GROW AT CAGR OF 12.24% ow do you see the Indian active pharma ingredients (API) market going ahead?

The Indian Active Pharmaceutical Ingredients (API) market stood at USD11806.93 million in FY2021 and is expected to grow at a CAGR of 12.24%.

This growth can be attributed to the high growth of the biopharmaceutical sector in the country. Additionally, the increasing geriatric population in India is further expected to boost the demand through FY2027. Furthermore, the growing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer, and respiratory disorders, among others is going to boost the market.

The Indian active pharmaceutical ingredients market is relatively fragmented. The API market has several manufacturers focusing on expanding their footprints by adopting various business strategies such as collaborations, facility expansion, and drug approvals.

According to the World Health Organization (WHO), cardiovascular diseases are the leading cause of death globally, accounting for an estimated 17.9 million lives each year. The major drivers boosting the growth of the Indian Active Pharmaceutical Ingredients Market are the rising drug research and increase in the development and manufacturing of drugs and the increasing uptake of biopharmaceuticals.

Besides, the sudden outbreak and spread of the COVID-19 pandemic across the globe, with India being severely hit by the pandemic crisis, also opened opportunities for the growth of India's active pharmaceutical ingredients market. Due to the pandemic spread major countries boycotted China for trade as it was where the virus originated, similarly, India also banned all kinds of imports and exports with China.

This led to the development of manufacturing facilities in the country and improved the status of domestic players.

Also, India being a major pharmaceutical hub witnessed demand from various countries across the globe for getting medical supplies and drugs.

Other factors boosting the market growth include the increasing prevalence of infectious, genetic, cardiovascular, and

H

140

What are your expectations from the government for the market?

• Supportive policies, simplified regulations of environment and simple GST norms.

• Provide incentives to startups.

• Reducing import dependence and promoting growth of domestic industry.

RAMESH CHODVADIA, MANAGING PARTNER AND CEO, PRUDENCE PHARMA CHEM SPOKE ABOUT THEIR EXPANSION PLANS

other chronic disorders, the growing geriatric population, expanding adoption of biologics and biosimilars, and the rising production of generic drugs in the country.

India operates over 250 facilities approved by the USFDA and UKMHRA and provides generic pharmaceuticals at affordable prices to millions of people worldwide.

The Indian API market has achieved tremendous growth over the past few decades. It is ranked as the third largest in the world, and the country contributes approximately 57 percent of APIs to prequalified list of the WHO. The increasing incidence of chronic diseases, along with the growing importance of generics are some of the major factors driving the growth of the Indian APIs market.

Advancements in active pharmaceutical ingredient (API) manufacturing, and the growth of the pharmaceutical sector are also driving the market growth.

What are the challenges and growth factors for the market?

The increasing cost of crucial manufacturing input factors such as energy, raw materials, and labor, has been a severe challenge to producers.

The increasingly volatile business environment has also led pharma companies to seek strong and sustainable partners.

API market is now well established so one has to remain innovative and competitive focusing on the portfolio of APIs in terms of size, quality, and cost.

Tell us about your company.

Prudence pharmachem was established in 2003. The company is involved in the manufacturing and development of a wide range of high-quality pharmaceutical bulk drugs (API) and its advanced intermediates in its ultra-modern state of art facilities conveniently located in the Ankleshwar industrial area which is 350 km away from Mumbai-India.

The company is a family enterprise and managed by dynamic and highly technically qualified partners and professionals who have sound and vast experience in manufacturing of Pharmaceutical bulk drugs (API) and Intermediates. We have equipped with modern manufacturing facilities and state-of-the-art technology for achieving Quality products manufactured by us. We are fast growing integrated and GMP & ISO 9001-2015 certified Pharmaceutical bulk drugs [API] and intermediates manufacturing company. We have an excellent multipurpose facility meeting WHO GMP standards, since its inception, we have been the sole and reliable manufacturer and exporter of Pharmaceutical bulk drugs [API] and intermediates.

We have equipped with modern manufacturing facilities and state-of-the-art technology for achieving Quality products manufactured by us. We specialize in the development of new processes and technology with the latest technical know-how which can be designed to ensure the noninfringement of patents, through the application of alternative synthetic procedures and to develop and manufacture various Pharmaceutical bulk drugs [API] and Intermediates with the highest quality, functionality, and cost-effectiveness.

Our services range from the manufacture of patent-free products to the manufacture of novel products through bilateral agreements between ourselves and our clients. Within a short span of time, we

Hypertensive, Loop Diuretic, Benign Prostatic Hyperplasia, NSAID, AntiGout, Anti-Alzheimer’s, Decongestant, IPF, Anti-coagulants/ DVT therapies, etc. Our product range is Rivaroxaban, Silodosin, Torsemide, Memantine, Glimepiride, Glibenclamide, Amlodipine, Celecoxib, etoricoxib and Febuxostat.

What makes you different from other players?

In the emerging market, we always ensure to maintain regulatory compliance and balance cost with quality and reliability.

We emphasize on continuously listening to our customers and make sure to meet their expectations with our speedy response and ability to anticipate problems before they occur.

Please tell us about your expansion plans.

We are in the progress to initiate a manufacturing unit of active pharmaceutical ingredients to accommodate higher potency and a wider range of molecules with increased production volume. have earned a good reputation in manufacturing Pharmaceutical bulk drugs [API] and Intermediates for consistency in quality and supplies at the right time and at the right cost. In the market today we are a strong, reliable, consistent manufacturer of key APIs & intermediates for global markets.

We have established ourselves as strong and consistence manufacturer of

Rivaroxaban, Silodosin, Torsemide, Memantine, Glimepiride, Glibenclamide, Amlodipine, Celecoxib, etoricoxib and Febuxostat.

How much will you be investing in expansions?

We are planning to invest Rs 200 cr for expansion in upcoming years.

Brief us about your product portfolio.

We are manufacturing high-value-added active pharmaceutical ingredients which are mainly used in Anti-Diabetic, Anti-

Any plans to launch new products?

Yes, our research team is currently focusing on efficient process development of new products.

ANAVEX LIFE SCIENCES INKS PACT WITH PARTEX GROUP navex Life Sciences Corp., a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome and other central nervous system (CNS) diseases, and Partex N.V. Group, the first Data-to-Drugs digital pharma platform, today announced a strategic partnership with the overall ambition to reshape the future of the biopharma business model.

By combining Anavex's innovative small molecule precision medicine drug development platform and Partex's disruptive approach of Artificial Intelligence (AI) enabled drug development and healthcare

A

sales marketing, this collaboration is intended to drive efficiency, effectiveness, and innovation across the value chain with patient-centric focus at every step.

Under the partnership, Anavex and Partex intend to co-develop a diseasefocused Patient App ecosystem. The first feature will be to inform patients and caregivers on preventive and curative options available in clinics and on the market.

Further, Partex will implement AI-based ‘Healthcare Sales Marketing’ in preparation for Anavex’s late stage drug pipeline.

Gunjan Bhardwaj, PhD, CEO of Partex, commented: “We are excited to embark on this impactful journey together with Anavex. We will start by extending our patient ecosystem together. Further, we

intend to leverage our Life Sciences Language Processing platform with Generative Artificial Intelligence capabilities, which is expected to significantly improve patient outcomes.”

"As a biopharmaceutical Company with a proprietary late stage pipeline for CNS indications, Anavex brings expertise in precision medicine drug development to the partnership and we are excited to collaborate with Partex and fully leverage AI to expand beyond our R&D into healthcare sales marketing to bring better treatment options to patients in a patient centric way,” said, Christopher U Missling, PhD, President and Chief Executive Officer of Anavex.

141

SPECIAL FEATURE

INDIAN API EXPECTED TO GROW AT CAGR OF 12.24% here does India stand compared to developed countries with respect to pharma equipment?

In recent few years, India has seen a rapid progress in the field of pharma equipment. The manufacturing capabilities of India has strengthen itself and is growing multifold. The growth driver for equipment industry is the research and production capabilities of drug manufacturers.

One of India's strengths in the pharma equipment sector is its cost-effectiveness. The country offers competitive pricing for pharmaceutical machinery, making it an attractive destination for companies seeking affordable solutions.

India has made progress in adopting new technologies and gap can be filled by collaborating with countries like China/Taiwan so that we can achieve technological advancement while maintaining our core strength of costeffectiveness.

India has made significant progress in the field of pharmaceutical equipment manufacturing and is considered one of the major players globally. However, when it comes to comparing India with developed countries in terms of pharma equipment, there are certain factors to consider : • Manufacturing capabilities • Costeffectiveness, Quality standards • Technological advancements • Collaboration and partnerships : Overall, India has emerged as a significant player in the global pharmaceutical equipment market, offering cost-effective solutions and a strong manufacturing base. While there may be variations in terms of technological advancements and adherence to quality standards, India continues to strengthen its position and contribute to the global pharma equipment industry.

Indian pharma equipment market has the potential to grow further, contribute to the healthcare sector, and establish itself as a global player in the industry.

W

The budget has extended customs duty exemption for imports of certain medical equipment, what impact it will have on the equipment market and treatment in India?

I have always believed that opening the borders and collaborating with companies across the border will help our companies in achieving new feat. While the exemption benefits the import of medical equipment, it can also incentivize technology transfer and domestic manufacturing. International manufacturers will be encouraged to establish local production units or enter into partnerships with Indian companies to produce equipment within the country. This can lead to job creation, skill

142

KARMENDRA DESAI, FOUNDER, INFOZEN INDIA ENTERPRISE, SPOKE ABOUT INDIAN PHARMA EQUIPMENT MARKET

development, and the growth of the domestic medical equipment manufacturing industry.

The extension of customs duty exemption for imports of certain medical equipment in India can have several impacts on the equipment market and healthcare treatment in the country:• Affordability and accessibility • Upgrading healthcare infrastructure • Expanded treatment options • Technology transfer and domestic manufacturing • Economic impact • Potential challenges: It's important to note that the impact of customs duty exemption will depend on the specific equipment covered, the implementation process, and other related factors.

Nevertheless, in general, the exemption can help improve access to medical equipment, upgrade healthcare infrastructure, expand treatment options, and stimulate economic growth in the healthcare sector in India.

How do you see the future of the Indian pharma equipment market?

The future of the Indian pharma equipment market appears promising, with several factors contributing to its growth and development: • Growing pharmaceutical industry • Increasing healthcare infrastructure • Technological advancements • Export potential • Regulatory compliance • Focus on innovation and research • While the future of the Indian pharma equipment market appears promising, it is essential to address certain challenges, including maintaining quality standards, bridging the technology gap with developed countries, and ensuring a conducive business environment.

With appropriate measures and support, the

Brief us about your product offerings.

Infozen India Enterprise is focused on Providing Most Advanced and Cost Effective Nano-Micron Technology Solutions and allied Pharma Technologies.

Infozen offers world’s Most Advanced and Cost Effective High Pressure 45000 psi Microfluidization Homogenizer for Nano Emulsion- Nano Suspension, Nano Particle Preparation, Micro Encapsulation to achieve the desired Particle Size @1 pass.

The company offers widest range of Liposome Extruders of Lab, Pilot and Commercial Scales with capacity ranging from 10 ml upto 400L/hr. Ultrafine powder Micronization and Mixing Technologies Ultrafine Powder API AIR JET MILL can achieve the desired Particle Size (D90< 2-5 Micron @1pass). The company is backed by Noozle Technology with Preparation Engineering Center, to carry out sample trials from the lab type to pilot scale production.

ISO9001: 2015 approved TUV, CE certificated TUV. We offer various technology solutions like High Pressure 45000 psi (3013 bar) Microfluidizaion Homogenizer, Liposome Extruders,Air Jet Mill, Isolator, DPI Dry Powder Mixer,Infozen also offers various wet Milling solutions like Bead Mills (Dyno- Nano Mills), In Line Himigenizer, Basket Mill, Dispersers, Mixers. Infozen also provide cost effective solutions for Lyophilizer, SprayDryer, Thin Film Evaporators,P articles Size Analyzers etc.

What makes you different from other players?

We offer the most advanced and highly cost effective solutions in a market space which is dominated by 2-3 Players and are very xpensive .Long Machine Life with least Maintannace cost with shortest lead time customers can have the advantage of first in market Our onsite training to the customer’s operators and Engineers is rated amongst the best.

Tell us about your expansion plans.

We are planning to expand product range by introducing New generation Microflow Reactor and API production Lines, Microsphere Technologies and other advanced technologies.

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 143 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

144

{ 144 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 145 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 146 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 147 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 148 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 149 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 150 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 151 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 152 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 153 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 154 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 155 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 156 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 157 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 158 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 159 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 160 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 161 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 162 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 163 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 164 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 165 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 166 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 167 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 168 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 169 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 170 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 171 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 172 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 173 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 174 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 175 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 176 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 177 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 178 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 179 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 180 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 181 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 182 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 183 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 184 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 185 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 186 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 187 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 188 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 189 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 190 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 191 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 192 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 193 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 194 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 195 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 196 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 197 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 198 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 199 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 200 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 201 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 202 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 203 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 204 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 205 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 206 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 207 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 208 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 209 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 210 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 211 }

2023-2024

Purchase Manager - Pharma Industry

All India API & Bulk Drugs Directory

{ 212 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS ANDHRA PRADESH

HYDREBAD

DELHI

All India API & Bulk Drugs Directory

{ 213 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

214

{ 214 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 215 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

216

{ 216 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 217 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

218

{ 218 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 219 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

220

{ 220 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 221 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

222

{ 222 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 223 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

224

{ 224 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 225 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

GOA

All India API & Bulk Drugs Directory

226

{ 226 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

GUJRAT

All India API & Bulk Drugs Directory

{ 227 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

228

{ 228 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 229 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

SUBSCRIPTION FORM

Subscriber's Name : Mr. / Mrs...................................................................... Company's Name :.........................................................................................

Company's Address:............................................................................................................................................................................................................

Rs.600 (12 Issues 1 Year) Rs.1500 (36 Issues 3 years)

City...........................State ............................. Pin ......................Country...........................

Tel. No. :

E m a il .............................................................

Manufacturer

You can deposit in your Town also

Indentor

BANK OF BARODA MAZADA PUBLICATIONS, A/C. 04150200000909, MUMBAI

azada

PUBLICATIONS Publishers Of Magazines, Directories & CD’S

Broker

Trader

Importer

Machinery

Enclosed Herewith Is Cheque / DD No. ................................................ Of Rs...........................

Dated ........................... Drawn On ................................................ Branch...............................

Towards Above Marked Subscription In Favor of MAZADA PUBLICATIONS Payable In Mumbai. (Please Pay Rs.30/- Extra In Case Of Outstation Cheques)

Signature of Subscriber

Date.

Please Send The Complete Form With Cheque / DD To Subscription Department

Gala No. 1 A, Sharma Compund, Old Nagardas Road, Andheri (E), Mumbai -400 069 Mob: Website : https://joom.ag/ITNa

All India API & Bulk Drugs Directory

230

{ 230 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

HARYANA

KARNATAKA

MADHYA PRADESH

All India API & Bulk Drugs Directory

{ 231 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

MUMBAI

All India API & Bulk Drugs Directory

232

{ 232 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 233 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS GUJRAT

All India API & Bulk Drugs Directory

234

{ 234 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 235 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

236

{ 236 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 237 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

238

{ 238 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 239 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

240

{ 240 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 241 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

242

{ 242 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 243 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

244

{ 244 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 245 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

246

{ 246 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 247 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

248

{ 248 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 249 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

250

{ 250 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 251 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

252

{ 252 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 253 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

HARYANA

All India API & Bulk Drugs Directory

254

{ 254 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 255 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

256

{ 256 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 257 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

HIMACHAL PRADESH

All India API & Bulk Drugs Directory

258

{ 258 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

KARNATAKA

All India API & Bulk Drugs Directory

{ 259 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

260

{ 260 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 261 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

262

{ 262 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 263 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

264

{ 264 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

KERALA

All India API & Bulk Drugs Directory

{ 265 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

MADHYA PRADESH

All India API & Bulk Drugs Directory

266

{ 266 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

MUMBAI

All India API & Bulk Drugs Directory

{ 267 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

268

{ 268 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 269 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

270

{ 270 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 271 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

272

{ 272 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 273 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

274

{ 274 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 275 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

276

{ 276 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 277 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

278

{ 278 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 279 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

280

{ 280 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 281 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

282

{ 282 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 283 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

284

{ 284 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 285 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

286

{ 286 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 287 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

288

{ 288 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 289 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

290

{ 290 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 291 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

292

{ 292 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 293 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

294

{ 294 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 295 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

296

{ 296 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 297 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

298

{ 298 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 299 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

300

{ 300 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 301 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

302

{ 302 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 303 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

304

{ 304 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 305 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

306

{ 306 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 307 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

308

{ 308 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 309 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

310

{ 310 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 311 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

312

{ 312 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 313 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

314

{ 314 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 315 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

316

{ 316 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 317 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

318

{ 318 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 319 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

320

{ 320 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 321 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

322

{ 322 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 323 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

324

{ 324 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 325 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

326

{ 326 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 327 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

328

{ 328 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 329 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

330

{ 330 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 331 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

332

{ 332 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 333 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

334

{ 334 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 335 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

336

{ 336 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 337 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

338

{ 338 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 339 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

340

{ 340 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 341 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

342

{ 342 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 343 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

PUNJAB

All India API & Bulk Drugs Directory

344

{ 344 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

RAJSTHAN

All India API & Bulk Drugs Directory

{ 345 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

TAMILNADU

All India API & Bulk Drugs Directory

346

{ 346 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 347 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

348

{ 348 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 349 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

350

{ 350 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 351 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

352

{ 352 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 353 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

354

{ 354 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 355 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

356

{ 356 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 357 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

358

{ 358 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 359 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

360

{ 360 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 361 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

362

{ 362 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 363 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

364

{ 364 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 365 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

366

{ 366 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 367 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

UTTARAKHAND

All India API & Bulk Drugs Directory

368

{ 368 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

UTTAR PRADESH

All India API & Bulk Drugs Directory

{ 369 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

370

{ 370 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 371 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

KOLKATA

All India API & Bulk Drugs Directory

372

{ 372 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 373 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

ANDHRA PRADESH

All India API & Bulk Drugs Directory

374

{ 374 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 375 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

376

{ 376 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 377 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

BIHAR

DELHI

All India API & Bulk Drugs Directory

378

{ 378 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 379 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

380

{ 380 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 381 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

382

{ 382 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 383 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

384

{ 384 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 385 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

386

{ 386 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 387 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

388

{ 388 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS GOA

All India API & Bulk Drugs Directory

{ 389 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS GUJRAT

All India API & Bulk Drugs Directory

390

{ 390 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 391 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

392

{ 392 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 393 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

394

{ 394 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 395 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

396

{ 396 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 397 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

398

{ 398 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 399 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

400

{ 400 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 401 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

402

{ 402 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 403 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

404

{ 404 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

{ 405 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

All India API & Bulk Drugs Directory

406

{ 406 }

2023-2024

API & BULK DRUGS TRADERS / MERCHANT IMPORTERS & EXPORTERS

azada

PUBLICATIONS Publishers Of Magazines, Directories & CD’S

All India API & Bulk Drugs Directory

{ 407 }

2023-2024

API & BULK DRUGS MANUFACTURERS ANDHRA PRADESH

All India API & Bulk Drugs Directory

{ 408 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

409

{ 409 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 410 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

411

{ 411 }

2023-2024

API & BULK DRUGS MANUFACTURERS

BIHAR

CHHATTISGARH

DELHI

All India API & Bulk Drugs Directory

{ 412 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

413

{ 413 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 414 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

415

{ 415 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 416 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

417

{ 417 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 418 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

419

{ 419 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 420 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

421

{ 421 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 422 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

423

{ 423 }

2023-2024

API & BULK DRUGS MANUFACTURERS GUJARAT

All India API & Bulk Drugs Directory

{ 424 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

425

{ 425 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 426 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

427

{ 427 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 428 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

429

{ 429 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 430 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

431

{ 431 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 432 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

433

{ 433 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 434 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

435

{ 435 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 436 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

437

{ 437 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 438 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

439

{ 439 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 440 }

2023-2024

API & BULK DRUGS MANUFACTURERS

(Monthly)

SIZE

M/C

B/W

Dimensions

Full Page

15,000/-

7,500/-

183mm x 250mm

Half Page

----

4,500/-

183mm x 120mm

1/3 Page

----

3,000/-

183mm x 78mm

1/4 Page

----

2,250/-

90mm x 120mm

----

1,500/-

90mm x 55mm

Visiting Card Size ( Bold Listing )

Premium Position Front Cover 30,000/Front Inside Cover 22,500/All India API & Bulk Drugs Directory

441

(M/C only)

Back Cover 30,000/Back Inside Cover 22,500/{ 441 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 442 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

443

{ 443 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 444 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

445

{ 445 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 446 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

447

{ 447 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 448 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

449

{ 449 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 450 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

451

{ 451 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 452 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

453

{ 453 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 454 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

455

{ 455 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 456 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

457

{ 457 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 458 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

459

{ 459 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 460 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

461

{ 461 }

2023-2024

API & BULK DRUGS MANUFACTURERS

HARYANA

All India API & Bulk Drugs Directory

{ 462 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

463

{ 463 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 464 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

465

{ 465 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 466 }

2023-2024

API & BULK DRUGS MANUFACTURERS

HIMAACHAL PRADESH

All India API & Bulk Drugs Directory

467

{ 467 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 468 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

469

{ 469 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 470 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

471

{ 471 }

2023-2024

API & BULK DRUGS MANUFACTURERS

JAMMU & KASHMIR

All India API & Bulk Drugs Directory

{ 472 }

2023-2024

API & BULK DRUGS MANUFACTURERS

KARNATAKA

All India API & Bulk Drugs Directory

473

{ 473 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 474 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

475

{ 475 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 476 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

477

{ 477 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 478 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

479

{ 479 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 480 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

481

{ 481 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 482 }

2023-2024

API & BULK DRUGS MANUFACTURERS

KERALA

All India API & Bulk Drugs Directory

483

{ 483 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 484 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

485

{ 485 }

2023-2024

API & BULK DRUGS MANUFACTURERS

MADHYA PRADESH

All India API & Bulk Drugs Directory

{ 486 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

487

{ 487 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 488 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

489

{ 489 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 490 }

2023-2024

API & BULK DRUGS MANUFACTURERS

MAHARASHTRA

All India API & Bulk Drugs Directory

491

{ 491 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 492 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

493

{ 493 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 494 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

495

{ 495 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 496 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

497

{ 497 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 498 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

499

{ 499 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 500 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

501

{ 501 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 502 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

503

{ 503 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 504 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

505

{ 505 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 506 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

507

{ 507 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 508 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

509

{ 509 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 510 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

511

{ 511 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 512 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

513

{ 513 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 514 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

515

{ 515 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 516 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

517

{ 517 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 518 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

519

{ 519 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 520 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

521

{ 521 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 522 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

523

{ 523 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 524 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

525

{ 525 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 526 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

527

{ 527 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 528 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

529

{ 529 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 530 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

531

{ 531 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 532 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

533

{ 533 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 534 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

535

{ 535 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 536 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

537

{ 537 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 538 }

2023-2024

API & BULK DRUGS MANUFACTURERS

ORISSA

All India API & Bulk Drugs Directory

539

{ 539 }

2023-2024

API & BULK DRUGS MANUFACTURERS

PUNJAB

All India API & Bulk Drugs Directory

{ 540 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

541

{ 541 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 542 }

2023-2024

API & BULK DRUGS MANUFACTURERS

RAJASTHAN

All India API & Bulk Drugs Directory

543

{ 543 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 544 }

2023-2024

API & BULK DRUGS MANUFACTURERS TAMILNADU

All India API & Bulk Drugs Directory

545

{ 545 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 546 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

547

{ 547 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 548 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

549

{ 549 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 550 }

2023-2024

API & BULK DRUGS MANUFACTURERS

TELANGANA

All India API & Bulk Drugs Directory

551

{ 551 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 552 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

553

{ 553 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 554 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

555

{ 555 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 556 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

557

{ 557 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 558 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

559

{ 559 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 560 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

561

{ 561 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 562 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

563

{ 563 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 564 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

565

{ 565 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 566 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

567

{ 567 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 568 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

569

{ 569 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 570 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

571

{ 571 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 572 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

573

{ 573 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 574 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

575

{ 575 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 576 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

577

{ 577 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 578 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

579

{ 579 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 580 }

2023-2024

API & BULK DRUGS MANUFACTURERS

UTTARAKHAND

All India API & Bulk Drugs Directory

581

{ 581 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 582 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

583

{ 583 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 584 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

585

{ 585 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 586 }

2023-2024

API & BULK DRUGS MANUFACTURERS

UTTAR PRADESH

All India API & Bulk Drugs Directory

587

{ 587 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 588 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

589

{ 589 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

{ 590 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

591

{ 591 }

2023-2024

API & BULK DRUGS MANUFACTURERS WEST BENGAL

All India API & Bulk Drugs Directory

{ 592 }

2023-2024

API & BULK DRUGS MANUFACTURERS

All India API & Bulk Drugs Directory

593

{ 593 }

2023-2024

API & BULK DRUGS MANUFACTURERS

azada

PUBLICATIONS Publishers Of Magazines, Directories & CD’S

All India API & Bulk Drugs Directory

{ 594 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 595 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 596 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 597 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 598 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 599 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 600 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 601 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 602 }

2023-2024

API & BULK DRUGS - BROKERS

REGULAR ADVERTISEMENT TARIFF Rate Per Insertion

(Fortnightly)

SIZE

M/C

B/W

Dimensions

Full Page

10,500/-

5,700/-

183mm x 250mm

Half Page

6,000/-

3,000/-

183mm x 120mm

1/3 Page

----

2,250/-

183mm x 78mm

1/4 Page

3,900/-

1,800/-

90mm x 120mm

1/6 Page

----

1,125/-

91mm x 78mm

Premium Position Front Cover 30,000/Front Inside Cover 22,500/All India API & Bulk Drugs Directory

(M/C only)

Back Cover 30,000/Back Inside Cover 22,500/{ 603 }

2023-2024

API & BULK DRUGS - BROKERS

All India API & Bulk Drugs Directory

{ 604 }

2023-2024